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Abstract 
Cosmetic products are used daily on a global scale. Therefore, it is necessary to ensure 
that these products, and their ingredients, do not cause any adverse human health effects 
under normal usage; to ensure this, risk assessment must be performed. Traditionally, 
risk assessments are performed in vivo, i.e. conducting tests on animals using the 
chemical(s) of interest. However, over the past decade there has been an increase in 
research into the use of alternative toxicity testing methods, such as in vitro, in chemico 
and in silico. Whilst there are a number of alternative techniques that may be employed, 
no one method can be used in isolation as a full replacement for an in vivo test. 
Therefore, the Adverse Outcome Pathway (AOP) concept is an emerging method by 
which information provided by the in vitro, in chemico, and in silico approaches can be 
utilised in an integrated testing strategy. The AOP concept links an upstream molecular 
initiating event to a downstream adverse outcome, via a number of testable key events. 
In silico approaches utilise computers in order to develop predictive models. Within the 
AOP paradigm in silico method work to identify the key features of a chemical 
(structural alerts) that induce a molecular initiating event (MIE). A collection of 
structural alerts that induce the same MIE are considered to be an in silico profiler. 
Typically, these in silico profilers are supported by associated toxicity, or mechanistic, 
information pertaining to the ability to induce a specific MIE. The overall aim of the 
work presented in this thesis was the development of an in silico profiler, based upon 
the hypothesis that the induction of mitochondrial toxicity is a key driver of organ-level 
toxicity. The research presented herein demonstrates the ability to identify, and develop, 
two types of structural alert; mechanism- and chemistry-based; that pertain to 
mitochondrial toxicity. Due to the differences inherent in these two types of alert they 
should be utilised for different purposes. As such, the main usage of the mechanism-
based alerts should be in the formation of chemical categories and subsequent data gap 
filling via read-across. In comparison, the chemistry-based alerts should be utilised for 
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the purposes of prioritising chemicals, within an inventory, that should undergo 
additional testing in in vitro and/or in chemico assays. It is envisaged that these two 
types of structural alerts could be used to profile chemical inventories as part of a tiered 
testing strategy. 
Therefore, the future work discussed in detail the need to expand the chemical space 
covered by the alerts. Additional future work involves utilising experimental 
information from in vitro/in chemico assays to verify the mechanism-based alerts and to 
refine the chemistry-based alerts by discerning mechanistic information associated with 
them. Furthermore, it is envisaged that these alerts could be incorporated into predictive 
tools, such as the OECD QSAR Toolbox, to enable their use for screening and 
prioritisation purposes. 
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Chapter 1: Introduction 
 
1.1 Risk assessment and conventional toxicological testing 
Cosmetic products are used extensively in many communities throughout the world on a 
daily basis. A cosmetic product is defined by Directive 76/768/EEC as ‘any substance or 
mixture intended to be placed in contact with the various external parts of the human body 
or with the teeth and the mucous membranes of the oral cavity with a view exclusively or 
mainly to cleaning them, perfuming them, changing their appearance and/or correcting 
body odours and/or protecting them or keeping them in good condition’ (EC 2003). Due to 
their global usage it is essential, both for producers and consumers, that these cosmetic 
products do not cause any adverse human health effects under normal use conditions. This 
makes undertaking risk assessment a critical step in product development. Risk assessment 
is used to assess the potential adverse effects following application or exposure to both 
human health and the environment of natural and synthetic agents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
There are, traditionally, four components needed in order for a risk assessment to be 
completed; identification and characterisation of the potential hazard; assessment of the dose 
required to cause toxicity; assessment of the potential exposure and characterisation of the 
likely risk to the exposed population; with the final outcome being a prediction of the 
possible risk to humans or the environment (van Leeuwen 2007). The information required 
for risk assessment to be undertaken is provided by toxicological studies, typically carried 
out using animal experiments. The science of toxicology is an inter-disciplinary subject that 
explores the relationship between chemistry, biology and pharmacology to determine the 
level of exposure to chemicals that are deemed safe to living organisms. There are three 
main methods that can be employed to determine the toxicity of a chemical:- 
In vivo – tests conducted on humans or animals (animal data are then used to infer 
toxicity in humans) 
Chapter 1 
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In vitro – tests conducted on model system(s) based on either animal or human cells 
and/or systems 
In silico – computer based models that provide predictions of toxicity, using existing 
in vivo or in vitro data. 
Historically, in vivo experimentation is the most frequently employed method in 
toxicological testing, as data derived from in vivo tests are considered the most 
representative of the endpoint of interest (in this case human toxicity).  A toxic endpoint is 
the effect that a test chemical has on the organ(s) of interest, or on the organism as a whole, 
during toxicity experimentation.  The most relevant endpoints, from a cosmetics perspective, 
are skin sensitisation, mutagenicity, carcinogenicity, reproductive, and repeat dose toxicity.  
These endpoints have been tested using a variety of in vivo procedures.  For example, skin 
sensitisation testing employs the Local Lymph Node Assay (LLNA) (OECD 2002) and 
Guinea Pig Maximisation Test (GPMT) (OECD 1992); whilst the rodent carcinogenicity 
assay is employed to test for carcinogenicity (OECD 2008); and the repeated dose 28- and/or 
90-day toxicity studies in rodents test for repeat dose toxicity (OECD 1995, OECD 1998). 
Chronic toxicity is the observed adverse health effect(s) that occur after the repeated 
exposure of an organism to a substance on a daily basis for an extended period of time; up to 
the entire lifespan of the test species. These studies are important as they enable a safe 
dosage for humans to be discerned through the derivation of a No Observed (Adverse) 
Effect Level (NO(A)EL); “the highest exposure level at which there are no biologically 
significant increases in frequency or severity of adverse effects between the exposed 
population and it appropriate control.” (EPA 1995, Lewis et al 2002). In order for a NOAEL 
value to be derived repeat dose toxicity testing must be conducted in, for example, a 28- or 
90-day oral, dermal, or inhalation rodent study. This type of study provides the identification 
of the organ(s) that drive the NO(A)EL value and the derivation of a Lowest Observed 
(Adverse) Effect Level (LO(A)EL) value; “the lowest exposure level at which there are 
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biologically significant increases in frequency or severity of adverse effects between the 
exposed population and its appropriate control group.” (EPA 1995, Lewis et al 2002). 
Due to the introduction, and implementation, of two key pieces of European legislation; 
namely REACH and the 7th amendment to the Cosmetics Directive (discussed below); over 
the past decade there has been an increased need to replace these in vivo repeat dose studies 
with in vitro and/or in silico alternatives (EC 2003, EC 2006, EC 2006). Some of this need 
has arisen from an increase in animal welfare campaigns from organisations such as People 
for the Ethical Treatment of Animals (PETA) and Lush Cosmetics Company against the use 
of animal testing. Another factor is the reduction in cost when utilising in silico (as 
compared to in vivo or in vitro) methods in the primary screening of new products. A single 
90-day oral repeat dose rodent study costs between $125,000-175,000 and uses 
approximately 80 animals (10 animals/sex/group and at least 4 dose groups) per chemical. It 
is envisaged that alternative techniques will reduce both the monetary and animal costs 
involved. However, the major contributing factor has been the introduction of legislation 
coming into force from international bodies, primarily the European Union (EU). 
 
1.2 European Union regulation 
In 2007, the EU Registration, Evaluation, Authorisation and restriction of Chemicals 
(REACH) regulation came into force. The REACH regulation acts to promote Russell and 
Burch’s “3Rs” principle in safety assessment (EC 2006). The 3Rs principles aim to reduce 
the number of test animals per experiment, to minimise the suffering of the animals by 
refining the experimental protocol, and to, ultimately, replace animal testing with alternative 
methods (Russell 1959). Under REACH, any substance produced or imported into the EU at, 
or above, one tonne per year is required to be registered with the European Chemicals 
Agency (ECHA). When registering with ECHA companies are obligated to provide details 
of the substance’s properties, along with assessments of the chemicals safety based upon 
Chapter 1 
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toxicity testing; with the emphasis on the use of alternative methods and animal 
experimentation occurring only as a last resort. 
Further to the REACH legislation, which encompasses all substances, is the Cosmetic 
Directive that focuses specifically on cosmetic products and their ingredients (EC 2003). 
Due to the variety of functions that are performed by cosmetic products their ingredients 
cover a wide range of chemical space; from low molecular weight chemicals such as 
cyanoacrylates (used in nail glue) to higher molecular weight chemicals such as sodium 
laureth sulphate (used in shampoos and toothpastes). Additionally, depending upon their end 
use, cosmetic ingredients may be inherently reactive towards proteins such as Acid Black 1 
(used as a colourant in hair dye products) or unreactive such as dimethicone (used as an 
emollient in hand/body lotions and hair conditioners). The Cosmetic Directive places the 
responsibility of cosmetic product safety on the company that is releasing the product onto 
the market. The aims of the most recent revision to the EU Cosmetic Directive, the 7th 
amendment introduced in 2004, were two-fold (EC 2003). Firstly, it prohibits the testing of 
finished cosmetic products on animals after 2004, along with a phasing out of testing of 
individual cosmetic ingredients as alternative methods became validated by EU regulatory 
bodies, such as the European Centre for the Validation of Alternative Methods (ECVAM). 
The deadline for this phasing out passed in 2009 and was imposed whether an alternative 
method was available or not. The second measure imposes a step-by-step Europe-wide 
marketing ban if either a finished product or its ingredients have been tested on animals after 
2009, in line with the above testing ban for individual ingredients. There were exceptions to 
this marketing ban (i.e. for repeat-dose, reproductive toxicity, as well as toxicokinetic 
studies) whereby the final deadline passed in March 2013. 
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1.3 Alternative testing methods 
Since the implementation of both REACH and the 7th amendment of the Cosmetic Directive 
there has been a marked increase in the effort to find alternative methods for chemical risk 
assessment. These alternatives have been developed employing in vitro, in chemico and in 
silico techniques. In vitro testing is performed under laboratory conditions on isolated 
biological organisms, such as cell lines or subcellular components. The Ames test, for 
example, uses a bacterial strain lacking the ability to produce histidine - grown on a media 
containing no histidine - to assess the mutagenic potential of compounds (Ames et al 1973, 
OECD 1997). In chemico testing is used to assess the ability of a compound to react with, 
and bind covalently to, important biological macromolecules such as proteins. For example, 
the glutathione assay is used to assess the ability of a compound to bind to proteins 
containing a thiol moiety (e.g. cysteine) (Aptula et al 2006). In silico techniques are 
computer-based alternatives that enable predictions to be made covering a broad range of 
endpoints, for example, skin sensitisation and teratogenicity (Enoch et al 2008a, Enoch et al 
2008b, Enoch et al 2009, Enoch et al 2011a). Aside from reducing the number of animals 
used within regulatory assessment these testing strategies also have numerous other, obvious, 
advantages over in vivo experimentation. For example, they are less time consuming and 
more cost-effective. There are a number of in silico approaches that can be employed to 
facilitate predictions regarding a substance’s toxicity useful for risk assessment. These in 
silico approaches can be classified as belonging to one of two broad categories; 
(Quantitative) Structure-Activity Relationships ((Q)SARs) and category formation and read-
across. Structure-activity relationships are a method that can be used to relate the structure or 
(arrangement of) functional groups of a chemical to its biological activity. QSARs are 
mathematical models that utilise numerical values of physico-chemical properties (also 
known as descriptors) in order to predict the activity, or potency, of a chemical. In 
comparison, category formation and read-across is a concept whereby the toxicity of a 
chemical (with no known toxicological profile) is predicted based upon its similarity to 
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analogous chemicals, for which toxicological data are available. Whilst there are numerous 
alternative techniques that can be used to predict various aspects of in vivo experimentation, 
no one method in isolation can replace animal testing. To overcome this problem these 
alternatives will need to be used in conjunction with one another as part of an integrated 
testing strategy (ITS) (Hartung et al 2013). 
 
1.3.1 Adverse Outcome Pathways and Molecular Initiating Events 
A framework is, therefore, required that enables the information provided by these different 
testing methods to be integrated and organised in a transparent and cohesive manner. To 
address this, the Adverse Outcome Pathway (AOP) paradigm has been introduced to provide 
such a framework (Ankley et al 2010, OECD 2013, Vinken 2013, Vinken et al 2013a, 
Vinken et al 2014). An AOP is a construct that means to establish a mechanistic connection 
between two anchors; the upstream Molecular Initiating Event (MIE) and the downstream 
adverse outcome relevant for risk assessment; via a number of key testable events at 
differing levels of biological organisation (such as the cellular, organ or organism level) 
(Ankley et al 2010, Schultz 2010, OECD 2013, Przybylak and Schultz 2013). The MIE is 
the primary event that triggers the progression of the AOP towards the adverse event. As 
such it provides mechanistic information pertaining to the initial interaction between the 
chemical and the biological system. Upon elucidation of the mechanistic information 
regarding the MIE it can be associated with structural fragments and, potentially, physico-
chemical properties. AOPs are generally represented as a linear construct, as shown in 
Figure 1.1, with toxicity progressing sequentially from one level to another. However, due to 
the complex and multi-faceted nature of toxicity, multiple key effects (e.g. at the cellular 
level) may by induced by one effect upstream (e.g. at the MIE). Therefore, the true pathway 
may include a number of branching tracks that, ultimately, culminate in the same adverse 
effect; for example the cholestasis AOP developed by Vinken et al (2013b). A number of 
AOPs have been developed for a wide variety of adverse outcomes including; oestrogen 
Chapter 1 
7 
 
receptor-mediated reproductive toxicity, cholestasis, weak acid respiratory uncoupling, skin 
sensitisation and voltage-gated sodium channel-mediated neural toxicity (Ankley et al 2010, 
Schultz 2010, OECD 2011, Landesmann et al 2012, OECD 2012). It should be noted that a 
more comprehensive list of the available AOPs can be found in the AOP wiki via the AOP 
knowledge base (available from https://aopkb.org/, accessed 17.11.2014). In addition, the 
OECD has published a guidance document, as a way to standardise this framework, 
outlining the process by which AOPs should be developed and assessed for their reliability 
and robustness (OECD 2013).  
 
Figure 1.1: Summary of the steps and examples within an adverse outcome pathway 
(adapted from Ankley et al (2010)) 
 
1.3.2 In silico profilers 
The main contribution that in silico techniques provide to the AOP approach is with respect 
to defining the MIE. This is achieved by identifying chemical structures (or fragments) that 
are associated with inducing toxicity. These structural fragments form the basis of structural 
alerts. A collection of structural alerts that culminate in the same outcome, for example 
DNA or protein binding, are considered to be an in silico profiler (Enoch and Cronin 2010, 
Enoch et al 2011b). There are two broad classifications of profilers: mechanistic and non-
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mechanistic (described as chemistry-based in this thesis). A mechanistic profiler consists of 
a (group of) structural alert(s) relating to an MIE that has the potential to induce a specific 
endpoint. It is essential that each of the structural alerts that comprise a mechanistic profiler 
have, associated with them, experimental data that provide evidence that demonstrate how 
the structural alert induces toxicity via the MIE. This experimental data can originate from a 
variety of sources, such as; (historical) in vivo, in vitro and/or in chemico data present in the 
available literature; or data generated by in-house in vitro and/or in chemico experimentation. 
In comparison, a chemistry-based profiler consists of a (group of) structural alert(s) that 
have been identified as being associated with inducing a specific endpoint. However, there is 
no mechanistic information pertaining to how these alerts initiate toxicity. Chemistry-based 
profilers generally use a chemoinformatics approach, in which the presence of a specific 
structural fragment is associated with inducing toxicity. Whilst chemistry-based structural 
alerts have been associated with toxicity, the nature of these alerts can make it difficult to 
identify the mechanism that initiates the observed toxicity. This is because these alerts may 
be small fragments found in a variety of chemicals that may induce toxicity via different 
mechanisms. Due to the inherent differences each type of profiler should be utilised for 
different purposes; with mechanistic profilers being useful for category formation and 
subsequent read-across analysis, whilst chemistry-based profilers can be useful for screening 
large datasets and prioritising those chemicals that should undergo in vitro and/or in chemico 
testing first. 
 
1.3.3 Category formation and read across 
Chemical category formation is an approach whereby a set of chemicals with similar 
common properties, or trends in properties, are grouped together into a category (ECHA 
2008, OECD 2011). Chemical categories may be developed based upon a similar 
mechanism of action or, more specifically, the MIE. Therefore, the mechanism-based 
structural alert(s) can be utilised in the formation of a chemical category, with the same 
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alert(s) needing to be present in both the target chemical and its analogues. The importance 
of the category formation approach has led to the development of the Organisation for 
Economic Co-operation and  evelopment’s (OEC ) QSAR Toolbox software package 
(discussed in Chapters 3 and 6). This software tool contains a number of mechanistic 
profilers enabling chemical categories to be formed for a range of toxicological endpoints 
(available from www.qsartoolbox.org). Once a chemical category has been developed, 
predictions can then be made, via read-across, using the premise that similar chemicals 
should have similar biological and/or chemical activities (Jaworska and Nikolova-Jeliazkova 
2007). These read-across predictions involve using existing toxicological data associated 
with the chemicals in the category in order to predict the activity of the target chemical (for 
which no toxicological data exist for the endpoint in question). Importantly, depending upon 
the data that are available for the analogous chemicals, within a specific category, both 
qualitative and/or quantitative predictions can be made using this approach.  
 
1.3.4 Profiling inventories for prioritisation 
A chemical inventory is a library of information, such as chemical name and other identifiers, 
pertaining to a set of chemicals. In contrast to a database, an inventory does not contain any 
toxicological data associated with the chemicals. Inventory screening is a process whereby 
an in silico profiler is utilised to quickly identify chemicals, within an inventory, with the 
potential to induce toxicity, due to the presence of a structural alert. As the chemistry-based 
structural alerts that compose a chemistry-based profiler do not contain any mechanistic 
information they are, therefore, less appropriate for use in read-across. This is because the 
structural fragment that is incorporated in the structural alert may be present in a multitude 
of different chemicals, each of which may induce toxicity via a different mechanism. 
However, these profilers can be utilised to screen large data sets, or inventories, for 
chemicals that contain one, or more, of the structural alerts. Therefore, any chemical that 
triggers an alert would be hypothesised to have the ability to induce toxicity. As such, the 
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identification of a chemistry-based alert within a (group of) chemical(s) can be utilised to 
prioritise these chemicals as requiring to undergo further testing within relevant in vitro or in 
chemico assays. It is envisaged that, from this additional testing, mechanistic information 
pertaining to how the chemical structure initiates the observed toxicity will be elucidated. 
This information can, thus, be utilised to support the adjustment of the chemical-based alert 
into a mechanistic alert. Whilst chemistry-based alerts can be used in order to screen an 
inventory, it should be noted that the use of mechanism-based alerts is preferable; as these 
would also provide an insight as to the mechanism by which the chemical may induce 
toxicity. 
 
1.3.5 Expert systems 
In addition to the development of novel mechanistic or chemistry-based profilers, there are a 
number of freely available, and subscription-based, software packages, known as expert 
systems, such as Toxtree, TIMES-SS, and DEREK Nexus (formerly DEREK for Windows). 
These expert systems are a repository of expert knowledge containing structural alerts for a 
variety of endpoints, such as mutagenicity, carcinogenicity, skin sensitisation, and skin 
irritation. Expert systems use libraries of endpoint specific structural alerts to enable a user 
to identify chemicals that may have the potential to induce toxicity; based upon the presence 
of a structural alert in the chemical of interest. Expert systems, such as DEREK Nexus, are 
utilised by a variety of companies in the pharmaceutical and/or cosmetics industries. These 
companies use the information held by the expert system to screen data sets, during the early 
phases of product development, as a method to guide chemical selection for prioritisation for 
further testing within in vitro and/or in chemico assays. Additionally, the predictions made 
by an expert system can be, and are, used in lead optimisation in order to identify those 
fragments that are required to be removed to reduce toxicity. 
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1.4 Molecular initiating events for repeat dose toxicity 
Repeat dose toxicity testing identifies the adverse effects that are observed after the test 
organism has been subjected to repeated exposure of a test chemical over a period of time, 
up to the entire lifespan of the organism. Covalent protein and DNA binding has been shown 
to be an initiating event in multiple toxicological endpoints such as, skin sensitisation, 
carcinogenicity, mutagenicity, and hepatotoxicity (de Groot and Noll 1983, Woodward and 
Timbrell 1984, Aptula and Roberts 2006, Aptula et al 2006, Enoch et al 2008a, Enoch et al 
2008b, Enoch and Cronin 2010, Enoch et al 2011a, OECD 2012, Hewitt et al 2013). As 
protein and DNA binding have been implicated in initiating numerous toxicological 
endpoints it is, therefore, plausible that these are also important in inducing repeat dose 
toxicity. In addition, research has shown that mitochondrial dysfunction is another 
etiological agent of toxicity, especially of pharmaceutical drugs, in a wide variety of organs, 
such as the heart, liver, and kidney (Dykens and Will 2007, Dykens and Will 2008, 
Nadanaciva and Will 2011). This implication of mitochondrial toxicity as a driver in various 
organ-level toxicities is partly attributable to the withdrawal of a number of pharmaceutical 
drugs from the market upon observation of mitochondrial dysfunction (Dykens 2008). 
However, even though there has been an increase in interest of screening chemicals for the 
ability to induce mitochondrial dysfunction, in comparison to protein/DNA binding, there 
have been relatively few in silico models or structural alerts developed (Zhang et al 2009, 
Naven et al 2013, Wallace et al 2013). It is for these reasons that the (potential) ability for 
chemicals to induce mitochondrial toxicity, after repeat exposures, was decided to be the 
main focus of this thesis. 
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1.5 Cellular function and mitochondrial toxicity 
1.5.1 Cellular function 
Every organism is composed of cells. A cell is the simplest collection of matter that can be 
considered to be alive. Complex, multicellular organisms, such as plants and animals, 
consist of a number of different organs that perform distinct functions. Organs are composed 
of specialised (eukaryotic) cells that enable the organ to function correctly. Whilst there are 
numerous cell types within the human body - such as hepatocytes, myocytes, and 
nephrocytes – the general structure and composition is well conserved. A typical somatic 
cell contains many integral internal structures (organelles) that perform specific functions 
within the cell. There are two categories of organelle: membrane-bound and non-membrane 
bound. Membrane-bound organelles include, but are not limited to –  
 The nucleus, a double-membrane bound organelle, which contains the majority of 
the cells genetic material, the ability to synthesis and assemble ribosomes, and 
controls the activity of the other organelles in the cell. 
 The endoplasmic reticulum (ER), a single-membrane bound organelle that is 
continuous with the outer membrane of the nucleus. There are two forms of ER: 
rough and smooth. Rough ER is associated with ribosomes and is involved in the 
synthesis and folding of proteins. Smooth ER is not associated with ribosomes and 
is involved in the synthesis of (phospho)lipids and steroids. 
 The Golgi apparatus, a single-membrane bound organelle, which forms vesicles to 
transport proteins (from the rough ER) throughout the cell or to be secreted into the 
extracellular space. 
 The mitochondria, a double-membrane bound organelle, which is discussed in more 
detail below. 
Non-membrane bound organelles include, but are not limited to: ribosomes, which are 
involved in protein synthesis; proteasomes, which are used in the degradation of damaged 
proteins; and the cytoskeleton, which performs a multitude of functions such as maintaining 
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cell shape, anchoring organelles within the cell and intracellular transport of vesicles and 
organelles. 
 
1.5.2 Cellular toxicity 
Cell death is an essential process within normal human development and homeostasis. 
However, it can also be initiated by either internal or external xenobiotics or toxins that 
disrupt normal cell physiology and function. There are three main pathways by which cell 
death can occur in mammalian cells: autophagy, necrosis, and apoptosis. 
 
1.5.2.1 Autophagy 
Autophagy is a highly regulated catabolic mechanism that is activated in response to cellular 
stressors such as oxidative stress, cellular starvation, irradiation, and/or xenobiotics (Levine 
et al 2008). The morphological characteristics observed during autophagy include the 
sequestration of cytoplasmic material within double-membraned vesicles (autophagosomes) 
(Klionsky et al 2000). These autophagosomes subsequently fuse with lysosomes degrading 
the contents of the autophagosome (Fink et al 2005, Levine et al 2008). 
 
1.5.2.2 Necrosis 
Necrosis is considered to be an uncontrolled pathway of cell death that is not energy-
dependent (Fink et al 2005). Disruption to normal physiological functioning of the cell – 
such as ATP production, ion transport, and pH balance – may all lead to necrotic cell death. 
Typical characteristics of necrotic cell death include: swelling and vacuolisation of the 
cytoplasm, dilation of membrane-bound organelles, and an inflammatory response 
surrounding the necrotic cell (Fink et al 2005). 
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1.5.2.3 Apoptosis 
Apoptosis (programmed cell death) is an essential pathway in maintaining cellular 
homeostasis within multicellular organisms. The progression of cell death via apoptosis is a 
well regulated and organised sequence of events that includes fragmentation of DNA, 
condensation of chromatin, blebbing of the cell membrane and fragmentation into ‘apoptic 
bodies,’ and finally engulfment of these ‘apoptic bodies’ by macrophages or neighbouring 
cells. There are two main pathways of inducing apoptosis: intrinsic and extrinsic.  
The extrinsic pathway is mediated by the binding of death receptor ligands to death 
receptors present within the plasma membrane, thus, triggering the activation of various 
downstream caspases (Green et al 2004). In contrast, the mitochondria are the main 
mediators of the intrinsic pathway. The pivotal event in the induction of the intrinsic 
pathway is the permeabilisation of the mitochondrial outer membrane. There are two 
mechanisms that can initiate this permeabilisation (Green et al 2004). The first mechanism is 
activated by members of the Bcl-2 family of proteins – which enable the formation of pores 
in the outer mitochondrial membrane – thereby releasing pro-apoptic molecules (such as 
cytochrome c) that initiate various downstream caspases. The second mechanism of intrinsic 
pathway initiation involves the induction of mitochondrial permeability transition, which is 
discussed in more detail in section 1.6. 
 
1.5.3 Mitochondria 
1.5.3.1 General structure and function 
The mitochondria are organelles present in virtually every cell type of the human body, the 
exception being mature erythrocytes (Cohen and Gold 2001). The number and shape of 
mitochondria varies greatly between cell types, with those cells with a higher energy 
demand such as cardiac and skeletal muscle containing a higher number of mitochondria 
(Amacher 2005, Pieczenik and Neustadt 2007, Nadanaciva and Will 2011). Whilst the 
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external morphology of mitochondria can vary between cell types, the constituent parts are 
conserved (Collins and Bootman 2003, Amacher 2005, Nadanaciva and Will 2011). The 
basic structure of mitochondria consists of two membranes (the outer and inner membrane) 
enclosing two components; the intermembrane space and the mitochondrial matrix (Figure 
1.2). The outer membrane is relatively smooth and, due to the presence of pores consisting 
of voltage-dependent anion channels, is permeable to molecules that are less than 5kDa in 
size (Amacher 2005, Dykens and Will 2008). In contrast, the inner membrane contains 
multiple invaginations (cristae); is permeable to relatively few molecules including O2, CO2, 
and H2O; and contains each of the protein complexes that comprise the electron transport 
chain, ATP synthase (Complex V) and various electron carriers (Dykens and Will 2008, 
Nadanaciva and Will 2011). Specialised transporting proteins are required in order to enable 
hydrophilic molecules and inorganic ions to pass across the inner mitochondrial membrane 
(Amacher 2005, Dykens and Will 2008). Mitochondria are essential for a number of 
functions vital to a cell’s normal functioning and survival. The primary function being the 
production of approximately 95% of the total adenosine triphosphate (ATP) generated by 
cells during oxidative phosphorylation; the remainder being made via glycolysis. 
 
Figure 1.2: Basic structure of mitochondria 
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1.5.3.2 Oxidative phosphorylation 
Oxidative phosphorylation is the process whereby the transfer of electrons, along the 
electron transport chain, is coupled to ATP synthesis, i.e. the phosphorylation of adenosine 
diphosphate (ADP) by inorganic phosphate. The electron transport chain is central to the 
process of oxidative phosphorylation and is comprised of four protein complexes 
(Complexes I – IV) situated within the inner mitochondrial membrane (Figure 1.3). In 
addition, Complex V (part of the wider respiratory chain) is the essential protein complex 
that phosphorylates ADP to produce ATP. Acetyl coenzyme A, generated either by 
glycolysis in the cytosol or fatty acid β-oxidation in the mitochondria, enters the citric acid 
cycle (Figure 1.4); whereby, electrons are used to reduce nicotinamide adenine dinucleotide 
(NAD+) and flavin adenine dinucleotide (FAD) to NADH and FADH2 respectively.  
 
 
Figure 1.3: An illustration of how the respiratory chain is involved in oxidative 
phosphorylation 
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Figure 1.4: The generation of NADH and FADH2 by the citric acid cycle 
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transports the electrons to Complex III, which, in turn, donates the electrons to another 
electron carrier: cytochrome c. Cytochrome c subsequently donates the electrons to the final 
protein complex in the electron transport chain: Complex IV. Finally, Complex IV donates 
the electrons to molecular oxygen producing water. This process of electron transfer from 
electron donor to electron acceptor (illustrated in Figure 1.3) can only take place due to the 
difference in redox potential between the two; with the electron acceptor having a larger 
redox potential than the electron donor. Complexes I, III and IV use the energy released 
from the transfer of electrons along the electron transport chain to pump protons out of the 
mitochondrial matrix into the intermembrane space (Hatefi 1985, Wallace an Starkov 2000, 
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phosphorylation, utilises the electrochemical gradient produced to transfer protons from the 
intermembrane space back into the mitochondrial matrix. The energy released from this 
action is used to phosphorylate ADP into ATP (Nadanaciva and Will 2011). 
 
1.6 Mechanisms of mitochondrial dysfunction 
There are five main mechanisms that have been associated with the induction of 
mitochondrial dysfunction: inhibition of the electron transport (respiratory) chain, 
uncoupling of oxidative phosphorylation, induction of membrane permeability transition, 
(in)direct inhibition of β-oxidation of mitochondrial fatty acids, and interfering with 
mitochondrial DNA. Chemicals that inhibit the electron transport chain can do so by either 
direct binding to the complexes of the electron transport chain or ATP synthase, or by acting 
as an alternative electron acceptor (Krahenbuhl 2001, Amacher 2005, Chan et al 2005). A 
large number of mitochondrial toxicants have been shown to bind directly to various sites 
within the electron transport chain complexes, e.g. rotenoids. This binding blocks the ability 
of the complex to interchange between the oxidised and reduced state, thus blocking electron 
transfer down the electron transport chain (Krahenbuhl 2001, Amacher 2005, Chan et al 
2005). Additionally, chemicals that are observed to act as alternative electron acceptors 
compete with the natural electron carrier(s), ubiquinone and/or cytochrome c, in order to 
liberate electrons from the electron transport chain in order to reduce themselves (Wallace 
2003). The inhibition of electron flow along the electron transport chain by both of these 
mechanisms induces the formation of reactive oxygen species (Krahenbuhl 2001, Amacher 
2005, Chan et al 2005). The increased production of reactive oxygen species within the 
mitochondrion results in oxidative stress; ultimately, leading to cell death.  
The second mechanism of mitochondrial toxicity is induced by uncoupling of oxidative 
phosphorylation, due to protons re-entering the mitochondrial matrix through the inner 
mitochondrial membrane and bypassing ATP synthase (Wallace and Starkov 2000, Chan et 
al 2005, Naven et al 2013). During uncoupling of oxidative phosphorylation the flow of 
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electrons along the electron transport chain and associated translocation of protons into the 
intermembrane space functions as normal. However, the protons return to the matrix through 
the inner membrane bypassing ATP synthase, resulting in the loss of ATP production. A 
number of studies have proposed a general, protonophoric mechanism via which a 
chemical’s uncoupling action can induce mitochondrial toxicity (Wallace and Starkov 2000, 
Kadenbach 2003, Mehta et al 2008, Naven et al 2013). Uncouplers act by scavenging a 
proton from the intermembrane space, migrating across the inner membrane into the matrix 
due to the membrane potential, where the chemical is deprotonated within the relatively 
more alkaline mitochondrial matrix. The deprotonated chemical can then return to the 
intermembrane space continuing the cycle. This assisted transport of protons back into the 
matrix dissipates the electrochemical potential, resulting in the loss of ATP production and 
ultimately cell death (Terada 1990, Schonfeld et al 1992, Sun and Garlid 1992, Wallace and 
Starkov 2000, Krahenbuhl 2001, Amacher 2005, Chan et al 2005, Spycher et al 2008, Cela 
et al 2010). Many chemicals that act to uncouple oxidative phosphorylation are lipophilic 
weak acids or bases, such as 2,4-dinitrophenol (Wallace and Starkov 2000, Krahenbuhl 2001, 
Amacher 2005). 
The third mechanism of mitochondrial toxicity is the induction of the membrane 
permeability transition. The membrane permeability transition is an increase in the 
permeability of the inner mitochondrial membrane to low molecular weight solutes 
(<1500Da), which leads to a disruption of the electron transport chain, loss of membrane 
potential, and swelling of both the inner- and outer mitochondrial membranes (Kroemer et al 
2007, Lemasters et al 2009). It is believed the membrane permeability transition is induced 
by the formation and opening of the membrane permeability transition pore. The membrane 
permeability transition pore is a mega channel complex consisting of at least three proteins - 
voltage-dependent anion channel, adenine nucleotide translocator, and cyclophilin D - that 
spans both of the mitochondrial membranes. 
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The fourth mechanism is that of (in)direct inhibition of β-oxidation of mitochondrial fatty 
acids (Krahenbuhl 2001, Amacher 2005). Fatty acid β-oxidation is the multi-step process of 
breaking down fatty acids into Acetyl Co-A, which can then be used by the citric acid cycle 
to reduce NAD+ and FAD into NADH and FADH2. Inhibition of this process reduces the 
amount of NADH and FADH2 available for oxidative phosphorylation and, therefore, 
reduces ATP production. In addition, because fatty acids are not broken down by the fatty 
acid cycle, they accumulate within cells inducing toxicity such as hepatic steatosis (Jaeschke 
et al 2002, Pessayre et al 2008). 
The final mechanism involves interfering with mitochondrial DNA, for example by 
inhibition of mitochondrial DNA replication, impairing mitochondrial DNA stability or 
inhibiting mitochondrial DNA transcription (Amacher 2005, Pessayre et al 2008). As 
mitochondrial DNA encodes for 13 components of the electron transport chain, damage that 
occurs to mitochondrial DNA can have a wide variety of downstream effects depending 
upon where it occurs. For example, if the damage leads to ill-formed respiratory chain 
complexes, electron flow can be inhibited leading to a decrease in the production of ATP 
and could ultimately lead to cell death (Pessayre et al 2008). Given the almost ubiquitous 
distribution of mitochondria throughout the body, and the central role mitochondria play in 
regulating normal physiological functioning, it is perhaps not surprising that mitochondrial 
dysfunction has been suggested as the cause of toxicity within a multitude of organs 
(Amacher 2005, Dykens and Will 2007, Dykens and Will 2008, Nadanaciva and Will 2011, 
Pessayre et al 2012).  
 
1.7 SEURAT-1 and the COSMOS project 
In January 2011, as the final deadline for the Cosmetic  irective’s 7th amendment 
approached, a cluster of European Union projects known as SEURAT-1 (Safety Evaluation 
Ultimately Replacing Animal Testing) was initiated. SEURAT-1 is a collaboration of six 
research projects, and one co-ordination project, combining the efforts from over 70 
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European universities, research institutes and commercial companies from across the EU 
and US. The five-year goal of SEURAT-1 is the development of solutions for the 
replacement of current in vivo repeat-dose toxicity testing with suitable in vitro and in silico 
alternatives. One of the six research projects that form SEURAT-1 is COSMOS. The 
COSMOS project is jointly funded by both the 7th Framework Programme of the European 
Commission and Cosmetics Europe, the industry’s trade association for cosmetics, toiletries 
and perfumes. The main objectives of COSMOS are: 
 The collation and curation of new sources of toxicological data from regulatory 
sources and the literature; 
 The creation of an inventory of cosmetic ingredients, populated with chemical 
structures and toxicological data; and 
 The development of freely available and accessible computational models to assist 
with predicting the repeated dose toxicity of cosmetic ingredients towards humans. 
Together, the COSMOS project and collaborators within the SEURAT-1 cluster are part of 
the largest effort to develop alternative tools to help in the safety assessment of chemicals 
(with a focus on cosmetics related chemicals) within the EU. It is envisaged that these tools 
could be implemented as a partial replacement of in vivo repeat-dose testing. Additionally, 
the outcomes of each of the six research projects are thought to be able to provide a 
foundation on which further investigation, and development, surrounding alternative tools 
and techniques may be made. This PhD project whilst falling under the aims of the 
COSMOS projects supports the general ethos of the SEURAT-1 cluster by providing 
frameworks, and tools, for read-across. 
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1.8 Research aims of this thesis 
In keeping with the research aims of the COSMOS project, the overall aim of this thesis was 
to develop an in silico profiler to assist in the safety assessment of repeated dose exposure of 
cosmetic ingredients to humans. The specific objectives to achieve this aim were to: 
i. Collate toxicological data from regulatory submissions for use within the COSMOS 
database. 
 A standard operating procedure, developed by colleagues from the 
COSMOS project, is described in detail in Chapter 2. This approach was 
followed to extract data from EU regulatory submissions and input into the 
ToxRefDB data entry system, ready for upload into the COSMOS database; 
 
ii. The development of chemistry-based structural alerts that can be used for 
prioritising chemicals for mitochondrial toxicity. 
 The ChemoTyper software was utilised in Chapter 3 to identify structural 
fragments, present within a data set from the available literature, associated 
with mitochondrial toxicity. Subsequently, these structural fragments were 
used in order to develop chemistry-based alerts; 
 
iii. Utilise qualitative mitochondrial toxicity data in order to identify, and develop, 
mechanism-based structural alerts for use in category formation.  
 The data set used in Chapter 3 underwent structural similarity, and 
subsequent mechanistic, analysis in Chapter 4 in order to develop 
additional mechanism-based structural alerts. This analysis was performed 
to demonstrate the various approaches that can be used on the same data set 
to identify structural alerts; 
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iv. Demonstrate how repeat dose toxicity data, from regulatory submissions, can be 
used to develop structural alerts capable of category formation. 
 The regulatory submission documents contain many valuable toxicological 
data. Therefore, in Chapter 5, it was demonstrated that data for a variety of 
chemicals used within hair dye products could be utilised to hypothesise 
and develop mechanism-based structural alerts; 
 
v. Show how in vitro and in chemico experimental data can be used in the 
identification and verification of the chemical domain of structural alerts. 
 After the development of structural alerts it is necessary that they be 
verified. Chapter 6 outlines an approach, using structural alerts related to 
protein binding and in vitro and in chemico assay results, which may be 
used to verify, and further refine, previously developed structural alerts. 
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Chapter 2: Extraction and collation of repeat dose toxicity data from Scientific 
Committee on Consumer Safety reports into the COSMOS database 
 
2.1 Introduction 
The availability of, ideally, high quality data relating to chemical(s) of interest is a 
prerequisite for undertaking any in silico modelling. In silico models can be developed for a 
multitude of endpoints as long as reliable data are available (Cronin 2010). The type of data 
that are required is wholly dependent on the endpoint under investigation and the type of 
model being developed. These data can be split into three broad categories: data relating to 
the identity and structure of the chemical, e.g. CAS number, chemical name, pictorial 
representation; data relating to the physico-chemical properties of the chemical, e.g. octanol-
water partition coefficient, molecular weight, surface area; and toxicity data relating to the 
activity of the chemical in biological systems and/or assays. These toxicity data can be 
further subcategorised as being either quantitative, i.e. identifying the concentration at which 
an effect is seen, or qualitative, i.e. identifying the presence or absence of an effect. There 
are a number of ways in which these toxicological data can be utilised in the context of in 
silico approaches, such as the development of a (Q)SAR, as a component of an integrated 
testing strategy, in the development of a profiler, in category formation and/or read-across. 
An in silico profiler is considered to be a collection of structural alerts that relate to the same 
outcome. These approaches are discussed in more detail in Chapter 1. The type of data that 
are required differs depending upon the approach being employed. For example, a 
‘traditional’ (Q)SAR will require a set of continuous quantitative data. Whereas, in the 
development of a profiler, i.e. a tool that enables the identification of a Molecular Initiating 
Event associated with a specific endpoint (Chapters 1, 3, 4, and 5), that can be used to screen 
for a certain endpoint, or organ level toxicity, then a set of qualitative data can be used. In 
order for these data to be useful for both hazard/risk assessment and modelling purposes 
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they should, ideally, be of high quality. This is due to the fact that the reliability of a 
prediction made by an in silico model can only be as good as the data used in the model’s 
development, i.e. a high quality prediction cannot be derived from low quality data. A 
number of schemes have been developed to help assess data quality, with the scheme set out 
by Klimisch et al (1997) becoming the most widely used (Przybylak et al 2012). Under the 
Klimisch scheme the assessment of data quality falls under three headings; adequacy, 
relevance and reliability; these were defined by Klimisch as (Klimisch et al 1997):- 
 Adequacy – the definition of the usefulness of data for hazard/risk assessment 
purposes. When there is more than one set of data for each effect, the greatest 
weight is attached to the most reliable and relevant 
 Relevance – the extent to which data and/or tests are appropriate for particular 
hazard identification or risk characterisation 
 Reliability – evaluation of the inherent quality of a test report or publication relating 
to preferably standardised methodology and the way the experimental procedure and 
results are described to give evidence of the clarity and plausibility of the findings 
Both the relevance and adequacy of data are context dependent, i.e. relevance identifies if 
data generated are appropriate for the endpoint of interest (for example the use of a protein 
binding assay to test for the potential for skin sensitisation), whilst adequacy identifies if 
data can be used to help inform a risk assessment decision. In contrast, reliability only 
identifies if the data are plausible in terms of the specific experimental procedure carried out. 
The final outcome of the Klimisch scheme is the assignment of the data to one of four 
categories for reliability (Table 2.1). 
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Table 2.1: Reliability categories as defined by Klimisch et al (1997) 
Code Category 
1 Reliable without restriction 
“Studies or data from the literature or reports which were carried out or generated 
according to generally valid and/or internationally accepted testing guidelines 
(preferably performed according to GLP) or in which the test parameters 
documented are based on a specific (national) testing guideline (preferably 
performed to GLP) or in which all parameters described are closely 
related comparable to a guideline method.” 
2 Reliable with restriction 
“Studies or data from the literature, reports (mostly not performed according to 
GLP), in which the test parameters documented do not totally comply with the 
specific testing guideline, but are sufficient to accept the data or in which 
investigations are described which cannot be subsumed under a testing guideline, 
but which are nevertheless well documented and scientifically acceptable.” 
3 Not reliable 
“Studies or data from the literature/reports in which there are interferences 
between measuring system and the test substance or in which organisms/test 
systems were used which are not relevant in relation to the exposure (e.g. 
unphysiologic pathways of application) or which were carried out or generated 
according to a method which is not acceptable, the documentation of which is not 
sufficient for an assessment and which is not convincing for an expert 
judgement.” 
4 Not assignable 
“Studies or data from the literature, which do not give sufficient experimental 
details and which are only listed in short abstracts or secondary literature (books, 
reviews, etc.)” 
 
In order to undertake any of the in silico approaches mentioned above, or discussed in 
Chapter 1, one of the preliminary steps is to identify relevant sources of available data, 
which fall under two headings; in-house and publically available (Madden 2013). In-house 
data sources are those held by private companies and, as such, are not readily available to 
those outside of these companies. Alternatively, there is an abundance of publically 
available data sources that hold a variety of toxicological information including:  
 The scientific literature, whereby journal articles may contain toxicological 
information for one, or many, chemical(s). These articles may contain data for 
chemicals carried out at one laboratory as a series of interlinked studies within a 
specific assay, or they may provide a compilation of data extracted from various 
articles; 
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 Internet resources that have collated a number of QSAR and/or toxicity datasets, 
such as the Cheminformatics and QSAR Society (www.qsar.org), which provides 
links to an array of available data sets. These resources can be useful for modelling 
purposes as the data they contain are often times well curated; and 
 Regulatory submissions, such as those submitted to the European Chemicals Agency 
(ECHA) or the Scientific Committee on Consumer Safety (SCCS). Both of which 
provide information regarding a chemical’s toxicity profile in a variety of different 
assays. The information provided by ECHA is as an online dossier summarising the 
studies undertaken and their results, whilst the SCCS provide the chemical 
information as a downloadable PDF. 
Whilst these are very useful sources of toxicological data one challenge of these data sources 
is the perception of a ‘lack of data’ (Yang et al 2006, Richard et al 2008). This ‘lack of data’ 
covers both the fragmentation of toxicological data across these data sources, and that the 
data are not usually structured in a manner that enables them to be readily utilised for 
modelling purposes, i.e. the information is usually contained as free-form text (Cronin 2002, 
Myshkin et al 2012). Free-form text is words and sentences whereby any character can be 
input by the user. The use of free-form text, within a toxicological database, does not lend 
itself well to searching and modelling purposes. This is because multiple words could be 
used to describe the same toxicological effect, e.g. hypersalivation or ptyalism. Therefore, 
collating toxicological information from these sources can be a time consuming process. To 
overcome this issue, over the past decade, there has been an increase in the compilation of 
toxicity data for the development of toxicity databases.  
A toxicity database is a large, organised set of data regarding the toxicity profile for certain 
endpoint(s) of interest that are associated with a chemical structure (Valerio Jr. 2009). These 
data should be held in an electronic, and searchable, format utilising both a controlled 
vocabulary and ontology (Yang et al 2006). In this instance, i.e. in a toxicity database, a 
controlled vocabulary is a way of collating multiple terms for the same effect under one 
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phrase, for example collating fatty liver, hepatic steatosis and non-alcoholic fatty liver under 
the term liver steatosis. The use of a controlled vocabulary enables one search to be 
undertaken to retrieve information that would, otherwise, require the use of multiple search 
terms. This is an important advantage as it only requires the end user to know one search 
term, rather than attempting to identify all possible terms for a toxicological effect in order 
not to miss chemicals held in the database. Ontology, meanwhile, is used to identify the 
hierarchical relationship between the data at various levels within a database (Yang et al 
2006, Bard 2007, Richard et al 2008). This provides a foundation to organise and 
standardise the chemical and toxicological data and how it relates across various aspects of 
the database, thereby facilitating easier data retrieval (Hardy et al 2012). Another advantage 
of ontology use is that it enables the unification of data extracted from multiple sources. The 
classification of the different regions within the liver - i.e. the centrilobular, midzonal, and 
periportal lobules - is an example of an anatomical ontology. This type of anatomical 
ontology serves to organise information with regards to the hierarchy of structures within an 
organ.  
A number of freely available, and commercial, toxicity databases and datasets covering a 
wide variety of toxicological endpoints are highlighted in Table 2.2. However, it should be 
noted that due to the plethora of databases and datasets available this is not an exhaustive list. 
As the descriptions in Table 2.2 show, each of the databases and datasets listed holds 
information pertaining to a variety of toxicities at either the organ or organism level. For 
example, the TETRATOX dataset (available at 
http://www.vet.utk.edu/TETRATOX/index.php, accessed 17.11.2014) contains toxicity 
potency, i.e. 50% inhibition growth concentration, information from a single laboratory, 
acute toxicity studies performed at the University of Tennessee (Schultz 1997). The 
advantage of studies performed at the same laboratory is that if the experiments are 
replicated the results are more likely to be consistent than if they were undertaken at 
multiple laboratories, i.e. they have a high level of repeatability. A previous study by Hewitt 
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and colleagues (Hewitt et al 2011) demonstrated that the data generated by the TETRATOX 
assay are of a very high quality, due to the high level of repeatability between replicates, i.e. 
there is a low level of variability in the data the assay generates. This high level of data 
quality has led to the TETRATOX dataset, and the information it contains, being utilised in 
the development of a variety of in silico approaches, such as the development of (Q)SARs, 
and the identification and verification of structural alerts (Schultz et al 2007, Ellison et al 
2008, Nelms et al 2013, Richarz et al 2013, Rodriguez-Sanchez et al 2013). Generally, 
sources of acute toxicity data are more abundant than those for repeat dose toxicity. The 
reason for this disparity is due to the extra time, money, and animal usage that are required 
to perform a repeat dose toxicity study. For example, using information from one laboratory, 
an acute oral toxicity study, following OECD test guideline 425, uses a maximum of five 
animals and costs approximately $1700. In comparison, to undertake a 90-day oral toxicity 
study, according to OECD test guideline 408, uses at least 80 rats (10 rats/sex/group, four 
groups needed) and costs approximately $164,000. The substantial difference in these three 
factors makes it difficult to justify performing multiple repeat dose studies. Therefore, 
outside of the repeat dose databases held by pharmaceutical companies, there are relatively 
fewer freely, and commercially, available databases that contain repeated dose toxicity 
testing information. Generally these databases include, but are not limited to, No Observable 
(Adverse) Effect Level (NO(A)EL) and/or Lowest Observable (Adverse) Effect Level 
(LO(A)EL) data. Of the databases highlighted in Table 2.2 several are commercially 
available and contain a number of repeat dose toxicity data, for example Leadscope 
(www.leadscope.com). There are a number of advantages to using commercial databases, 
one of the most important, in terms of predictive toxicology, is that of data curation and 
quality checking, i.e. data contained within a commercial database should be highly curated 
and have undergone quality assessment. Another advantage is that the database may contain 
a large number of toxicity data that may not be freely available in the public domain. 
Additionally, as professional products, the databases themselves are usually well-supported 
and the data held by the database are updated. However, as these are commercial endeavours, 
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a disadvantage of these databases is that gaining access to the information held within can, 
potentially, be quite expensive. In contrast, the main advantage of freely available databases, 
as their name suggests, is that the information they contain is freely accessible. The main 
disadvantages of this class of databases are that 1) the data may not have undergone curation 
or quality checking, and 2) it may be that only information relating to one chemical at a time 
can be searched, making extracting a dataset of usable data for modelling purposes a time 
consuming process. It should also be noted that whilst the majority of repeat dose toxicity 
databases contain NO(A)EL and/or LO(A)EL data, only a limited number also contain organ 
level effect data associated with the LO(A)EL value, for example Fraunhofer RepDose and 
Leadscope (Bitsch et al 2006). This scarcity of available databases, which are able to link 
chemical structure to an adverse effect within a specific organ, represents one of the key 
problems of modelling repeat dose toxicity data. 
Without the presence of organ level data, no association can be made between the LO(A)EL 
and the organ that has been affected. This presents a problem when attempting to identify, 
and link, structural features of a chemical that are associated with certain adverse effects (e.g. 
liver fibrosis or kidney necrosis). To overcome this problem, one of the main goals of the 
COSMOS project (discussed in Chapter 1) is the development of a single, comprehensive, 
and freely available database that links chemical structure to repeat dose toxicity data, 
including organ level toxicity data. The inclusion of the organ level data provides modellers 
with an extremely useful tool that can be used to undertake a variety of in silico approaches. 
 n addition, novel repeat dose toxicity data have been extracted from ‘Opinions On’ reports 
submitted to the Scientific Committee on Consumer Safety1 (SCCS), and used to create the 
oral repeat dose toxicity (oRepeatToxDB) dataset that constitutes part of the COSMOS 
database. This enables the COSMOS database to be used for a variety of in silico approaches, 
such as; data mining, the development of mechanism based models, grouping chemicals and 
developing categories for use in read-across and to build profilers.  These reports consist of a 
number of different toxicity studies, including acute, (sub)chronic, and developmental 
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toxicity, that have been undertaken for a specific chemical and submitted to the SCCS in 
order for a health and safety assessment to be carried out. The SCCS reports are an 
extremely useful source of repeat dose toxicity data as they provide detailed information on 
the study design, test substance, species the test was performed on, dosage levels, and route 
of administration. Possibly the most important information, from a modelling perspective, 
contained in the reports is the detailed organ level results observed at the different dosage 
levels. Therefore, as the extraction of this information was carried out by several people 
from the COSMOS consortium, in order to be consistent it was crucial that a standard 
operating procedure was followed. In the context of data extraction from the SCCS reports, 
the standard operating procedure was used to ensure the same level of information was 
extracted from each report. 
The primary aim of this chapter is to describe how the extraction of the data held in the 
SCCS reports was carried out and entered into the data entry system of the oRepeatTox 
dataset. In addition, the secondary aim of this chapter is to demonstrate one application of 
the COSMOS database, i.e. exploiting the 28- and 90-day toxicity data for chemicals in 
order to ascertain whether data gathered from a 28-day study would negate the need to 
undergo a 90-day, thereby reducing animal usage. 
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Table 2.2: A list of freely, and commercially, available databases containing toxicity data (adapted from Madden 2013) 
Available database Description Reference 
Birth Defects Systems 
Manager (BDSM) 
Open-source software to consolidate information regarding developmental toxicity http://systemsanalysis.louisville.edu/ 
Carcinogenic Potency 
Database 
Contains standardised information regarding carcinogenic bioassay results for over 
6,500 chronic animal cancer tests performed on over 1,500 chemicals held in the 
available literature 
http://toxnet.nlm.nih.gov/cgi-
bin/sis/htmlgen?CPDB.htm 
ChEMBL Database containing data for over 12 million activities and 1 million assays for over 
1.36 million chemicals. An attempt has been made by the developers to standardise the 
information contained in ChEMBL. 
https://www.ebi.ac.uk/chembl/ 
ChemIDPlus Web-based database containing information, including physico-chemical and toxicity 
information on over 400,000 chemicals 
http://chem.sis.nlm.nih.gov/chemidpl
us/ 
ChemSpider An amalgamation of data from over 450 data sources and for more than 30 million 
unique structures, providing physico-chemical information and toxicological data from 
various species and different routes of administration 
http://www.chemspider.com 
COSMOSdb Freely available database containing over 81,000 chemical records and over 44,500 
unique chemical structures. Also contains two datasets (US FDA PAFA and 
oRepeatToxDB) that hold information for 12,538 toxicological studies across 27 
endpoints for 1,660 compounds. 
http://cosmosdb.cosmostox.eu/ 
DevTox Standardises terminology used to describe developmental toxicities and provides a 
historical control database of developmental toxicity studies 
http://www.devtox.org/datintro.htm 
Drugs@FDA US FDA-approved drug products http://www.fda.gov/Drugs/Informatio
nOnDrugs/ucm135821.htm 
DSSTox US EPA Distributed Structure-Searchable Toxicity database provides a ‘public forum 
for publishing downloadable, structure-searchable, standardized chemical structure 
files associated with chemical inventories or toxicity data sets of environmental 
relevance’ 
http://www.epa.gov/ncct/dsstox/ 
ECOTOX US EPA database of single chemical toxicity information for aquatic and terrestrial life http://cfpub.epa.gov/ecotox/ 
eTox The eTox project is developing a drug safety database from pharmaceutical 
industry legacy toxicology reports and public toxicology data 
www.etoxproject.eu/ 
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Fraunhofer RepDose Repeated Dose toxicity is a relational database containing more than 2,200 studies on 
subacute to chronic toxicity within a variety of routes of administration for about 650 
chemicals. 
http://www.fraunhofer-repdose.de/ 
HESS Hazard Evaluation Support System contains information regarding repeat dose toxicity 
and toxicity mechanisms. Also supports the evaluation of repeat dose toxicity by 
utilising category formation 
http://www.safe.nite.go.jp/english/kas
inn/qsar/hess-e.html 
IRIS Integrated Risk Information System is an aggregation of electronic reports on 
environmental substances and their potential to cause human health effects 
http://cfpub.epa.gov/ncea/iris/index.cf
m 
ITER International Toxicity Estimates for Risk Assessment is a database of human health 
risk values and cancer classifications for over 680 chemicals of environmental concern 
http://www.tera.org/iter/ 
Leadscope Provides commercial databases containing over 400,000 results covering acute, (sub-) 
chronic, carcinogenicity, genotoxicity, and reproductive toxicity studies for nearly 
180,000 chemicals 
http://www.leadscope.com/toxicity_d
atabases/ 
MDL Toxicity database A commercially available structure-searchable database containing data from both in 
vitro and in vivo studies covering acute, carcinogenicity, mutagenicity and reproductive 
toxicity studies for over 150,000 chemicals. Also includes information from Registry 
of Toxic Effects of Chemical Substances (RTECS) 
http://www.iop.vast.ac.vn/theor/confe
rences/smp/1st/kaminuma/ChemDra
w/toxicity.html 
NTP National Toxicology Program provides information of agents registered in the US that 
are of public interest 
http://ntp.niehs.nih.gov/ 
OECD eChemPortal Access to information on physico-chemical properties, environmental fate and toxicity webnet3.oecd.org/echemportal/ 
OECD QSAR Toolbox The Toolbox is a software application that incorporates data from various data sources 
for a variety of human health and environmental endpoints. For example it contains 
repeat dose toxicity information from Fraunhofer RepDose, HESS and ToxRefDB. 
http://www.qsartoolbox.org 
OSIRIS The OSIRIS project collated data on aquatic toxicity, carcinogenicity, mutagenicity and 
repeat dose toxicity 
www.osiris.ufz.de 
Tox21 US EPA Tox21 is currently screening over 10,000 chemicals at the National Institutes 
of Health using the ToxCast high throughput screening assays to provide risk assessors 
with data for use when making decisions about protecting human health and the 
environment 
http://www.epa.gov/ncct/Tox21/ 
ToxCast US EPA is using various high throughput screening assays to measure changes in 
biological activity. Currently ToxCast has evaluated over 2,000 chemicals within over 
http://www.epa.gov/ncct/toxcast/ 
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700 high throughput assay covering roughly 300 signalling pathways 
ToxRefDB Contains information of over 30 years and $2 billion worth of historical in vivo study 
results including acute, (sub-)chronic, developmental and reproductive endpoints for 
474 chemicals ToxRefDB also links with both ACToR and ToxCast databases. 
http://www.epa.gov/ncct/toxrefdb/ 
TETRATOX A collection of acute aquatic potency data for more than 2,400 industrial organic 
chemicals 
http://www.vet.utk.edu/TETRATOX/
index.php 
TOXNET US National Library of Medicine Toxicology Data Network is a group of databases 
covering chemicals and drug, environmental health, occupational safety, risk 
assessment and regulations, and toxicology  
http://toxnet.nlm.nih.gov/ 
US EPA ACToR Aggregation of data from over 1,000 public sources for over 500,000 environmental 
chemicals. Contains chemical structure, physico-chemical properties, and in vitro assay 
and in vivo toxicology data 
http://actor.epa.gov/actor/faces/ACTo
RHome.jsp 
US FDA Chemical 
Estimation Risk Evaluation 
System (CERES) 
A centralised, sustainable data management, and storage, system that will provide 
support in decision making for both pre- and post-market safety assessment for food 
ingredients and food contact substances. 
http://www.accessdata.fda.gov/FDAT
rack/track-
proj?program=cfsan&id=CFSAN-
OFAS-Chemical-Evaluation-and-
Risk-Estimation-System 
VITIC Nexus A not for profit database and information management system providing information 
for a variety of toxicological endpoints including carcinogenicity, mutagenicity, and 
hepatotoxicity 
http://www.lhasalimited.org/products
/vitic-nexus.htm 
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2.2 Method 
The harvesting of data from the SCC(NF)P/SCCS reports, recording of data using the 
ToxRefDB data entry tool, and collation of data into a Microsoft Excel spreadsheet, were 
performed by the current author and collaborators from the COSMOS project, using the 
standard operating procedures developed by Chihae Yang (Altamira, LLC) and Vessela 
Vitcheva (Medical University Sofia, Bulgaria), which are described below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Workflow identifying the key steps in the standard operating procedure for 
repeat dose data collection. 
 
The workflow above (Figure 2.1) outlines the key steps in the standard operating procedure 
for repeat dose data collection. The first stage is the identification of the study producing the 
NO(A)EL in the most recent SCC(NF)  SCCS ‘Opinion On’ report for the chemical in 
question. It is important to use the latest report as new studies performed may have a new 
NO(A)EL value or extra information in them. The second stage is to input the study and 
1. Data harvesting from 
SCC(NF)  SCCS ‘Opinion On’ report 
2. Input information in Microsoft Excel 
spreadsheet 
3. Input study information into 
ToxRefDB 
4. Input treatment group information into 
ToxRefDB 
5. Input toxicological information into 
ToxRefDB 
 Chapter 2 
 
36 
 
NO(A)EL/LO(A)EL information into the relevant tabs in the Microsoft Excel spreadsheet. 
Subsequently, the study, treatment group and toxicological effect information were each 
input separately into the ToxRefDB data entry system. It is important that the data entry 
system be used to populate the oRepeatTox database as it provides a process by which data 
harvesters can input the information in a systematic way. In addition, the controlled 
vocabulary for the input of the toxicological effects ensures consistency when inputting the 
same effect, which may have multiple terms, under one phrase. This allows for easier 
searching of the database by the end user as only one search term needs to be known, and 
utilised, in order to identify all chemicals with data to the specific effect. In total, the 
SCC(NF)P/SCCS reports for 154 chemicals were used for data mining purposes in order to 
extract the NO(A)EL, LO(A)EL (if present), and the adverse effects observed at the 
LO(A)EL. The majority of these chemicals were organic chemicals used in hair dyes, with a 
smaller proportion being used in sunscreens and as preservatives. These 154 chemicals were 
divided amongst three researchers, including the current author, each of whom was given 
approximately 45 reports to harvest. Within this chapter the chemical ‘3-aminophenol’ will 
be used as an example of how the standard operating procedure was utilised (Figure 2.2) 
(SCCP 2006).  
 
 
Figure 2.2: Structure of 3-aminophenol 
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Step 1 Data harvesting from the SCC(NF)P/SCCS ‘Opinion On’ reports 
The following steps were undertaken to extract the NO(A)EL and LO(A)EL values, as 
well as the adverse effects associated with the LO(A)EL and other dose values. 
 
Step 1.1 Identification of the NO(A)EL and/or LO(A)EL values 
Upon finding the most recent SCC(NF)P/SCCS report for the chemical in question the 
first requirement was to identify the study that provided the NO(A)EL/LO(A)EL value. 
This information is usually provided under the heading “Safety evaluation (including 
calculation of the MoS)” present towards the end of the report (Figure 2.3). 
 
Step 1.2 Identification of the study report used to generate the NO(A)EL/LO(A)EL 
The information in parentheses (circled red in Figure 2.3) was used to identify the type 
of study that generated the NO(A)EL/LO(A)EL value, it was then required that this 
study be found within the report. It should be noted that only studies undertaken via the 
oral route of administration were used. 
 
Step 1.3 Extraction of data from the study report 
Upon finding the study report that generated the NO(A)EL value, the information 
contained within it was extracted. The information that was extracted included, but was 
not limited to: study type, study duration, dosage levels, and effects noted at each dosage 
level. This information was then entered into both the Excel spreadsheet and the 
Toxicity Reference DataBase (ToxRefDB) data entry tool, which are described below. 
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Figure 2.3: The ‘Safety evaluation’ section for 3-aminophenol extracted from the associated 
SCC  ‘Opinion On’ report 
 
Step 2 Data recording in Microsoft Excel spreadsheet 
The following steps were undertaken to input the information retrieved from the 
SCC(NF)P/SCCS report into a Microsoft Excel spreadsheet. The spreadsheet contained three 
datasheets; ‘study info’, ‘noael_loael’, and ‘reference’; where information provided by the 
report could be input. 
 
Step 2.1 Input of information into ‘study info’ datasheet 
The first datasheet was designed to capture information pertaining to the study from which 
the NO(A)EL/LO(A)EL was derived. The information to be input into this tab included: the 
study title, species of animal used, duration of study, route of administration, dose range, 
purity, Klimisch score if present in document, whether study was GLP compliant or not, and 
if a study guideline was followed. 
 
Step 2.2 Input of information into ‘noael_loael’ datasheet 
The second datasheet was designed for the input of data regarding the NO(A)EL and 
LO(A)EL of the study. The information to be input into this tab included: the source 
document, the NO(A)EL identified by the SCCS for use within the safety evaluation, the 
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LO(A)EL of the study (if one could be identified), the target organ, the critical effects 
observed at the LO(A)EL, and any comments regarding the NO(A)EL/LO(A)EL value. 
 
Step 2.3 Input of information into ‘reference’ datasheet 
The final datasheet was designed for the input of data regarding the reference of the study. 
The information to be input into this tab included: the type of reference the data were 
extracted from (e.g. regulatory document), the author of the study, the journal title, the study 
title, the volume and issue number, the start page, the year of publication, the document 
source, the report number, the year the study was conducted, the laboratory that performed 
the study, and if the data were extracted from a book the book title, chapter and publisher 
were required. 
 
Step 3 Data recording in ToxRefDB data entry tool 
The following steps were undertaken to input the information extracted from step one into 
the ToxRefDB data entry tool. The data entry tool was used so that all the information was 
input consistently, and so that the controlled vocabulary held within ToxRefDB could be 
utilised to build a consistent and more easily searchable database. The main page of the data 
entry tool required information pertaining to (Figure 2.4): 
 
Step 3.1 Study identifiers 
 Document source (SCCP) 
 Document number (SCCP/0978/06) 
 The year the study was performed (1996) 
 The data usability (OECD Guideline) 
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Step 3.2 Test material information 
 Chemical name (3-aminophenol) 
 Purity percentage (100%) 
 Lot/batch number (4090202) 
 Test material comment (parent compound) 
Step 3.3 Study type 
 Type of study used (subchronic) 
 Study duration (90 days) 
Step 3.4 Animal dose information 
 Species (rat) 
 Strain (Sprague Dawley) 
 Route of administration (gavage/intubation) 
 Comments, information of dose, vehicle (Doses: 20, 70, 200, 600 mg/kg 
bw/day. Vehicle: 0.5% methylcellulose solution and 1% d-iso-ascorbic acid) 
Step 3.5 Treatment group list 
 Information regarding treatment groups and associated effects (described in 
more detail below) 
Step 3.6 Reference 
 The reference given in the report for the study in question 
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Figure 2.4: Study information required to be input into main page of ToxRefDB data entry 
system 
 
Step 4 Entering treatment group and toxicological effect level information 
These steps were undertaken in order to input the toxicological information at each dosage 
as described within the study; thereby, associating the toxicological information with the 
chemical structure 
 
Step 4.1 Populating treatment group form 
In order to populate the Treatment Group list the Excel Treatment Group Form 
hyperlink was pressed (circled red in Figure 2.5), opening the Excel Treatment Group 
form table. Within this table information related to the gender, dosing period, dose given, 
dose duration and number of treatment animals were input, if available within the study 
description (Figure 2.6). 
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Figure 2.5: Hyperlink used to open the Excel treatment group form table (circled in red). 
 
 
Figure 2.6: Excel table completed with treatment group information relating to 3-
aminophenol 
 
Step 4.2 Inserting treatment group information into Bulk Upload table 
Once all the available treatment information had been entered into the Excel Treatment 
Group Form table it was copied, and pasted, into the Bulk Upload table (Figure 2.7). The 
Bulk Upload table was opened by pressing the Bulk Upload button present on the main 
page of the data entry tool (circled red in Figure 2.8). 
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Figure 2.7: Bulk upload table where the treatment group information is pasted before being 
uploaded to the main page of ToxRefDB 
 
 
Figure 2.8: The buttons that were pressed in order to open the Bulk Upload table (circled in 
red) and to update the Treatment Group List (circled in black) 
 
 
Step 4.3 Updating ‘Treatment Group list’ on the main page 
After the information had been copied into the Bulk Upload table the Upload Treatment 
Groups button was pressed (circled red in Figure 2.7). Subsequently, pressing the Update 
list button on the main page uploaded into the Treatment Group list information onto the 
main page (circled black in Figure 2.8). After the Treatment Group list table was 
populated the effects noted within the study could be added. 
 
Step 4.4 Inserting toxicological effects 
The Study Effect list table was opened, by pressing the Study Effect List button on the 
main page, and the information about each dose group was checked to make sure it was 
correct before proceeding further. 
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Step 4.4.1 Entering effect type information 
To input the effect level data the first step was to choose an effect from the study report and 
identify it within the drop down list under Effect Type Target, e.g. ‘ n-Life Observations’ 
(Figure 2.9). The second drop down list underneath Effect Type Target was used to identify 
the organ affected (for local effects) or to further refine the effect type (for systemic effects), 
e.g. ‘Body Weight’.  
 
 
Figure 2.9: The drop down menu showing the categories of effects under the ‘Effect 
Type_Target’ heading 
 
Step 4.4.2 Entering target site information 
If the effect was observed within a specific region of an organ the Target Site drop down 
menu could be used to further refine where the observation was made within the organ. 
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Step 4.4.3 Entering effect description and direction of change 
Next, in the drop down menu under Effect Description the specific effect discussed in the 
study report was chosen, e.g. ‘Body Weight  ain,’ the direction of change for the effect was 
then picked up in the adjacent drop down menu, e.g. ‘ ecrease’ (Figure 2.10). 
 
Figure 2.10: Entering effect description and direction of change information 
 
Step 4.4.4 Applying information to treatment groups 
Once all of the above information related to the effect was identified, using the drop down 
menus, the treatment group(s) with which this effect was associated was highlighted and the 
Apply button was pressed (circled red in Figure 2.10). 
This procedure was followed for every effect and every direction within the study report. It 
should be noted that if there was no change for a particular effect for all treatment groups the 
effect was still included in the Study Effect list table. After entering all effects described in 
the study report the Treatment Group list table was closed. 
 
Step 5 Entering the statistical significance and treatment relationship 
The steps below were undertaken in order to input the information regarding whether or not 
an effect, for a particular dose and gender, was deemed to be statistically significant and/or 
treatment related within the SCC(NF)P/SCCS report.  
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Step 5.1 Opening the effect input form 
Initially, the dose(s) and gender(s) to which a statistically significant and/or treatment related 
effect was observed were identified in the SCC(NF)P/SCCS document, e.g. only males in 
the 600 mg/kg bw/day dose showed a decrease in Body Weight Gain. To input this 
information into the data entry tool the effect type was selected from the drop down menu 
under the heading View or Add Effect Data by Type for the dose and gender in question, 
e.g. ‘ n-Life Observations’ for the males in the 600 mg kg bw day (highlighted in black, 
Figure 2.11). 
 
Figure 2.11: Identification of effect that is statistically significant and/or treatment related 
 
Step 5.2 Identifying the endpoint affected 
Subsequently, the Effect Input form appeared displaying all effects input previously under 
the Effect Description heading, e.g. body weight gain, anaemia, lacrimation, salivation 
(Figure 2.12). For every effect with an associated change it had to be stated, using the Study 
Endpoint drop down menu, which endpoint was affected, e.g. systemic (circled red in 
Figure 2.12). For most effects from (sub)chronic studies the endpoint affected was 
‘systemic’, effects on dams from reproductive and developmental were classed as ‘maternal’ 
and effects affecting reproduction and development were ‘reproductive’ and ‘developmental’ 
respectively. 
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Figure 2.12: The Effect Input form with the Study Endpoint drop down menu circled in red 
 
Step 5.3 Opening add quantitative data table and inputting statistical significance and 
treatment related effect data 
Next, the Add Quantitative Data table was opened by pressing the corresponding button 
(circled red in Figure 2.13). It was within this pop-up table where statistical significance and 
treatment related information were input. If the study report stated the results were 
statistically significant and/or treatment related the blue box under ‘SS’ or ‘TR’ was clicked 
so that a tick-mark was present (circled red in Figure 2.14). The severity of the observed 
change was input in the ‘severity’ box, the ‘comments’ box was used for any additional 
information regarding the effect. After all the information was entered for the first effect 
type the Add Quantitative Data form and Study Effects Input form were closed by 
pressing ‘Finished.’ This procedure was repeated for each dose and gender where a change 
in the effect was observed. 
 
 
Figure 2.13: The button pressed to open the Add Quantitative Data table 
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Figure 2.14: Add Quantitative Data Table used to identify if an effect was statistically 
significant and/or treatment related 
 
This standard operating procedure was followed for each of the 154 chemicals that were 
extracted from the SCC(NF)P/SCCS reports. This procedure has been described in detail so 
as to illustrate the depth of information that has been captured, and reported, for each 
individual chemical. Hence, there is a wealth of detailed, novel information within the 
COSMOS database. The chemical and toxicological data held within the COSMOS database 
can be exploited for many purposes, one such example is that of ascertaining whether results 
from 28 day repeat dose studies were protective of results from 90 day repeat dose studies, 
i.e. if both studies had results at, or above, 1000mg/kg bw/day. This example is discussed in 
more detail below. 
 
2.3 Application of the COSMOS database using 28- and 90-day repeat dose toxicity data 
Whilst the previous section of this chapter discussed how novel toxicological data were 
extracted from regulatory dossiers and entered into the COSMOS database, the remainder of 
this chapter will demonstrate one application of how the data held within the COSMOS 
database can be utilised. 
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2.3.1 Introduction to COSMOS database 
The current release of the COSMOS database provides access to over 12,000 toxicological 
studies covering 27 different endpoints for more than 1,600 chemicals. These studies are 
contained within two separate datasets: the US FDA Priority-based Assessment of Food 
Additives (PAFA) and the oRepeatToxDB. The US FDA PAFA dataset was kindly donated 
to the COSMOS project by the US FDA Office for Food Safety and contains 12,198 studies. 
The oRepeatToxDB, meanwhile, contains data for a variety of toxicological effects from 
340 in vivo repeat dose studies for over 200 chemicals, including those extracted as part of 
the data harvesting process described above. Due to the quantity of toxicity data held in the 
COSMOS database and the presence of results for both 28-day and 90-day repeat dose 
studies therein, researchers at Liverpool John Moores University, including the current 
author, were approached by researchers from the British Union for the Abolition of 
Vivisection (BUAV) and the European Coalition to End Animal Experiments (ECEAE). The 
researchers from BUAV and ECEAE wanted to use this information from repeat dose 
studies in order to ascertain whether the results from 28-day repeat dose studies were 
protective of results from 90-day repeat dose studies. Researchers from both the UK 
Competent Authority for REACH (the Health and Safety Executive) and BUAV have 
previously undertaken similar studies using data from the Notification of New Substances 
(NONS) system and eChemPortal (echemportal.org) respectively (HSE 2011, Taylor et al 
2014). In both instances a No Observed Adverse Effect Level (NOAEL) value of 1000 
mg/kg body weight/day (mg/kg bw/day) was used as a profile for low toxicity. In the context 
of toxicological testing a NOAEL value is considered to be the highest tested dose of a 
chemical at which no adverse effect is observed. Both studies demonstrated that where a 
chemical had a profile of low toxicity in a 28-day repeat dose study it was highly likely that 
the chemical would have a profile of low toxicity in the 90-day repeat dose study, i.e. the 
results of the 28-day study were protective of the 90-day study. Therefore, the aim of this 
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section is to demonstrate one of the uses of the data held within the COSMOS database by 
replicating the studies performed by both the HSE and Taylor et al (2014). 
 
2.3.2 Method 
In order to maintain consistency with the previous studies conducted the method described 
by Taylor et al (2014) was followed as much as possible; this method is described below. 
Step 1.1 Initial selection of the dataset 
A property search of the OEC ’s eChem ortal (www.echemportal.org) was undertaken to 
identify those chemicals for which there was both 28- and 90-day repeat dose data. The 
initial search was undertaken using eChemPortal as performing a property search of the 
ECHA CHEM database was not possible at the time. However, the ECHA CHEM database 
is the main provider of property data to eChemPortal, therefore, a search of eChemPortal 
was effectively a search of the ECHA CHEM database. In order to undertake the search of 
eChemPortal the procedure below was followed: 
1) ‘ roperty search’ was selected 
2) Under the subheading ‘Toxicological information’ ‘repeated dose toxicity:oral’ was 
selected 
3) On the Query Block page that opens the search criteria input included: 
a. Under the ‘Study result type’ dropdown menu only the box marked 
‘experimental result’ was checked 
b. Under the ‘Test guideline,  uideline’ dropdown menu the following boxes 
were checked 
i. EPA OPP 82-1 (90-day oral toxicity) 
ii. EPA OPPTS 870.3100 (90-day oral toxicity in rodents) 
iii. EPA OPPTS 870.3150 (90-day oral toxicity in non-rodents) 
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iv. EPA OTS 798.2650 (90-day oral toxicity in rodents) 
v. EU Method B.26 (sub-chronic oral toxicity test: repeated dose 90-
day oral toxicity study in rodents) 
vi. EU Method B.27 (sub-chronic oral toxicity test: repeated dose 90-
day oral toxicity study in non-rodents) 
vii. OECD guideline 408 (repeated dose 90-day oral toxicity in rodents) 
viii. OECD guideline 409 (repeated dose 90-day oral toxicity in non-
rodents) 
4) The search criteria were then saved by pressing ‘Save’ and the query was 
subsequently executed by pressing ‘Execute Query.’ 
 
Step 1.2 Inclusion criteria 
A manual analysis was then conducted on the initial dataset to identify those chemicals that 
had oral, rat experimental data for both 28- and 90-day studies. This process involved 
opening the hyperlink in the ‘Results’ column for each chemical individually.  n every case 
the results were held in the ECHA CHEM database. Chemicals for which there was no 28- 
or 90-day experimental study data, i.e. read across was used or no studies were included, 
were rejected at this stage. 
 
Step 1.3 Exclusion criteria 
The dataset was then reviewed to exclude all chemicals that had a ‘Key study’ with a No 
Observed Effect Level (NOEL) or NOAEL value of less than 1000mg/kg bw/day. 
Importantly, if a chemical had a NOAEL of 1000mg/kg bw/day but the NOEL value was 
lower these chemicals were also excluded. Additionally, where multiple key studies were 
present a chemical was excluded if any rodent study had a NOAEL below 1000mg/kg 
bw/day. 
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Step 1.4 Quality of data 
Subsequently, the dataset was reviewed to remove those chemicals with poor quality data for 
either the 28- or 90-day studies. The criteria as to what constituted poor quality data, in the 
context of this study, are as follows: 
 Any study which did not follow the OECD (or equivalent) guidelines for 
28- or 90-day repeat dose testing with regards to duration, species, number 
of animals or main parameters measure were excluded. 
 The study was not conducted up to the limit dose of 1000mg/kg bw/day. 
 The study was conducted prior to 1981, as this was when both the OECD 
test guidelines were introduced. 
 A study equivalent to the OECD guidelines but given a Klimisch score of 3 
or 4 for any reason. 
 
Step 1.5 Acute toxicity profile 
Finally, chemicals were excluded if they did not have toxicity data conducted within acute 
toxicity, skin or eye irritation, skin sensitisation, or genotoxicity studies. 
 
However, in order to perform the analysis in this chapter a few minor alterations to the 
method set out by Taylor et al (2014) were required. These alterations were required due to 
the variations in data held within the COSMOS database compared to eChemPortal, these 
being: the extraction of Highest No Effect Level (HNEL) data, as opposed to NOAEL data; 
a study completeness Klimisch score of ‘A, B or C’ (as defined in the COSMOS database) 
was accepted in instances where only one HNEL value was present; and no acute toxicity 
profile was gathered. The alterations were necessary as 1) the current version (v1.0) of the 
COSMOS database does not contain NOAEL data; 2) if more than one HNEL value above 
1000mg/kg bw/day was present the value with the highest Klimisch score was used; and 3) 
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information pertaining to acute toxic, skin/eye irritation, skin sensitisation and/or 
genotoxicity was not available for every chemical. 
 
Step 2 Development of the 28- and 90-day repeat dose study dataset from the COSMOS 
database 
The initial search of the COSMOS database was undertaken using the search term ‘C’. 
Within the COSMOS database the search term ‘C’ identifies all chemicals containing a 
carbon atom. Additionally, queries were added to identify chemicals that also had a short-
term and/or subchronic toxicological studies associated with them; returning a total of 618 
chemicals. However, the majority of these chemicals contained only one study and were, 
therefore, disregarded at this stage. Subsequently, each chemical with more than one study 
in the ‘# studies’ column was manually analysed  in order to identify those chemicals 
containing toxicity data for both 28- and 90-day repeat dose studies conducted via the oral 
route in rats; reducing the dataset to 54 chemicals. The data gathered at this stage are 
available in the Appendix for this chapter (Appendix I). Further analysis was undertaken on 
the dataset to remove those chemicals that did not have a HNEL value at 1000mg/kg bw/day 
or greater for both the 28- and 90-day repeat dose study durations; reducing the final dataset 
to nine chemicals, constituting 15% of the dataset that contained both 28- and 90-day repeat 
dose study data (Table 2.3). This is in keeping with the previous studies conducted, whereby 
Taylor et al and the HSE identified 10% and 15%, respectively, of the original chemicals 
were present in the final dataset as having both 28- and 90-day repeat dose study data with a 
NOAEL value at, or greater than 1000mg/kg bw/day.  
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Table 2.3: A comparison of the 28- and 90- day repeat dose studies with Highest No Effect Level data at, or greater than 1000mg/kg bw/day 
Chemical name COSMOS ID Short-term toxicity 
study value (mg/kg 
bw/day) 
Length of short-
term toxicity 
study (days) 
Sub-chronic 
toxicity study value 
(mg/kg bw/day) 
Length of sub-
chronic toxicity 
study (days) 
Is the short-term study 
protective of sub-chronic 
study? 
Hydroxypropyl 
Methylcellulose 
CMS-7567 HNEL 10,000 
 
30 
 
HNEL 2339 
HNEL 5000 
HNEL 6500 
HNEL 7700 
HNEL 505 
90 
90 
90 
90 
91 
Yes (if using Weight of 
Evidence) 
No (if using most 
protective value) 
Ascorbic acid CMS-108 HNEL 10,000 28 HNEL 2500 90 Yes 
Glycyrrhizin, 
ammoniated 
CMS-8524 HNEL 1000 
HNEL 1000 
30 
35 
HNEL 500 90 No 
Sucrose acetate 
isobutyrate 
CMS-5115 HNEL 2226 
HNEL 2592 
28 
28 
HNEL 5300 91 Yes 
Maltodextrin CMS-5576 HNEL 10,000 30 HNEL 3882 90 Yes 
Butyl acetate CMS-1941 HNEL 2000 28 HNEL 600 90 No 
Hydroxypropyl 
cellulose 
CMS-10327 HNEL 6000 30 HNEL 5000 90 Yes 
Potassium 
bicarbonate 
CMS-1189 HNEL 2132 
HNEL 4000 
28 
28 
HNEL 1482 
HNEL 2000 
91 
91 
Yes 
Polyethylene, 
oxidised 
CMS-34680 HNEL 4650 32 HNEL 5000 
HNEL 5000 
90 
90 
Yes 
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2.3.3 Results and discussion of the analysis performed on the dataset 
Overall, the analysis carried out in this chapter identified six (67%), using the most 
protective HNEL value, or seven (77%), using a Weight of Evidence approach, of the nine 
chemicals that had a HNEL value at, or greater than, 1000mg/kg bw/day in the 28-day repeat 
dose study also had a value at, or greater than, 1000mg/kg bw/day in the 90-day repeat dose 
study, i.e. the 28-day study was protective of the 90-day study. The two chemicals that were 
not protective within the COSMOS database are butyl acetate and glycyrrhizin (ammoniated) 
(Table 2.3). The identification of butyl acetate as being non-protective in this chapter 
correlates to the findings of Taylor et al, whereby one of the two non-protective chemical in 
that study was also an acetate (EC 231-710-0). However, the other chemical (glycyrrhizin) 
in this chapter does not appear in the ECHA CHEM database and does not correlate with the 
other non-protective chemical in the Taylor et al study, which is a sulfonanilide (EC 649-
383-6). These results are marginally below those found previously by the HSE and Taylor et 
al (2014), who identified 100% and 89%, respectively, of the chemicals with 28-day repeat 
dose day at or greater than 1000mg/kg bw/day were protective of the 90-day repeat dose 
study respectively, i.e. it also was at or above 1000mg/kg bw/day. This difference in 
percentage of chemicals that are protective between the previous studies and the analysis 
presented here could be due to the variances in the total number of chemicals in the final 
dataset. The analysis conducted in this chapter further supports those results from the HSE 
(2011) and Taylor et al (2014). It can be seen from each of these analyses that only a 
relatively small proportion of the three databases utilised (10-15%) contain data for both 28- 
and 90-day repeat dose studies that can be considered to be of low toxicity. Even though this 
may not be considered to be of great significance, if 15% of the 90-day repeat dose studies 
required under REACH (described in more detail in Chapter 1), for those chemicals 
manufactured or imported over 100 tonnes per year, did not have to be performed, due to 
low toxicity observed in a 28-day study, over €50 million, and approximately 44,000 
animals, could be saved (Taylor et al 2014). Thus, this would have a major impact not only 
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on the financial burden of registering chemicals, but additionally on the time and resources 
required. 
In order to identify, and gather data for, those chemicals with both 28- and 90-day toxicity 
data Taylor et al were required to visit different databases, i.e. eChemPortal to search for 
substances for which there was a 28- and 90-day study and the ECHA CHEM database to 
retrieve the toxicity data for both study lengths. In comparison, the use of the COSMOS 
database within this chapter enabled the analysis conducted by Taylor et al to be carried out 
in an easier and less time consuming manner. This was due to the efforts within the 
COSMOS consortium to compile both chemical and toxicological data from various sources 
into one database.  The presence of both the chemical, and toxicological, data in one easy to 
search database is one of the key benefits the COSMOS database provides. An additional 
benefit is the ability to narrow down search results based upon specific endpoints, test 
systems, routes of exposure or species. 
In this instance, it has not been possible to identify chemical classes that are protective in 
both 28- and 90-day repeat dose studies. This is most likely due to the number of chemicals 
currently present within the COSMOS database that contain each of the prerequisites 
described in the method above, these numbers are likely to increase as and when more data 
become available. In order to identify chemical classes, and therefore develop structural 
alerts, that are protective further work could include compiling tables of chemicals from the 
work conducted here, by the HSE, and Taylor et al to ascertain if any chemical classes are 
consistently protective. Alternatively, for those chemicals that are not protective, an 
investigation could be undertaken to elucidate mechanistic information for both the 28- and 
90-day studies in an attempt to understand whether different mechanisms are responsible for 
initiating the adverse events in the 28-day study compared to the 90-day study. Additionally, 
an investigation into the mechanistic information pertaining to the adverse effects used to 
derive the HNEL value may enable a distinction to be identified between those chemicals 
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that are protective and those that are not protective as part of the same chemical class, 
thereby potentially facilitating the development of structural alerts for those chemical classes. 
 
2.4 Conclusions 
This chapter shows the current need for a single, comprehensive, and freely available 
database containing chemical structures linked to repeat dose toxicity data. As part of the 
development of the COSMOS database novel repeat dose data have been extracted from the 
SCC(NF)P/SCCS reports. These reports have not previously been utilised to extract repeat 
dose data from in order for it to be collated into a freely available database. In order to 
maintain consistency, across the data harvesters, whilst extracting the repeat dose data from 
this source it was essential that both an SOP and a controlled vocabulary were used. The use 
of these two factors also enables any future data harvesting to proceed with the same 
consistency, also the controlled vocabulary makes the COSMOS database simpler and easier 
to search. To maximise the use of the COSMOS database the repeat dose data gathered were 
not only the NOAEL and LOAEL values themselves, but also the further information 
concerning the adverse effects observed at the LOAEL. This additional information 
regarding the adverse effects enables the development of a variety of in silico models. One 
such model is discussed in more detail in Chapter 5. With regards to the investigation 
undertaken in this chapter having the toxicological data compiled in one easy to use database, 
as opposed to spread across multiple databases, made this analysis much easier to do. As 
more toxicological data is input into the COSMOS database it is envisaged that the analyses 
that can be undertaken will also expand to cover more endpoints. 
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Chapter 3: The development of structural alerts using the ChemoTyper software 
 
3.1 Introduction 
Both Chapters 3 and 4 refer to the use of mitochondrial toxicity data that were extracted 
from the same journal article, i.e. Zhang et al (2009). Whilst the same data are used, 
different in silico approaches have been utilised; in Chapter 3, a software tool (ChemoTyper) 
comprised of pre-defined structural features has been used. In comparison, Chapter 4 utilises 
structural similarity, and a subsequent literature search. These methods have been used to 
demonstrate how using various techniques can enable the identification of different 
structural alerts from the same data set. When compiled together structural alerts that relate 
to the same toxicological outcome develop an in silico profiler. These profilers fall into two 
categories: mechanism- and chemistry-based. A mechanism-based profiler is comprised of 
structural alerts relating to a Molecular Initiating Event (MIE) that are supported by 
experimental data illustrating how the alert initiates the MIE. In comparison, a chemistry-
based profiler consists of structural alerts that have been associated with inducing toxicity; 
thus, in contrast to mechanism-based profilers, a chemistry-based profiler does not contain 
mechanistic information relating to how the observed toxicity is initiated. Due to these 
intrinsic differences, the two types of profiler should be used for different purposes; 
mechanistic profilers should be used for category formation and read-across, whilst 
chemistry-based profilers should be used to screen an inventory to prioritise chemicals to 
undergo (non-animal) testing. A category developed utilising a mechanism-based profiler 
enables missing toxicological data for a chemical to be filled using available information 
from analogues within the same category via read-across predictions (Enoch et al 2011a).  
The general premise of developing a category is based upon chemicals within the category 
being similar to one another (ECHA 2008, OECD 2011). This similarity can arise from a 
variety of properties including: structural features, physico-chemical properties or similarity 
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in the mechanism of action (Chapters 1 and 6). In addition, the subsequent read-across 
predictions are made based upon the assumption that similar chemicals should have similar 
chemical and biological activities (ECHA 2008, ECHA 2012). Whilst there are some 
exceptions, this assumption provides a useful grounding on which to build. Depending upon 
the data available for the chemicals used in the read-across, i.e. the analogues, the 
predictions made can either be qualitative or quantitative. A qualitative prediction would 
enable, for example, a positive/negative or high/low result to be associated with the chemical. 
In comparison, a quantitative prediction could identify the concentration at which an effect 
would be expected to occur.  
In order for predictions made by read across to be more acceptable, chemical grouping 
should be based upon a similar mechanism of action, specifically the MIE. The use of this 
knowledge with regards to the MIE means any prediction is more mechanistically 
interpretable and, therefore, more acceptable for regulatory purposes. The MIE; as discussed 
in Chapters 1, 4, and 5 and defined by the AOP paradigm; is the initial interaction between 
the non-endogenous chemical and the biological system that initiates the perturbation of 
normal physiological functioning. The chemistry-based structural alerts do not have 
mechanistic information associated with them. It is, therefore, anticipated that the 
subsequent in vitro and/or in chemico testing will enable mechanistic knowledge to be 
elucidated and, subsequently, associated with the structural alert. Additionally, it should be 
noted that mechanism-based profilers can also be used for screening and prioritisation 
purposes. The benefit of this is that the mechanistic information associated with the 
structural alert can be utilised to guide which in vitro and/or in chemico test should be 
performed; based upon the knowledge held by an AOP.  
A number of studies have developed profilers, focussing on a variety of organ-level 
toxicities, and demonstrated their use in chemical category formation and subsequent read-
across analysis (discussed in Chapters 4 and 5). The focus of the work undertaken within 
Chapters 4 and 5 was to develop (mechanism-based) structural alerts that could be collated 
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together to form a profiler for mitochondrial toxicity. As discussed further in Chapter 6 
several profilers have been encoded computationally within the OECD QSAR Toolbox 
software program. The QSAR Toolbox contains both mechanism- and chemistry-based 
profilers. The QSAR Toolbox holds a number of mechanism-based profilers covering a 
variety of endpoints such as skin sensitisation, respiratory sensitisation, acute aquatic 
toxicity, carcinogenicity, eye irritation and in vitro mutagenicity. These mechanistic profilers 
are used to assign an MIE to a chemical (for example, covalent protein or covalent DNA 
binding) and, thus, this information can be utilised to develop mechanism-based categories 
that enable read-across and other structure-activity relationship predictions to be made. In 
order to justify these predictions the user can view the supporting information that is 
associated with the structural alert. This supporting information consists of a visual 
representation of the alert, the rationale as to why this alert was triggered, and the 
mechanistic information relating the alert to the endpoint in question, for example protein 
binding. In comparison, the chemistry-based profilers held within the QSAR Toolbox enable 
chemical categories to be formed based upon the presence of certain structural features, 
chemical elements or functional groups.  
The ChemoTyper software is a freely available chemoinformatics tool that enables a set of 
chemicals to be searched against a pre-defined set of structural features (denoted as 
chemotypes in the ChemoTyper software). This application was developed by Molecular 
Networks GmbH under contract by the US FDA and is freely available from 
https://chemotyper.org/ (accessed 17.11.2014). The ChemoTyper is a data mining tool that 
enables a data set to be screened for the presence of certain structural features. The features 
contained within the ChemoTyper are from the predefined Toxprint library (Yang et al 2013) 
of structural fragments. The resulting outcome of this screening process is a pictorial 
representation of the ‘chemotype’ searched for overlaid on top of the whole chemical. Figure 
3.1 shows a pictorial representation of the ChemoTyper output; this, coupled with the ability 
to filter the chemicals based upon structural features, enables a user to readily identify 
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structural fragments that are associated with toxicity. Therefore, those fragments that are 
associated with a higher proportion of toxic chemicals can be considered to be associated 
with (a specific) toxicity, thus, enabling them to be defined as a structural alert. Due to these 
capabilities the ChemoTyper has, therefore, been proposed to be of use for developing 
structural alerts.  
 
Figure 3.1: Identification of a nitrile chemotype contained within a larger set of chemicals. 
The nitrile fragment is highlighted green in those chemicals containing the chemotype. 
Given the potential that the ChemoTyper has for developing structural alerts, the aim of this 
chapter was to perform a chemoinformatics analysis of a dataset of chemicals associated 
with mitochondrial toxicity. This analysis involved identifying structural alerts in the dataset 
that were associated with mitochondrial toxicity. The work performed in this chapter (along 
with Chapters 4 and 5) is important as relatively little work has been performed in the area 
of developing structural alerts for mitochondrial toxicity; especially with regards to AOPs. 
This issue is discussed further in Chapters 1, 4, and 5. 
 
3.2 Methods 
3.2.1 Data set 
The 288 chemicals reported by Zhang et al (2009) were used as the basis from which to 
generate the structural alerts associated with mitochondrial toxicity. This article was chosen 
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for use as it provides one of the largest freely available datasets, for which the chemical list 
has qualitative mitochondrial toxicity data associated with it. Within this data set 171 
chemicals have been reported within the literature as inducing mitochondrial toxicity and 
were therefore considered to be mitochondrial toxicants. The chemicals with a negative 
result for mitochondrial toxicity were selected from the FDA-approved drug list, whereby 
the therapeutic action mechanism, of common and safe oral drugs, was not associated with a 
mechanism of drug-induced mitochondrial toxicity. Data for the 288 chemicals, including 
SMILES and toxicity towards mitochondria are available in Appendix II. From this data set 
the chemical structures were identified in, and the corresponding SMILES strings were 
extracted from, the Royal Society of Chemistry’s ChemSpider website 
(www.chemspider.com). These chemical structures were subsequently combined with the 
‘toxic to mitochondria’ and ‘non-toxic to mitochondria’ result from Zhang et al (2009) and 
saved as a .smi file using the chemical visualisation software Marvin View (v6.0.0) 
developed by Chemaxon (available at www.chemaxon.com/products/marvin/marvinview/, 
accessed 17.11.2014).  
 
3.2.2 Generation of structural alerts using the ChemoTyper software 
The workflow below (Figure 3.2) outlines the steps in the development of the structural 
alerts within this chapter. This workflow is split into two sections: the first section relates to 
utilising the ChemoTyper software in order to identify the structural alerts (denoted as 
chemotypes within the ChemoTyper software) that are associated with mitochondrial 
toxicants. The second section relates to the generation of SMARTS (SMiles ARbitrary 
Target Specification; Daylight 2014) patterns using the chemotypes identified in section one. 
SMARTS is a language utilised when developing structural alerts as it enables the user to 
identify a specific substructure that may be associated with toxicity. 
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Figure 3.2: Workflow outlining the process undertaken in order to identify and develop the 
structural alerts 
 
Workflow 1.1. Identification of chemotypes (structural alerts) 
The following steps were adhered to in order to develop structural alerts using the freely 
available ChemoTyper software (v1.0). Additionally, the workflow illustrated in Figure 3.3 
shows an outline of how the ChemoTyper was utilised to develop structural alerts. 
(1.1) Identification of a master list of chemotypes 
(structural alerts) 
(1.2) Removal of redundant chemotypes within the 
master list 
(2.1) Generation of SMARTS patterns from visual 
representation 
(2.2) Verification of the SMARTS patterns 
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Figure 3.3: Flowchart describing the process of generating the structural alerts using the ChemoTyper software 
1. Select a Chemotype set from the 
list of ‘Bond’ or ‘Ring’ chemotypes 
2. From the chemotype set selected 
in step 1 select a single chemotype. 
Does it meet the inclusion criteria? 
3. Include the selected chemotype in the master 
list of ‘predictive’ chemotypes. 
Unselect the current chemotype. 
Are there any more chemotypes in the current 
Chemotype set that have not been analysed? 
4. Are there more 
Chemotype sets to 
analyse? 
5. Manually inspect the master list of 
‘predictive’ chemotypes by Chemotype set.  s it 
possible to reduce the number of chemotypes 
within a Chemotype set based on a chemically 
sensible rationale? 
6a. Remove redundant 
chemotypes. Outline a 
clear rationale as to why 
their removal is justified 
6b. Keep all chemotypes 
and use them to identify 
chemicals in an ‘OR’ 
fashion 
Yes 
Yes 
Yes 
No 
No 
No 
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Step 1 – The Toxprint chemotypes; inherent in the ChemoTyper software; and the 
data set to be examined; in this instance the data set extracted from Zhang et al 
(2009); were opened within the ‘Match’ component of the ChemoTyper. The 
Toxprint chemotypes are the structural fragments against which the data set was 
analysed. 
Step 2 - The drop-down menu adjacent to ‘Filter Structures’ was set to ‘Containing 
any selected chemotype (OR)’ (circled in black, Figure 3.4). This was necessary as it 
enabled chemicals that contain a chemotype to be rapidly identified, by filtering out 
those chemicals that did not contain the current chemotype. 
Step 3 – A chemotype set was selected from the list present within the ChemoTyper 
(circled in red, Figure 3.4). From this chemotype set a single chemotype was 
selected (circled in blue, Figure 3.4). 
Step 4 – If the chemotype met the inclusion criteria; i.e. at least three chemicals 
‘toxic to mitochondria’ and no more than a single chemical ‘non-toxic to 
mitochondria’ are identified; the chemotype was included in the master list of 
‘predictive’ chemotypes. The use of the inclusion criteria aimed to prevent the 
development of structural alerts based upon chemotypes that identified a large 
number of chemicals ‘non-toxic to mitochondria’, thereby, limiting the number of 
false positive results predicted by the structural alert. 
Step 5 – The current chemotype was unselected and steps 3 and 4 were repeated 
until all chemotypes had been analysed. 
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Figure 3.4: A screenshot of the ChemoTyper software. On the right is the chemotype 
selected. Whilst on the left is a visual representation of each of the chemicals containing the 
chemotype and whether they were identified by Zhang and colleagues (Zhang et al 2009) as 
being ‘toxic to mitochondria’ or ‘non-toxic to mitochondria.’ 
 
Workflow 1.2. Removal of redundant chemotypes within master list 
Upon completion of the previous process the master list of ‘predictive’ chemotypes was 
inspected so as to remove any redundant chemotypes present (steps 5 and 6 in Figure 3.3). 
The removal of redundant chemotypes was only undertaken if multiple chemotypes 
identified the same set of chemicals (or one chemotype identified a sub-set of chemicals 
identified by a second chemotype). For example, as can be seen in Figure 3.5, there is an 
overlap between the chemicals identified by the three selected chemotypes (Figure 3.6). 
 iven this overlap, the most specific chemotype (‘bond:CX_halide_aromatic-
Cl_trihalo_benzene_(1_2_4-)’) was selected, with the remaining two being removed from 
the master list.  
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Figure 3.5: Results from the ChemoTyper software, illustrating the redundancy between the 
three chemotypes 
 
 
Figure 3.6: A depiction of the ‘bond:CX_halide_aromatic-Cl_trihalo_benzene_(1_2_4-),’ 
the ‘bond:CX_halide_aromatic-X_dihalo_benzene(1_2-),’ and the 
‘bond:CX_halide_aromatic-X_dihalo_benzene(1_4-)’ chemotypes respectively, where X 
can be any halide atom. The ‘bond:CX_halide_aromatic-Cl_trihalo_benzene_(1_2_4-)’ 
chemotype was retained.
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Workflow 2.1 Generation of SMARTS patterns from visual representation 
The SMARTSeditor software, developed by Universität Hamburg (available from 
www.zbh.uni-hamburg.de/?id=426, accessed 17.11.2014), was used to generate all 
SMARTS patterns. SMARTSeditor is a graphic editing tool that enables the user to draw, 
and edit, a visual representation of a chemical structure, whereby the visual representation is 
simultaneously converted into a SMARTS pattern. In this instance the chemical phenol will 
be used as an example of how the SMARTS patterns were generated. 
Step 1 – The ‘draw’ function was used to sketch the structural alert into the 
SMARTS editor software (circled in red, Figure 3.7). 
Step 2 – Any alterations to the sketched structure were made using the ‘edit’ 
function. Alterations were required for all structural alerts that contain an aromatic 
ring system. This is due to aliphatic carbon atoms being inserted as a default by the 
SMARTSeditor software. 
Step 3 – The finalised SMARTS pattern generated was displayed above the visual 
representation in the SMARTSeditor (circled in blue, Figure 3.7). 
Step 4 – The SMARTS pattern generated in Step 3 was, thus, included in the master 
list of ‘predictive’ structural alerts. 
Step 5 - The visual representation, and associated SMARTS pattern, was deleted 
from the SMARTSeditor software and Steps 1 to 4 were repeated until SMARTS 
patterns were generated for all of the structural alerts identified in stage 1. 
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Figure 3.7: The SMARTSeditor program with a visual representation, and SMARTS pattern, 
for phenol. 
 
Workflow 2.2 Verification of the SMARTS patterns 
Each of the SMARTS patterns developed was verified using the ‘depictmatch’ tool 
developed by Daylight Chemical Information Systems Inc. (available at 
http://www.daylight.com/daycgi_tutorials/depictmatch.cgi, accessed 17.11.2014). This was 
to ensure the SMARTS pattern could correctly identify chemicals containing the structural 
alerts. The verification process was undertaken as described below. 
Step 1 – The SMARTS pattern, generated using the SMARTSeditor, was entered 
into the depictmatch tool under the heading ‘SMARTS’ (circled red, Figure 3.8). 
Step 2 – A SMILES notation for a chemical containing the structural alert was 
entered under the heading ‘SM LES’ (circled blue, Figure 3.8). 
Step 3 – The SMARTS pattern was identified as being correct if the depictmatch 
tool highlighted the structural fragment correlating to the SMARTS pattern in 
yellow (in the black box Figure 3.8). 
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Step 4 – If the SMARTS pattern was incorrect, i.e. the visual depiction remained 
white; the SMARTS pattern was investigated to determine where corrections were 
required. 
Step 5 – Any corrections made were subsequently tested using the depictmatch tool. 
Step 6 – Steps 4 and 5 were repeated until the SMARTS pattern correctly identified 
the structural fragment coded for. 
Step 7 –The steps 1 through 6 were repeated for each SMARTS pattern developed in 
section 2.2. 
 
Figure 3.8: Use of the depictmatch tool to identify whether previously created SMARTS 
patterns correctly identified chemicals contained the structural fragment coded for. 
 
3.3 Results and discussion 
The aim of this chapter was to use the newly developed ChemoTyper software in order to 
perform chemoinformatics analysis of a dataset of 288 chemicals (Zhang et al 2009) and 
identify structural alerts associated with mitochondrial toxicants. From this 
Chapter 3 
71 
 
chemoinformatics analysis twenty structural alerts were developed (Table 3.1). In total, 
these twenty alerts covered 83 chemicals. Of these 83 chemicals, 77 were identified as being 
mitochondrial toxicants; the remaining six chemicals were identified as not being 
mitochondrial toxicants. These structural alerts covered twelve of the 61 chemotype sets 
(under the heading ‘bond,’ ‘chain,’ and ‘ring’) that are present within the ChemoTyper 
software. A chemotype set consists of a group of chemotypes that contain the same 
structural fragment. Of these twelve chemotype sets, the ‘bond:CX’ set contains the most 
chemotypes that were seen to be associated with mitochondrial toxicants; i.e. four 
chemotypes (listed in Table 3.1). Structural alert 13 (Table 3.1) identified the highest 
number of chemicals ‘toxic to mitochondria,’ i.e. ten chemicals.  
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Table 3.1: A list of the chemotypes identified as being associated with mitochondrial toxicants.  
Structural 
alert 
number 
Structural alert Chemotype name 
(as denoted within the ChemoTyper software) 
Number of 
chemicals 
identified* 
Is an all-encompassing 
mechanistic hypothesis 
possible for the alert? 
1 
 
R = any C atom 
bond:C#N_nitrile 5 (5) No 
2 
 
R = aliphatic C atom 
bond:C(=O)N_carbamate_thio_generic 3 (3) Yes 
3 
 
R1 = aliphatic C or H atom 
R2 = aliphatic C or N atom 
bond:C(=O)N_carbamate 7 (6) No 
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4 
 
R = aliphatic C atom 
bond:C(=O)N_carboxamide_(NH2) 7 (6) No 
5 
 
R = any C atom 
bond:C=N_imine_C(connect_H_gt_0) 3 (3) No 
6 
 
R1 = aliphatic O or H atom or cyclic C atom 
R2 = sp2 cyclic C atom 
R3 = sp2 cyclic C atom 
bond:CC(=O)C_ketone_alkene_cyclic_3-en-1-
one 
5 (5) No 
7 
 
bond:CC(=O)C_quinone-1_4-benzo 8 (8) Yes 
8 
 
R1 = sp2 cyclic C atom 
R2 = any C atom 
bond:COC_ether_alkenyl 4 (4) No 
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9 
 
R = aliphatic C atom 
bond:COH_alcohol_allyl 4 (3) No 
10 
 
bond:CX_halide_alkyl-Cl_dichloro_(1_1-) 4 (4) No 
11 
 
X = any halide atom 
bond:CX_halide_alkyl-X_benzyl_alkane 5 (4) No 
12 
 
X = any halide atom 
bond:CX_halide_aromatic-
Cl_trihalo_benzene_(1_2_4-) 
4 (4) No 
13 
 
X = any halide atom 
bond:CX_halide_generic-X_dihalo_(1_2-) 10 (10) No 
14 
 
R = aromatic C atom 
bond:N(=O)_nitro_aromatic 9 (9) No 
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15 
 
N = aliphatic 
R = aliphatic S or N atom 
bond:N[!C]_amino 4 (3) No 
16 
 
R1 = aliphatic C atom 
R2 = aromatic C atom 
bond:NN_hydrazine_acyclic_(connect_noZ) 3 (3) No 
17 
 
ring:fused_[6_6]_naphthalene 7 (7) No 
18 
 
R = aromatic N or O atom 
ring:hetero_[5]_Z_1_2-Z 5 (4) No 
19 
 
ring:hetero_[6_6]_N_quinoline 7 (7) No 
or
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20 
 
ring:hetero_[7]_N_diazepine_(1_4-) 3 (3) No 
 
*The number in column four relates to the total number of chemicals identified by each alert, whilst the number in parenthesis correlates to the number of 
toxic chemicals identified.
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The chemoinformatics analysis showed that two types of structural alert can be identified 
using the ChemoTyper: 1) well defined alerts for which a mechanistic hypothesis can be 
defined, 2) more diverse alerts for which a mechanistic hypothesis may not be possible.  
 
3.3.1 Structural alerts for which an all-encompassing mechanistic hypothesis is possible 
A mechanistic hypothesis can be attributed to two of the structural alerts identified whilst 
undertaking this analysis. For example, the group of eight chemicals identified by structural 
alert 7 (those containing a quinone moiety, Figure 3.9) are likely to induce mitochondrial 
dysfunction by acting as an alternative electron acceptor, thereby, inhibiting the electron 
transport chain (Figure 3.10). It has been demonstrated that chemicals containing a quinone 
moiety can sequester electrons from the electron transport chain by competing with the 
natural electron carrier: ubiquinone (Wallace and Starkov 2000, Wallace 2003). Upon 
sequestration of an electron from Complex I the quinone is, itself, reduced to a semi-quinone 
radical intermediate (Gerwirtz 1999, Wallace 2003). This radical species may transport the 
electron directly to Complex IV, thus, becoming oxidised back into a quinone. Alternatively, 
the semi-quinone radical may indirectly induce mitochondrial toxicity by reacting with 
molecular oxygen, producing reactive oxygen species. Interfering with the electron transport 
chain in this manner could lead to a multitude of effects such as oxidation of mitochondrial 
DNA, proteins and/or lipids; and reduction in ATP production (Ohkuma et al 2001, Chan et 
al 2005). Additionally, four of the eight chemicals identified by structural alert 7 contain a 
structure similar to doxorubicin. Chapter 4 discusses in more detail how anthracycline 
antibiotics act to induce mitochondrial toxicity.  
Structural alert 2 identifies a group of three toxic chemicals, each of which contain a 
thiazolidinedione moiety. This moiety has been identified by Naven et al (2013) as inducing 
mitochondrial toxicity via uncoupling of oxidative phosphorylation due to its ability to act as 
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a protonophore. Further discussion surrounding the mechanism of toxicity due to the 
thiazolidinedione moiety can be found in Chapter 4. 
 
Figure 3.9: A screenshot of the group of chemicals identified by structural alert 7: the 
quinone moiety is highlighted in red in each of the chemicals. 
 
 
Figure 3.10: An illustration of the mechanism of inhibition of the electron transport chain, 
via alternative electron cycling, leading mitochondrial toxicity  
 
3.3.2 Structural alerts for which an all-encompassing mechanistic hypothesis is not possible 
In contrast, for the remaining alerts, for example the nitro aromatic alert (structural alert 14), 
it may be more difficult (or not possible) for a mechanistic hypothesis to be identified that 
encompasses each of the chemicals ‘toxic to mitochondria’ present in the group. This is due 
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to the fact that these alerts are broader in scope and, therefore, the chemicals identified are 
(generally) more diverse (Figure 3.11). This diversity increases the likelihood that the 
observed toxicity will be induced by a variety of mechanisms. However, within this type of 
category, where an all-encompassing mechanism may not be readily identifiable, it may still 
be possible to hypothesise a mechanism for individual chemicals. For example, 2,4-
dinitrophenol (circled red, Figure 3.11) is a well-known and well-characterised uncoupler of 
oxidative phosphorylation (Chan et al 2005, Dykens and Will 2008), whilst chloramphenicol 
(circled blue, Figure 3.11) has been shown to inhibit mitochondrial protein synthesis by 
binding to the 50S subunit of the ribosome (Kroon and de Vries 1969, Dykens and Will 
2008). As there is no single unifying mechanism associated with this class of chemistry-
based alerts, these alerts should not be used to develop chemical categories and, 
subsequently, perform read-across for novel chemicals. In this instance, and throughout this 
thesis, the use of read-across pertains to hypothesising a mechanism by which 
(mitochondrial) toxicity is induced, i.e. an MIE, and does not relate to the wider use of read-
across in predicting toxicity. However, this type of chemistry-based alert can be used to 
screen an inventory in order to prioritise the chemicals within it for further (non-animal) 
testing. This is due to the statistical evidence that chemicals containing one (or more) of 
these chemistry-based alerts are more likely to be associated with toxicity (Table 3.1). 
Utilising these types of chemistry-based (rather than mechanism-based) structural alerts, 
identified in this study, would enable a user to ascertain how many chemicals, within a given 
inventory, have the potential to induce mitochondrial toxicity. Nonetheless, it is worth 
noting that chemistry-based structural alerts (such as those identified within this chapter) 
could be refined to a mechanism-based alert by utilising the results of in vitro/in chemico 
testing undertaken to establish a mechanistic hypothesis.  
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Figure 3.11: A screenshot of the group of chemicals identified by structural alert 14: the 
nitro aromatic moiety is highlighted in green in each of the chemicals. 
 
The chemoinformatics analysis performed in this chapter shows that the ChemoTyper 
software has a number of benefits: firstly, it is useful for rapidly identifying structural alerts 
that are associated with (mitochondrial) toxicity. The ChemoTyper software facilitates this 
type of analysis due to the visual representation of the structural feature and the chemicals 
associated with a feature (from a given dataset). In the current chapter the toxicity data 
associated with the chemicals in the dataset were mitochondrial data; however, other toxicity 
data could be used. Therefore, this approach could be utilised to develop mechanism- and/or 
chemistry-based structural alerts for a wide variety of toxicity endpoints where a toxic/non-
toxic outcome is available. In addition to allowing for the identification of chemical 
structures associated with mitochondrial toxicity, the approach laid out within this chapter 
inherently results in structural alerts with a low false positive prediction rate. This is due to 
the fact that no more than one chemical, within the category, ‘non-toxic to mitochondria’ (as 
identified by Zhang et al 2009) could be associated with a structural alert in order for it to be 
identified as being associated with mitochondrial toxicity. Additionally, the ChemoTyper 
software enables structural alerts to be defined without the user needing to have any prior 
mechanistic knowledge of how the alert initiates toxicity. However, this also results in the 
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main disadvantage of this approach in that a single chemical could, potentially, contain 
multiple structural alerts making it more difficult to distinguish which of the identified alerts 
is responsible for inducing toxicity. 
 
3.4 Conclusions 
The aim of this chapter was to utilise the ChemoTyper software in order to identify 
structural alerts associated with mitochondrial toxicity. Overall, twenty structural alerts were 
developed. Two types of structural alert could be discerned from this analysis: those 
whereby a mechanistic hypothesis can be defined for all chemicals containing a specific alert; 
and those where the alert was too broad to be able to hypothesise an all-inclusive mechanism. 
Whilst this second class of chemistry-based structural alerts should not be used for grouping 
for read-across purposes (in terms of hypothesising an MIE), they can be of use for 
screening large data sets of chemicals that will, subsequently, undergo testing within in 
vitro/in chemico assays. However, if further testing is undertaken for a subset of chemicals 
containing a specific chemistry-based alert, it may be possible to associate mechanistic 
information with a number of the chemistry-based alerts, thereby, enabling them to be 
rationalised into mechanism-based structural alerts, such as those discussed in subsequent 
chapters. The development of mechanism based structural alerts and their relative 
advantages over chemistry-based structural alerts are discussed further in Chapters 4 and 5. 
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Chapter 4: The use of category formation in the development of an in silico profiler for 
mitochondrial toxicity 
 
4.1 Introduction 
Over the past decade a number of changes have occurred in European cosmetic legislation 
that have led to an increase in efforts to develop alternative methods to traditional animal 
testing for risk assessment (EC 2003, EC 2006, EC 2006, ECHA 2008, ECHA 2012). These 
alternatives have been developed employing in silico, in chemico and in vitro methods 
focussing on replacing or reducing animals used in short- and long-term toxicity tests (Adler 
et al 2011). In order to be relevant, and useful, for regulatory assessment these alternatives 
should be based upon specific in vivo endpoints. Within recent years, interest has grown in 
developing a greater understanding of toxicity pathways. One such pathway approach is the 
Adverse Outcome Pathway (AOP) paradigm. An AOP is a framework that means to 
establish a mechanistic connection between an upstream Molecular Initiating Event (MIE) 
and a downstream adverse outcome relevant for risk assessment (Ankley et al 2010, OECD 
2013, Vinken 2013, Vinken et al 2013a, Vinken 2014) (Chapter 1). The MIE is the critical 
event in the progression of an AOP as it provides insight into the initial interaction(s) 
between the chemical behaviour of the non-endogenous chemical and the biological system 
that initiates the perturbation of the normal pathway. Elucidation of the mechanistic 
information relating to specific MIEs enables the identification of structural (and physico-
chemical) features of chemicals that are responsible for the interaction with biological 
macromolecules, thus, facilitating the development of structural alerts.  
This process can be labour intensive, another method could be to utilise an automated 
clustering technique; one such clustering approach is to use the Toxmatch software. 
Toxmatch is an open source program; developed by Ideaconsult, Sofia; that can be used to 
group chemicals based upon one of a variety of different similarity indices. The Toxmatch 
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program contains two molecular graph-based similarity methods: molecular fingerprints and 
atom environments (Enoch et al 2009). Within this chapter, and Chapter 5, the atom 
environment similarity measure has been utilised. The atom environment approach identifies 
the “fragments surrounding each atom in a molecule, up to a predefined level” and is 
calculated according to the explanation in Jaworska and Nikolova-Keliazkova (2007). 
Subsequently, the program calculates the average Hellinger distance between the atom 
environments of one chemical and the atom environments of the set. This generates a matrix 
consisting of similarity scores, between 0 and 1, for each chemical within the data set, with 0 
meaning the two chemicals are completely dissimilar and 1 meaning the two chemicals are 
completely similar. Whilst it is appreciated that more complex clustering approaches may be 
implemented this is beyond the scope of this thesis. 
When combined, multiple structural alerts pertaining to the same MIE form the basis of an 
in silico profiler (Enoch 2010, Enoch and Cronin 2010 Enoch et al 2011a, Hewitt et al 2013, 
Przybylak and Schultz 2013) (discussed in more detail in Chapters 1, 3, and 5). The 
information within an in silico profiler can, in turn, be used to develop chemical categories 
centred on a common MIE (note that multiple MIEs can be initiated by a single chemical). 
This allows for read-across and data gap filling to be applied. The premise behind these 
structurally developed categories is that similar chemicals should have similar biological 
activities and therefore, should have the same MIE. Furthermore, the categories produced 
using in silico profilers can be supported by, and used to prioritise, additional testing using 
in vitro and/or in chemico methods, within an integrated testing strategy (ITS) or an 
integrated approach to testing and assessment (IATA). Such strategies can be used for 
hazard identification and risk assessment purposes, as well as being incorporated into in 
silico software tools such as the OECD QSAR Toolbox (available at www.qsartoolbox.org, 
accessed 17.11.2014) (Gutsell and Russell 2013, OECD 2013, Przybylak and Schultz 2013, 
Vinken 2013). 
Chapter 4 
84 
 
A number of in silico profilers have been developed for a variety of organ-level toxicities, 
such as skin sensitisation, respiratory sensitisation, genotoxicity, protein binding and 
hepatotoxicity (Enoch et al 2008a, Enoch et al 2008b, Enoch and Cronin 2010, Enoch et al 
2011a, Hewitt et al 2013, Sakuratani et al 2013a, Sakuratani et al 2013b, Vinken et al 2013a, 
Vinken et al 2013b). However, very few have dealt with toxicity induced by mitochondrial 
dysfunction (Zhang et al 2009, Naven et al 2013, Wallace et al 2013). This is, in part, due to 
the number of mechanisms by which a chemical could induce mitochondrial dysfunction 
(Nadanaciva and Will 2011). An additional complication is that a single chemical might 
have the ability to induce more than one of these mechanisms, making it difficult to define a 
single MIE within the AOP paradigm.  Over the past decade, interest in screening chemicals 
for an ability to induce mitochondrial dysfunction has increased (Dykens and Will 2008, 
Nadanaciva and Will 2011). This is, in part, due to the withdrawal of a number of 
pharmaceuticals from the market after observed mitochondrial dysfunctions (Wallace and 
Starkov 2000, Brunmair et al 2004, Rolo et al 2004, Chan et al 2005, Dykens and Will 2007, 
Dykens et al 2007). Toxicity to mitochondria has led to such withdrawals as these are 
important organelles present within almost every cell type of the body, the exception being 
mature erythrocytes (Cohen and Gold 2001, Pieczenik and Neustadt 2007). Previous 
research has shown that mitochondrial dysfunction may be induced by a range of chemicals 
and has been linked to a variety of organ toxicities within kidney, liver and nervous tissues 
(Wallace and Starkov 2000, Brunmair et al 2004, Rolo et al 2004, Chan et al 2005, Dykens 
and Will 2007, Dykens et al 2007). The most susceptible tissues to mitochondrial 
dysfunction are those containing a higher concentration of mitochondria or those exposed to 
a higher concentration of chemical: such as the liver, kidneys and heart (Amacher 2005, 
Dykens and Will 2007, Dykens and Will 2008, Nadanaciva and Will 2011). Five general 
mechanisms of mitochondrial dysfunction have been identified (Krahenbuhl 2001, Amacher 
2005): inhibitors of the electron transport chain and ATP synthase (Complex V), uncouplers 
of oxidative phosphorylation, opening of the membrane permeability transition pore, 
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inhibition of fatty acid β-oxidation, and oxidation or inhibition of mitochondrial DNA 
(discussed in more detail in Chapter 1).  
As an example of the importance of mitochondrial toxicity approximately 35%, of more than 
500 pharmaceutically relevant chemicals, have been shown to be directly involved in 
impairing normal mitochondrial functioning by inhibition of the electron transport chain 
and/or by uncoupling of oxidative phosphorylation (Dykens and Will 2008). Additionally, 
there are chemicals that can induce mitochondrial toxicity via alternative mechanisms, such 
as inducing the membrane permeability transition, inhibition of β-oxidation of mitochondrial 
fatty acids, or interfering with mitochondrial DNA. Briefly stated, chemicals that inhibit the 
electron transport chain can do so by either direct binding to the complexes of the electron 
transport chain or ATP synthase or by acting as an alternative electron acceptor (Krahenbuhl 
2001, Amacher 2005, Chan et al 2005). The inhibition of electron flow along the electron 
transport chain by both of these mechanisms induces the formation of reactive oxygen 
species resulting in oxidative stress (Krahenbuhl 2001, Amacher 2005, Chan et al 2005). 
Uncouplers of oxidative phosphorylation induce mitochondrial toxicity by shuttling protons 
into the mitochondrial matrix, via the inner mitochondrial membrane, bypassing ATP 
synthase. This assisted transport of protons back into the matrix dissipates the 
electrochemical potential, resulting in the loss of ATP production and, ultimately, cell death 
(Terada 1990, Schonfeld et al 1992, Sun and Garlid 1992, Wallace and Starkov 2000, 
Krahenbuhl 2001, Amacher 2005, Chan et al 2005, Spycher et al 2008, Cela et al 2010). 
Induction of the membrane permeability transition increases the permeability of the inner 
mitochondrial membrane to low molecular weight solutes (<1500Da), leading to a disruption 
of the electron transport chain, loss of membrane potential, and swelling of both the inner- 
and outer mitochondrial membranes (Kroemer et al 2007, Lemasters et al 2009). Inhibition 
of β-oxidation of mitochondrial fatty acids reduces the amount of NADH and FADH2 
available for oxidative phosphorylation that, in turn, reduces ATP production (Pessayre et al 
2008). Mitochondrial DNA encodes 13 components of the electron transport chain, damage 
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that occurs to mitochondrial DNA can have a variety of downstream effects depending upon 
where it occurs (Amacher 2005, Pessayre et al 2008). It should be noted, however, that there 
is the potential that multiple, competing, mechanisms could initiate mitochondrial toxicity 
observed for a single (group of) chemical(s), i.e. one chemical may induce several MIEs. 
Given the importance of mitochondria within most cell systems, and the wide range of 
organ-level toxicities that may arise from mitochondrial dysfunction, the aim of this chapter 
was to utilise structural similarity, and subsequent information in the available literature, to 
identify structural alerts that could be combined to form an in silico profiler. Consequently, 
this profiler could be incorporated into software tools, to enable large datasets to be screened 
to identify chemicals with the ability to induce mitochondrial toxicity. 
 
4.2 Methods 
4.2.1 Data set 
The data set extracted from Zhang et al (2009), discussed in Chapter 3, was utilised to 
perform the clustering analysis within this chapter. Given the lack of supporting mechanistic 
information to confirm the presence, or absence, of mitochondrial toxicity additional 
analysis was carried out, as detailed below.  
 
4.2.2 Category formation based upon structural similarity 
All chemical structures were encoded into Simplified Molecular Input Line Entry System 
(SMILES) strings, neutralised and had salts removed. Each of the SMILES strings was 
extracted from the Royal Society of Chemistry’s ChemSpider website 
(http://www.chemspider.com/). Similarity calculations were implemented within the freely 
available Toxmatch software (v1.07) using the atom environment nearest neighbour 
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approach, generating a data matrix with a Tanimoto similarity score for each chemical to all 
others within the data set. Subsequently, in-house code was implemented within Microsoft 
Excel that identified analogues with a similarity index of 0.6 or greater; this was used in 
order to develop categories for the chemicals within the dataset with two, or more, analogues. 
Further analysis was undertaken upon those categories that met the following criteria: they 
contained three or more chemicals and at least one mitochondrial toxic chemical.  
 
4.2.3 Mechanistic hypothesis and the development of alerts 
Once categories had been developed using structural similarity a detailed search of the 
available literature was undertaken to elucidate the mechanistic information behind the 
molecular initiating event, along with other downstream key events, leading to the disruption 
of the mitochondria. This mechanistic information was subsequently utilised to support the 
definition of a structural alert suitable for grouping chemicals. These structural alerts were 
defined by identifying the common fragment present within each of the chemicals found to 
have positive mitochondrial toxicity according to literature information associated with them. 
Any additional information regarding the limits of the fragment found during the literature 
search, such as the requirement for an electron withdrawing group or the type of bond 
needed (e.g. a tertiary amine), was used to refine the structural alert further. The resulting 
alerts were subsequently defined as SMARTS patterns (www.daylight.com). The process of 
how the SMARTS patterns were developed is described in detail in Chapter 3. A structural 
alert was only developed if information linking category members to mitochondrial toxicity 
was present within the scientific literature. The benefit of undertaking the analysis for each 
category is that it enabled the chemical space associated with a known, and tested, 
mechanism of mitochondrial toxicity to be identified. The development of chemical 
categories and identification of additional mechanistic information from the literature was 
crucial in addressing the limitations of the information in the original dataset. 
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4.3 Results and discussion 
The aim of this chapter was to develop an in silico profiler for mitochondrial toxicity based 
around clearly defined mechanistic information. This was achieved by grouping chemicals 
based upon their structural similarity, followed by a literature search to elucidate 
mechanistic information for the chemicals in categories associated with toxicity to 
mitochondria. Overall, 35 of the 288 chemicals were identified as belonging to categories 
containing toxic chemicals: local anaesthetics, anti-anginal, and anti-arrhythmic; anti-
diabetic drugs; non-steroidal anti-inflammatory drugs; anthracycline antibiotics; 
hypolipodemic drugs; bile acids; anti-histaminic, anti-psychotic and anti-emetic drugs; and 
β-blockers. A summary of the categories developed within this chapter is shown in Table 4.1. 
In total, eight structural alerts were formed: two separate molecular initiating events for the 
hypolipodemic drugs category were identified, whilst no structural alert for the β-blocker 
category could be defined. A summary of the associated structural alerts developed within 
this chapter is shown in Table 4.2. These structural alerts cover five mechanisms of 
mitochondrial toxicity: inhibition of the electron transport chain, alternative electron 
acceptance, initiation of the death receptor pathway, uncoupling of oxidative 
phosphorylation and induction of the membrane permeability transition.  
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Table 4.1: Chemicals grouped into categories using structural similarity and their associated 
mitochondrial toxicity   
Category Name Mitochondrial toxicity 
1 Lidocaine Positive 
Bupivacaine Positive 
Etidocaine Positive 
Ropivacaine Positive 
Ranolazine Positive 
Tocainide Negative 
2 Rosiglitazone Positive 
Pioglitazone Positive 
Troglitazone Positive 
3 Mefenamic acid Positive 
Flufenamic acid Positive 
Tolfenamic acid Positive 
4 Daunorubicin Positive 
Doxorubicin Positive 
Epirubicin Positive 
Idarubicin Positive 
5 Perfluorodecanoic acid Positive 
Perfluorooctanoic acid Positive 
Perfluorooctane-sulphonamide Positive 
6 Cholic acid Positive 
Chenodeoxycholic acid Positive 
Deoxycholic acid Positive 
Glycocholic acid Positive 
Lithocholic acid Positive 
Taurocholic acid Positive 
7 Promethazine Negative 
Chlorpromazine Positive 
Fluphenazine Positive 
Mequitazine Negative 
Methdilazine Negative 
Thiethylperazine Negative 
Trimeprazine Negative 
8 Alprenolol Negative 
Atenolol Positive 
Propranolol Positive 
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Table 4.2: Structural alerts developed in the current chapter  
Category Structural alert Number of mitochondrial 
toxic chemicals in the 
category 
(mitotoxic/total) 
Mechanism(s) associated 
with the structural alert 
1 
 
R = CH2, CH3 
5/6 Uncoupling of oxidative 
phosphorylation 
2 
 
3/3 Inhibition of the electron 
transport chain and 
uncoupling of oxidative 
phosphorylation 
3 
 
3/3 Uncoupling of oxidative 
phosphorylation 
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4 
 
4/4 Inhibition of the electron 
transport chain 
5a 
 
n = 5-11 
2/2 Induction of mitochondrial 
membrane permeability 
transition 
5b 
 
n = 5-11 
1/1 Uncoupling of oxidative 
phosphorylation 
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6 
 
R1 = OH, H 
R2 = OH, NHR (R = CH2) 
 
6/6 Inhibition of the electron 
transport chain and the 
extrinsic pathway 
7 
 
R = CH2, CH3 
2/7 Inhibition of the electron 
transport chain and 
uncoupling of oxidative 
phosphorylation 
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A more detailed discussion surrounding each of the chemical categories and the mechanism 
by which mitochondrial toxicity is initiated is presented below. 
Category 1: Local anaesthetics, anti-anginal and anti-arrhythmic 
The local anaesthetics category consisted of six analogues, four of which are anaesthetics, 
with ranolazine and tocainide being an anti-anginal and anti-arrhythmic respectively. All but 
one of the chemicals, tocainide, has been shown to exhibit toxicity towards mitochondria 
enabling a single structural alert to be defined (Table 4.2). The structural alert is supported 
by a number of studies that have shown that such chemicals affect mitochondrial metabolism 
by uncoupling oxidative phosphorylation (Dabadie et al 1987, Wallace and Starkov 2000, 
Dippenaar 2007, Mehta et al 2008, Cela et al 2010). This uncoupling has been suggested to 
be mediated by both the protonophoric properties and the pKa of these chemicals. As the 
pKa is relatively similar to the intracellular pH, the level of protonated and deprotonated 
chemical is roughly at equilibrium. The presence of deprotonated chemical within the 
intermembrane space means that protons can be scavenged. Subsequently, the protonated 
chemical can combine with a hydrophobic anion to form a neutral ion-pair complex, which 
can then migrate across the inner mitochondrial membrane into the matrix, where the 
complex dissociates and the proton is released. Both the chemical and the hydrophobic anion 
then return to the intermembrane space, continuing the cycle. This assisted transport of 
protons back into the matrix dissipates the electrochemical potential, resulting in a loss of 
ATP production and ultimately cell death (Terada 1990, Schonfeld et al 1992, Sun and 
Garlid 1992, Sztark et al 1997, Wallace and Starkov 2000, Mehta et al 2008, Cela et al 
2010). It has been suggested that bupivacaine, and other highly lipophilic anaesthetics, can 
also act to uncouple oxidative phosphorylation via the mechanism outlined above without 
the need to complex with a lipophilic anion (Dabadie et al 1987). The structural alert defined 
for this category can be seen in Table 4.2. The presence, and pKa, of the tertiary amine 
group is thought to be responsible for the ability of these chemicals to scavenge protons 
within the intermembrane space. Therefore, the lack of a tertiary amine group offers an 
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explanation as to why no mitochondrial toxicity has been associated with tocainide and also 
allows for further refinement of the structural alert. 
 
Category 2: Anti-diabetic drugs  
This category consists of three thiazolidinediones: pioglitazone, rosiglitazone, troglitazone: 
each of which were identified as inducing mitochondrial toxicity. Thiazolidinediones are the 
major orally administered drugs used in the treatment of Type 2 (non-insulin dependent) 
diabetes. These drugs are used to improve insulin sensitivity and lower blood glucose levels 
within diabetic patients. Many of the thiazolidinediones have been suspected of initiating 
hepatotoxicity via mitochondrial dysfunction (Dykens and Will 2007). For example, 
troglitazone was withdrawn from the world market in 2000 due to hepatotoxicity observed in 
a number of patients (Chan et al 2005, Mehta et al 2008).  
Research into the thiazolidinediones suggests the chemicals within this category elicit their 
mitochondrial dysfunction by inhibiting the electron transport chain and uncoupling 
oxidative phosphorylation (Brunmair et al 2004, Dykens and Will 2007, Mehta et al 2008, 
Naven et al 2013). These drugs have been shown to inhibit the activity of mitochondrial 
complexes, the main target being Complex I (Brunmair et al 2004, Chan et al 2005, 
Nadanaciva et al 2007a, Nadanaciva et al 2007b, Mehta et al 2008). These chemicals 
subsequently induce mitochondrial swelling and decrease the membrane potential across the 
inner mitochondrial membrane, in turn inducing mitochondrial permeability transition 
(Masubuchi 2006, Nadanaciva et al 2007a, Nadanaciva et al 2007b). Additionally, 
thiazolidinediones have been shown to uncouple oxidative phosphorylation in a manner 
similar to that described above for the chemicals within category one (Brunmair et al 2004, 
Naven et al 2013). The structural alert defined for this category is shown in Table 4.2. It is 
thought that the properties that enable the thiazolidinediones to bind to the nuclear PPAR-
gamma receptor confers the ability to bind to Complex I (Brunmair et al 2004). Additionally, 
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the heterocyclic properties of the ring system are thought to enable the thiazolidinedione to 
cycle between a protonated and deprotonated form conferring the ability to transport protons 
across the inner mitochondrial membrane thereby uncoupling oxidative phosphorylation 
(Naven et al 2013). 
 
Category 3: Nonsteroidal anti-inflammatory drugs 
The third category comprises three chemicals: mefenamic acid, flufenamic acid, and 
tolfenamic acid: each of which has been identified as being able to induce mitochondrial 
toxicity. Each of these three chemicals are part of a group of nonsteroidal anti-inflammatory 
(NSAIDs). NSAIDs are some of the most widely used pharmaceutical drugs on the market 
that are used for their analgesic, anti-pyretic and anti-inflammatory properties to reduce and 
relieve symptoms for a variety of conditions. In order for the anti-inflammatory properties 
associated with NSAIDs to be present a carboxylic acid moiety is needed (Mehta et al 2008). 
The carboxylic acid moiety acts to inhibit cyclooxygenase activity, an enzyme responsible 
for the production of mediators of the inflammatory response, thereby reducing the level of 
inflammatory signalling. Previous research substantiates the positive mitochondrial toxicity 
result for each chemical within this category. A variety of literature sources identify each of 
these chemicals as having the ability to uncouple oxidative phosphorylation via a similar 
mechanism as that described above for the lidocaine category (Uyemura et al 1997, 
Masubuchi et al 1998, Moreno-Sanchez et al 1999, Boelsterli 2002, Siraki et al 2005). 
However, due to their lipophilicity, these chemicals do not necessarily need to be associated 
with a separate hydrophobic anion in order to translocate into the mitochondrial matrix. A 
single structural alert could be developed for this category, as shown in Table 4.2. The 
carboxylic acid moiety, which is required for the anti-inflammatory properties of the 
NSAIDs, is believed to also be required to induce the uncoupling ability of this group of 
chemicals (Mehta et al 2008). 
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Category 4: Anthracycline antibiotics 
Anthracycline antibiotics are a group of hydroxylated tetracycline quinones with a 
duanosamine sugar sidechain attached. One of the category members, doxorubicin, is one of 
the most widely used anti-neoplastic drugs within the U.S. (Wallace 2003). Structural 
similarity identified three similar chemicals. A number of studies have shown that the 
anthracycline antibiotics cause mitochondrial dysfunction by acting as alternative electron 
acceptors interfering with, and inhibiting, the electron transport chain, leading to oxidative 
stress. This occurs because under normal physiological conditions anthracyclines are usually 
deprotonated and can permeate across the outer mitochondrial membrane. Once within the 
intermembrane space these chemicals disrupt the electron transport chain by sequestering an 
electron from Complex I and are thus reduced to a semiquinone radical intermediate 
(Gerwirtz 1999, Wallace 2003). These semiquinone radicals subsequently interact with 
molecular oxygen present within the mitochondria, producing reactive oxygen species 
(ROS), including hydroxyl and superoxide anion radicals. Downstream these ROS lead to a 
variety of effects such a mitochondrial permeability transition induction and oxidative 
damage of DNA, proteins and lipids (Kappus 1986, Ohkuma et al 2001, Kim et al 2003). 
Due to the high level of similarity between the chemicals it can be assumed that the 
mechanism of action is conserved throughout the category. Analysis of the literature enabled 
a structural alert to be defined based upon the quinone-type moiety (Table 4.2). 
 
Category 5: Hypolipodemic drugs 
Perfluorinated chemicals have been widely used in a variety of commercial and 
pharmaceutical products, such as flame retardants, surfactants and hypolipidemic drugs. 
These hypolipidemic drugs induce the proliferation of peroxisomes and thus increase β-
oxidation of fatty acids. Three perfluorinated chemical analogues; perfluorodecanoic acid, 
perfluorooctanoic acid, perfluorooctane sulphonamide; were identified as having a high level 
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of similarity. However, despite the high levels of similarity between the chemicals multiple 
mechanisms were seen to induce mitochondrial dysfunction. This highlights the need to 
undertake mechanistic analysis of the categories as structural similarity on its own is not 
enough. As is shown with this category slight variations in structure have the potential to 
induce different mechanistic pathways. Accordingly, information in the literature suggests 
that for this category there are two potential mechanisms by which the perfluorinated 
chemicals elicit their mitochondrial toxicity; uncoupling of oxidative phosphorylation and 
induction of the mitochondrial membrane permeability transition pore. 
Perfluorooctane sulphonamide has been shown to uncouple oxidative phosphorylation in 
vitro via a protonophoric mechanism, similar to that described above, within various species 
(Schnellmann 1990, Schnellmann and Manning 1990, Starkov and Wallace 2002, Wallace et 
al 2013). In comparison to p-trifluromethoxyphenylhydrazone, one of the most potent 
uncouplers, perfluorooctane sulphonamide has been known to uncouple oxidative 
phosphorylation with a potency of a similar magnitude. It has been suggested that the pKa 
and ionisability of the amino acid moiety, in conjunction with the relatively high 
lipophilicity of the chemical, enables the shuttling of protons across the inner mitochondrial 
membrane into the matrix, dissipating the membrane potential (Starkov and Wallace 2002). 
In addition, perfluorooctane sulphonamide is one of a very limited number of uncoupling 
chemicals that does not contain a ring structure (Schnellmann and Manning 1990).  
In contrast, the perfluoroalkyl acids are believed to induce the mitochondrial membrane 
permeability transition at lower concentrations, whilst higher concentrations can uncouple 
oxidative phosphorylation (Langley 1990, Keller et al 1992, Starkov and Wallace 2002). It 
has been observed that perfluorodecanoic acid forms reactive oxygen species (ROS), 
hydrogen peroxide and peroxynitrite anion (Kleszczynski et al 2009). The presence of 
elevated ROS levels initiates oxidative stress within mitochondria. Oxidative stress has been 
shown to induce the membrane permeability transition (MPT) (Kowaltowski et al 2001, 
Battaglia 2005). The MPT is an increase in permeability of the inner mitochondrial 
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membrane to low molecular weight solutes (<1500 Daltons). The subsequent influx of 
solutes into the matrix instigates swelling of the inner and outer membranes causing 
disruption of the electron transport chain and a release of apoptotic proteins such as 
cytochrome c (Kleszczynski 2009, Kleszczynski and Skladanowski 2011, Wallace et al 
2013). The uncoupling action of the two perfluoroalkyl acids is similar to that described for 
category one. Two alerts were defined due to two distinct MIEs being identified (Table 4.2).  
Previous research has shown there to be an increase in toxicity concomitant to an increase in 
alkyl side chain length up to C12, with the most marked increase in toxicity (a five- to ten- 
fold increase) occurring between C6 and C8 perfluoroalkyl acids and sulphates (Wallace et al 
2013). An unsubstituted amide fragment has been shown to be required in order for 
uncoupling by perfluorinated sulphonamides to occur: fully substituted sulphonamides, 
which lack the protonated amide moiety, were found to lack the ability to uncouple oxidative 
phosphorylation (Starkov and Wallace 2002). The carboxylic acid moiety of the 
perfluoroalkyl acids chemicals is thought to be responsible for the uncoupling action of these 
chemicals at higher concentrations. However, it is unclear which fragments are required in 
the induction of the MPT. 
 
Category 6: Bile acids 
The bile acid category consists of three secondary bile acids: chenodeoxycholic acid, 
glycocholic acid and taurocholic acid: and two conjugated bile acids: deoxycholic acid and 
lithocholic acid: all with a high level of similarity to the primary bile acid; cholic acid. Bile 
acids are one of the main constituents of bile and are synthesised from cholesterol by 
hepatocytes. They play a vital role in multiple functions within both the liver and intestines, 
the main function being the sequestration of fats within micelles for excretion. Bile acids 
have been shown to decrease the membrane potential of mitochondria, alongside a decrease 
in state 3 respiration and an increase in state 4 respiration. The specific cellular mechanism 
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of bile acid-induced toxicity has not been elucidated. However, both the intrinsic 
(mitochondrial) and extrinsic (death receptor) pathways have been implicated in the 
disruption of normal mitochondrial function.  
Intrinsic pathway 
The intrinsic apoptotic pathway results in mitochondrial dysfunction due to an increase in 
intracellular stress. Hydrophobic bile acids have been shown to inhibit the electron transport 
chain by decreasing the activity of complexes I, III and IV, resulting in a decrease in state 3 
respiration and a concomitant generation of ROS (Krahenbuhl et al 1994, Winklhofer-Roob 
et al 1996, Sokol et al 2001, Yerushalmi et al 2001, Palmeira and Rolo 2004, Perez 2009). It 
has been proposed that the inhibition of complex III leads to a subsequent electron leak 
through the ubiquinone-complex III site and a concomitant ROS generation (Winklhofer-
Roob et al 1996, Yerushalmi et al 2001). The increased oxidant stress may then cause the 
induction of the MPT by oxidation of the thiol sites on the membrane permeability transition 
pore (Sokol et al 2001). Induction of the MPT triggers the release of cytochrome c, thus, 
stimulating the translocation of Bax to the mitochondrial membrane, stimulating further 
release of cytochrome c (Spivey et al 1993, Rodrigues et al 1999, Yin and Ding 2003). 
Cytochrome c is also able to initiate downstream caspase activation events discussed below 
(Yerushalmi et al 2001, Yin and Ding 2003, Palmeira 2004, Taylor et al 2008, Perez 2009). 
Extrinsic pathway 
Mitochondrial dysfunction and apoptosis initiated via the extrinsic pathway results from 
extracellular signals triggering downstream caspase activity. The oxidative stress generated 
by bile acids induces an increased presentation of Fas receptor within the plasma membrane, 
following phosphorylation of the Fas receptor by the epidermal growth factor receptor 
(Faubion et al 1998, Qiao et al 2001, Perez 2009). Upon presentation of Fas within the 
plasma membrane Fas agonists can interact with the receptor, initiating the formation of the 
death-inducing signalling complex (DISC) and subsequent activation of caspase-8. In turn, 
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caspase-8 activates caspases-3 and -7 triggering a caspase cascade that culminates in 
apoptosis (Faubion et al 1998, Jaeschke et al 2002, Yin and Ding 2003, Taylor et al 2008, 
Perez 2009). Additionally, caspase-8 can initiate the intrinsic pathway via proteolytic 
cleavage of Bid. Truncated Bid activates Bax and Bak proteins present on the mitochondria 
via oligomerisation and induction of MPT. The activated Bak and Bax proteins form 
channels within the mitochondria releasing additional cytochrome c. Cytosolic cytochrome c 
causes the assembly of apoptotic protease-activating factor-1 (APAF-1) and caspase-9, thus, 
activating caspase-9. Upon caspase-9 activation a proteolytic caspase cascade is initiated 
ultimately leading to cell death (Yin and Ding 2003, Taylor et al 2008). The generation of 
ROS, induction of MPT and activation of the caspase cascade seem to be essential steps 
within both pathways to initiate mitochondrial perturbation and apoptosis. Therefore, it 
seems likely that both pathways work synergistically to induce mitochondrial dysfunction. 
Together these chemicals enabled the definition of a single structural alert; based on the 
steroid structure to be defined (Table 4.2).  
 
Category 7: Anti-histaminic, anti-psychotic and anti-emetic drugs  
Phenothiazines are a group of heterocyclic chemicals composed of a nitrogen and a sulphur 
atom joining two benzene rings. These chemicals are widely used in the treatment of mental 
disorders, such as schizophrenia, psychosis, and anxiety, as well as conferring anti-
histaminic and anti-emetic action. This category comprises seven chemicals: chlorpromazine, 
fluphenazine, mequitazine, methdilazine, promethazine, thiethylperazine, and trimeprazine: 
five of which have been identified have been identified as being non-toxic, whilst the 
remaining two have been shown to be toxic (Table 4.1). It is important to rationalise the 
mixed toxicity results for the chemicals within this category. A number of studies in the 
literature report toxicity induced by chlorpromazine and fluphenazine (Saito et al 1982, 
Lucas-Heron et al 1994, Balijepalli et al 1999, Chan et al 2005, Nadanaciva et al 2007a, 
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Mehta et al 2008) that corroborate the data in the current chapter (obtained from Zhang et al 
2009). 
Both chlorpromazine and fluphenazine have been observed to inhibit mitochondrial 
respiration within brain and liver tissues (Guth et al 1964). This toxicity was induced by 
binding to, and inhibiting, Complex I of the electron transport chain (Chan et al 2005, Mehta 
et al 2008, Nadanaciva and Will 2011). Further investigation revealed that chlorpromazine is 
also capable of impairing mitochondrial function by inhibiting Complex IV and acting as an 
uncoupler of oxidative phosphorylation (Matsubara and Hagihara 1968, Eto et al 1985, 
Mehta et al 2008). Eto et al (1985) noted the addition of the chlorine atom increases and 
alters the mechanism by which mitochondrial toxicity occurs, i.e. chlorpromazine acts as an 
uncoupler of oxidative phosphorylation at low concentrations and an electron transport chain 
inhibitor at higher concentrations.  
Each chemical within this category contains a phenothiazine fragment. This class of drugs 
were found to cause toxicity towards mitochondria by inhibiting oxidative phosphorylation 
within liver mitochondria (Gallagher et al 1965). Due to this conserved fragment it can be 
hypothesised that the other chemicals within this category may elicit toxicity via a similar 
mechanism. Research into promethazine has shown that it can act as an uncoupler of 
oxidative phosphorylation by impeding both state 3 and state 4 respiration and 
intramitochondrial potassium ion compartmentalisation at high and low concentrations 
(Matsubara and Hagihara 1968, Eto et al 1985). Further investigation into chlorpromazine 
reveals that this chemical elicits its electron transport chain inhibitor action by inhibiting 
Complex V of the electron transport chain. The associated structural alert is as shown in 
Table 4.2. Based upon information in the literature the tertiary amine moiety is required in 
order to initiate the uncoupling of oxidative phosphorylation; whilst the phenothiazine 
fragment with an associated electron-withdrawing group leads to an increase in toxicity 
(Cela et al 2010, Cruz et al 2010, Eto et al 1985, Matsubara and Hagihara 1968, Terada 
1990). 
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Category 8: β-blockers 
Alprenolol, propranolol and atenolol are a group of (non-)selective β-blockers used in the 
treatment of hypertension. As can be seen in Table 4.1 two chemicals, atenolol and 
propranolol, were reported within Zhang et al as inducing mitochondrial toxicity, whilst the 
remaining chemical, alprenolol, was reported as being negative for mitochondrial toxicity. 
Propranolol has been seen to inhibit, via non-competitive binding, Complex V of the 
respiratory chain (Wei et al 1985, Almotrefi and Dzimiri 1992). Chemicals that inhibit 
Complex V can do so by binding to one of two subunits (F0/F1) that comprise the ATP 
synthase enzyme, thus blocking the passage of protons back into the mitochondrial matrix 
(Wei et al 1985). Together the membrane-bound F0 and matrix protruding F1 subunits are 
responsible for catalysing both the synthesis and hydrolysis of ATP. Wei et al have 
described previously that propranolol binds to the Mg2+-ATPase (F0 subunit) of Complex V 
inhibiting state 3 respiration. It has also been seen that the potency of ATPase inhibition 
induced by propranolol is of the same order of magnitude as its ability to inhibit other 
membrane-bound enzymes (Almotrefi and Dzimiri 1992). Therefore, this inhibitory effect 
induced by propranolol is due to its membrane stabilising activity and its ability to bind to 
the lipophilic F0 subunit of Complex V. In contrast, atenolol, a relatively more hydrophilic 
drug, has been shown to act via stimulating Complex V activity. The decrease in 
lipophilicity and, therefore, a decrease in ability to penetrate and interact with membrane 
macromolecules is pertinent to the decrease in inhibitory potency of atenolol (Almotrefi and 
Dzimiri 1992). Additionally, results from Almotrefi and Dzimiri (1992) suggest that atenolol 
may interact with the more hydrophilic subunit (F1) of Complex V, resulting in 
mitochondrial toxicity by stimulating the hydrolysis of ATP to ADP and inorganic 
phosphate (Almotrefi and Dzimiri 1992). As propranolol and atenolol elicit their 
mitochondrial toxicity via separate, and contrasting, mechanisms a structural alert could not 
be defined. In order to overcome this, further testing is required to elicit more information 
regarding the mitochondrial toxicity of other, structurally similar, β-blockers. This category 
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further highlights the necessity of undertaking mechanistic analysis of categories formed 
using structural similarity prior to defining a structural alert. 
 
Categories one through seven have enabled the development of structural alerts for 
mitochondrial toxicity, as the chemicals in the same category initiate the same toxicity 
pathway. These structural alerts may be used for read-across purposes within risk assessment. 
Meanwhile, category eight highlights an area where further investigation, and testing, is 
needed based around the differing pathways initiated by structurally similar chemicals. 
 
4.3.1 Profiling and grouping for mitochondrial toxicity as part of the AOP paradigm 
The ability to predict organ-level toxicity will become increasingly important to the long 
term goal of replacing animal use in determining a Lowest Observed (Adverse) Effect Level 
(LO(A)EL). Traditionally, LO(A)ELs are identified after undertaking a 28- or 90-day 
repeated dose study, with the lowest dose initiating a treatment related adverse effect in an 
organ(s) producing the LO(A)EL value. However, as no animal testing is permissible for 
cosmetic ingredients in Europe alternatives are required. As discussed previously this 
requirement has led to increased interest in the understanding of toxicity pathways and in the 
development of AOPs. As such the structural alerts that have been developed in this chapter 
are intended for use in chemical risk assessment within the AOP paradigm. Importantly for 
the data within the current chapter, it has been reported that toxicity to a number of organs is 
likely to be driven by toxicity to mitochondria (Amacher 2005, Dykens and Will 2007, 
Nadanaciva and Will 2011, Vinken et al 2013a, Vinken et al 2013b). Therefore, in order for 
a full AOP to be developed, further investigation into the organ(s) affected is required; this 
was, however, beyond the scope of the current chapter. The main outcome from the current 
chapter is that the structural alerts defined enable chemicals to be grouped into 
mechanistically-based categories based around the knowledge of a number of key MIEs for 
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mitochondrial toxicity. The resulting categories can thus be used for either prioritisation of 
chemicals for further in vitro testing or, where sufficient in vivo data exist, for read-across 
predictions of organ-level toxicity (from, for example, repeat dose toxicity testing). In terms 
of predicting organ-level toxicity in the future it is likely that additional steps in the AOP 
will need to be investigated within in vitro assays using a range of organ specific cell lines. 
For example, the use of primary human renal proximal tubule epithelial cells in the MTT 
assay to investigate nephrotoxicity due to mitochondrial dysfunction. This will enable a 
mechanistically-based weight of evidence to be constructed based around the AOP. 
Currently, chemistry-based grouping methods such as those outlined above offer the most 
immediate solution to risk assessment without using animals. 
 
4.4 Conclusions 
The aim of this chapter was to develop an in silico profiler for mitochondrial toxicity based 
around clearly defined mechanistic information utilising structural similarity and chemical 
category formation. The analysis resulted in the development of eight chemical categories 
and the definition of eight (mechanism-based) structural alerts. Of the alerts developed 
within this chapter, seven have not been defined in terms of the mechanism by which they 
initiate mitochondrial toxicity; whilst, the remaining alert (thiazolidinedione) has been 
identified previously by Naven et al (2013). Importantly, these structural alerts were derived 
using mechanistic information in the available literature to elucidate knowledge of a number 
of key Molecular Initiating Events that disrupt the normal functioning of mitochondria. It is 
envisaged that structural alerts, such as those defined in this chapter, will be combined with 
other alerts pertaining to mitochondrial toxicity; such as those within Chapters 3 and 5 and 
in the available literature; to develop a single profiler (discussed in Chapter 7). This profiler 
could be useful for grouping chemicals into categories, thus, enabling predictions to be made 
regarding mitochondrial toxicity. Additionally, the work discussed in Chapters 3 and 4 
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demonstrates how different in silico tools can be utilised in the identification of structural 
alerts. 
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†This chapter is based on a published article by Nelms et al (2014) 
Chapter 5: Development of an in silico profiler for categorisation of repeat dose 
toxicity data of hair dyes† 
 
5.1 Introduction 
Each year millions of people worldwide use hair dye products. It is estimated that over one 
third of women aged 18 or over, and approximately ten percent of men aged 40 or over, in 
the United States and Europe, use at least one type of hair dye product (Huncharek and 
Kulpelnick 2005). Hair dyes can be separated into three classes: temporary, semi-permanent, 
and permanent. Permanent, or oxidative, hair dyes are the most widely used class of hair 
dyes, accounting for approximately 80% of the hair colouring product market in the US and 
EU (Corbett et al. 1999, Cosmetics Europe 2014). This class of hair dyes is different to the 
other two classes in respect to their composition: oxidative dyes require a chemical reaction 
between a primary intermediate and a coupler in order to generate the coloured dye on/in the 
hair (Nohynek et al. 2010). The primary intermediates are normally aryl diamine or 
aminophenol compounds substituted at either the ortho- or para- position, such as p-
aminophenol. In contrast, couplers are normally aryl aminophenol or diphenols substituted at 
the meta- position, such as resorcinol. In the presence of a developer, such as hydrogen 
peroxide, the primary intermediate is oxidised and reacts with the coupler to produce a 
coloured aromatic dye (Nohynek et al. 2010) (Figure 5.1).
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Figure 5.1: A suggested reaction pathway showing how the oxidative hair dye 
phenylenediamine (primary intermediate) results in a coloured dye in the presence of 
resorcinol (a coupler) and hydrogen peroxide (adapted from Nohynek et al 2010). 
Typically, hair dye products contain between 0.05-2% primary intermediate, with the higher 
the percentage producing a darker shade of dye. In comparison, temporary and semi-
permanent hair dyes are typically acidic or basic chemicals that bind to the proteins of hair 
and do not use developers or couplers. Typical classes of temporary and semi-permanent 
hair dyes include anthraquinones and nitroaminophenols respectively.  The large number of 
people exposed to, and the reactivity of, hair dye products has led to them becoming some of 
the most widely studied cosmetic ingredients. A number of studies, both in vitro and in vivo, 
have raised concern about the carcinogenic potential of certain members of chemicals used 
within hair dye products (Baan et al. 2008; Freudenthal et al. 1999; Gago-Dominguez et al. 
2001; IARC 2010; Skipper et al. 2010). 
Previously, safety assessments for cosmetic ingredients, including hair dyes, would have 
been made, at least in part, using data from in vivo experimentation. However, significant 
changes in the European cosmetic and chemical legislations during the last decade have 
concentrated efforts in the development of alternative methods for safety testing purposes 
(EC 2003; EC 2007). The Adverse Outcome Pathway (AOP) paradigm has emerged as a 
+
+H2O2
Indoaniline dye (green) Indoaniline dye (red)
Leuco-dye (colourless)
+H2O2
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promising approach in that it enables key events in the pathway that leads to a toxicological 
outcome to be identified (Ankley et al. 2010; Vinken 2013; Vinken et al. 2013a). Key 
amongst these events is the Molecular Initiating Event (MIE), which has been the focus for 
the development of in silico profilers (Przybylak and Schultz 2013). These profilers define 
the chemical features associated with a given MIE in terms of collections of structural alerts 
and are intended to be used to categorise chemicals based on a common MIE (Enoch et al. 
2011a; Enoch et al. 2013b; Enoch and Roberts 2013; Przybylak and Schultz 2013; 
Sakuratani et al. 2013a; Sakuratani et al. 2013b; Vinken 2013; Vinken et al. 2013a) 
(discussed in more detail in Chapters 1, 3 and 4). The development of mechanism-based in 
silico profilers suitable for category formation is a time-consuming, literature-intensive 
process. Previous research leading to the establishment of in silico profilers for toxicological 
endpoints such as skin and respiratory sensitisation utilised a mechanistic hypothesis as a 
starting point for structural alert development (Enoch et al. 2008; Enoch et al. 2012b). 
However, for complex endpoints such as organ-specific toxicity for which knowledge 
relating to possible MIEs is lacking, a chemoinformatics approach, coupled with a posteri 
mechanistic rationalisation, has been shown to be successful (Hewitt et al. 2013). Given the 
complexity of potential mechanisms driving oral repeat dose toxicity, the current chapter 
employed the latter approach using the protocol described hereafter. The mechanism-based 
categories of chemicals that result from such AOP-derived profilers are applicable to predict 
hazard via read-across and, hence, assist in the filling of data gaps. In addition, these 
groupings also form the basis for the more in-depth analysis that is required for an overall 
risk assessment. In such a situation, additional testing using in vitro and/or in chemico 
methods to assess other key steps in the AOP is required. The ability to group chemicals into 
mechanism-based categories using in silico profilers enables in vitro and/or in chemico 
assays to be developed to enable the prioritisation of chemicals (Gutsell and Russell 2013).  
In order to generate structural alerts and, thus, mechanism-based chemical categories 
information pertaining to the endpoint, and chemicals, of interest are required. With respect 
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to the work undertaken in this chapter, and as part of the wider goal of the COSMOS project 
(discussed in Chapter 1), information relating to the repeat dose toxicity of cosmetic 
ingredients is required. One available source of toxicological data associated with cosmetic 
ingredients are the ‘Opinion On’ reports published by the Scientific Committee on 
Consumer Safety (SCCS) and its predecessors, the Scientific Committee on Cosmetic 
products and Non-Food Products intended for consumers (SCCNFP) and the Scientific 
Committee on Consumer Products (SCCP). The reports are generated for cosmetic 
substances for which some concern exists with regards to human health (e.g. colourants, 
preservatives, UV-filters and hair dyes) and contain data for a variety of toxicological 
endpoints, such as; skin irritation, acute toxicity, carcinogenicity and (sub-)chronic repeat 
dose studies. These reports usually contain No Observable Adverse Effect level (NOAEL)-
values, and Lowest Observable Adverse Effect Level (LOAEL)-values generated by the 
repeat dose studies. NOAEL and LOAEL values are determined upon the completion of 
various repeated dose toxicity studies, such as (sub-) chronic, developmental or reproductive 
toxicity (discussed in more detail in Chapter 1). These data, ideally the NOAEL, are used by 
the SCCS, within the ‘Opinion On’ reports, in order to calculate the margin of safety (Figure 
2.3, Chapter 2). Clearly, such data could provide a useful starting point for developing MIEs 
and identifying the chemistry required for the grouping of chemicals for read-across.  
In particular for hair dyes, high quality toxicological data became available as a consequence 
of the step-wise strategy of the European Commission to regulate all hair dyes listed as 
substances in cosmetic products. The trigger for this action was the major concern of the 
scientific community for a putative link between the use of hair dyes and the development of 
cancer, with a focus on leukaemia and bladder cancer (Gago-Dominguez et al. 2001, IARC, 
Baan 2008, Huncharek 2005, Nohynek 2004, Skipper 2010). As such, industry was required 
to submit safety dossiers for hair dye components and possible mixtures for evaluation by 
the Scientific Committee on Consumer Safety and its predecessors. Despite the requirement 
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to assess the toxicity of hair dyes, few in silico models or structural alerts for their toxic 
effects, or rationale for their grouping, are currently available.  
Therefore, the aim of this chapter is to develop an in silico profiler from a retrospective 
analysis of oral repeat dose toxicity data, available for hair dyes, retrieved from the 
Scientific Committees ‘Opinions On’ reports published between 2000 and 2013. These data 
were used to group hair dyes based upon structural similarity, with subsequent mechanistic 
analysis being undertaken using information from the peer reviewed literature. This 
mechanistic information, relating these structural alerts to potential MIEs, is important as it 
provides evidence for the interaction between the chemical and the biological system. The 
profiler could, thus, be used for a variety of process including screening data sets to identify 
chemicals of concern or to prioritise those chemicals that should undergo in chemico/in vitro 
testing first. 
 
5.2 Methods  
5.2.1 Experimental data  
NOAEL values from oral 90-day rat studies for 94 hair dyes were extracted from the 
SCC(NF)  SCCS ‘Opinion On’ reports published between 2000 and 2013, and provided to 
the current author, by Professors Vera Rogiers and Mathieu Vinken from Vrije Universiteit 
Brussel. Chemical names, CAS numbers and chemical structures were also taken from these 
reports. These data were used in the chemoinformatics analysis, described in more detail 
below, leading to the development of mechanism-based structural alerts. All data are 
available within Appendix III. 
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5.2.2 Development of in silico profiler 
The workflow below (Figure 5.2) outlines the key steps in the development of the in silico 
profiler within this chapter. Step (1) is the formation of the initial chemical categories, based 
upon the similarity of one chemical to another within the data set. Step (2) is to identify the 
structural fragment that is conserved within each of the chemicals that populate the chemical 
category. Subsequently, the conserved fragment is encoded into a SMARTS pattern and 
used to identify further chemicals from the data set that were missed by the structural 
similarity analysis (Step (3)). It was also at this stage that LOAEL values, and the associated 
adverse effects, were extracted from the SCC(NF)P/SCCS reports: this information was 
utilised when attempting to identify the potential MIE for each category. Step (4) involved 
using the peer-reviewed literature, in conjunction with the adverse effect information, to 
identify a potential MIE for each category that had been developed in the previous step. Step 
(5) is to utilise the mechanistic knowledge of the potential MIE in order to identify 
additional structural alerts capable of triggering the same MIE. Whilst also collating each of 
the alerts developed in to one in silico profiler. 
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Figure 5.2: Workflow identifying the key steps in the procedure to develop an in silico 
profiler 
 
Step 1 Structural similarity-based category formation  
All chemical structures were encoded as SMILES strings, neutralised and salts removed 
prior to chemical similarity analysis. Structural similarity of each chemical to all others in 
the dataset was calculated using the atom environments/Tanimoto coefficient approach as 
implemented in the freely available Toxmatch software (V1.07) (available from 
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/laboratories-
research/predictive_toxicology/qsar_tools/toxmatch, accessed 17.11.2014) (discussed further 
in Chapter 4). Categories were developed for each chemical in the dataset using an in-house 
code implemented in Excel software that identified analogues with a similarity index of 0.7 
or greater. The cut-off value of 0.7 was adapted from previous research by Enoch et al 
(2009), who identified that a value of 0.6 produced ‘meaningful’ categories for a diverse set 
(1) Structural similarity-based category formation 
(2) Structural alert-based category formation 
(4) Development of mechanism-based structural 
alerts 
(5) Development of a refined set of structural alerts 
and defining the profiler 
(3) Generation of SMARTS pattern and re-
screening data set 
Extraction of LOAEL 
values and associated 
toxicological effects 
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of chemicals. This adaptation was made in this chapter as the chemicals contained within the 
dataset were all hair dye chemicals and, therefore, assumed to have a relatively higher level 
of structural similarity given their use. Categories containing three or more chemicals were 
selected for further analysis.  
 
Step 2 Structural alert-based category formation  
Each similarity-based category containing three of more chemicals was inspected visually in 
order to identify key structural fragments present in all category members. This structural 
fragment was then encoded as a SMARTS pattern.  
 
Step 2.1 Generation of SMARTS patterns from visual representation 
The procedure, described in more detail in Chapter 3, was followed in order to develop 
SMARTS patterns from the structural fragments identified above. 
 
Step 3 Use of initial SMARTS patterns to re-profile dataset 
Subsequently, an in-house workflow, developed in the software package KNIME (v2.8.2), 
was utilised to re-profile each chemical in the dataset against these structural alerts (Figure 
5.3). The re-profiling was carried out in order to expand the groupings to include chemicals 
that were not found by the structural similarity analysis. This is an important step in the 
protocol as pure structural similarity-based categories are frequently unable to detect 
chemicals containing the key structural fragments. Additionally, LOAEL data, and the 
associated adverse effects, were extracted from the SCC(NF)P/SCCS reports for each 
chemical within the categories formed. 
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Figure 5.3: An overview of the workflow that screens a data set of chemicals for 
mitochondrial toxicity developed using the software program KNIME 
 
Step 4. Development of mechanism-based structural alerts  
Each of the structural alerts were then subjected to a mechanistic analysis involving detailed 
literature work in order to outline an MIE for the corresponding category members. This 
mechanistic analysis involved establishing potential MIEs related to chronic toxicity and 
linking them to the chemistry of the structural alerts. The literature work entailed performing 
keyword searches within a variety of scientific journal databases; including ScienceDirect 
and Web of Science; and using the Google Scholar search engine to find relevant full-text 
journal articles. The keywords used within these searches included: 
 The name of the conserved structural fragment for each category or the common (or 
IUPAC) name of each of the chemicals within the category, and 
 The type of toxicity observed or the organ in which the toxicity was observed 
A search including the keyword ‘mitochondria’, in addition to the above keywords, was 
undertaken separately. This additional keyword was used as it was believed that 
Chapter 5 
115 
 
mitochondrial toxicity may explain the observation of toxicity in multiple organs by 
chemicals in the same category. Structural alerts were only considered as robust if a clear 
correlation between their chemistry and an MIE identified from relevant scientific literature 
could be established. 
 
Step 5 Development of a refined set of structural alerts and in silico profiler  
The final stage in the analysis was to use the mechanistic knowledge to extend the 
applicability domain of the structural alerts enabling an in silico profiler to be developed. 
This analysis involved identifying additional structural alerts capable of triggering the same 
MIEs based on chemical information. The mechanistic rationale for these additional 
structural alerts was supported by evidence drawn from the scientific literature. All structural 
alerts identified in this chapter were then converted into SMARTS patterns and collated into 
an in silico profiler that allowed chemicals capable of causing the same MIE to be assigned 
to a single category. In keeping with the development of previous in silico profilers present 
in the literature, the structural alerts were described within the resulting in silico profiler 
based on commonality of the underlying chemistry. 
 
5.3 Results and discussion 
The aim of this chapter was to develop an in silico profiler suitable for chemical 
categorisation of oral repeat dose toxicity data of hair dyes. The analysis involved utilising 
chemical similarity to identify groups of chemicals from a dataset of 94 hair dyes. The 
similarity analysis (conducted in step 1) identified four categories of hair dyes containing 
either a 2-nitroaminobenzene, 4-nitroaminobenzene, aromatic azo or anthraquinone moieties. 
These key structural fragments were used to develop a mechanistic hypothesis for the MIE 
for each category. This analysis resulted in the definition of four structural alerts related to 
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the ability of aromatic chemicals to disrupt mitochondrial function due to their free radical 
chemistry. This mechanistic chemistry allowed an in silico profiler containing a refined set 
of structural alerts to be defined. The resulting in silico profiler assigned 56 of the 94 
chemicals in the dataset to a mechanism-based chemical category. However, further 
experimental analysis is required to identify additional key steps to allow an AOP (or AOPs) 
to be defined. 
 
5.3.1 Development of mechanism-based structural alerts for category formation 
The chemoinformatics analysis identified four similarity-based categories in the dataset, a 
category is defined here as a cluster containing three or more analogues. These included 2-
nitroaminobenzenes, 4-nitroaminobenzenes, aromatic azos and anthraquinones. In all 
datasets, a structural alert was defined based on the key fragment in each of the clusters. 
These structural alerts were used to identify additional related chemicals not identified by 
the structural similarity analysis. This re-profiling is a crucial step in the development of 
mechanism-based structural alerts when using chemical similarity to cluster the initial 
dataset as related chemicals are frequently omitted. The resulting structural alerts and the 
number of analogues identified using them to re-screen the data are summarised in Table 5.1. 
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Table 5.1: Structural alerts identified from the similarity analysis carried out on the 93 hair dye chemicals 
Structural alert Key structural fragment 
Number of 
analogues 
Mechanism(s) associated with 
the structural fragment 
2-nitroaminobenzenes 
 
R = hydrogen, carbon 
21 
Inhibition of the electron 
transport chain and uncoupling 
of oxidative phosphorylation 
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4-nitroaminobenzenes 
 
R = hydrogen, carbon 
6 
Inhibition of the electron 
transport chain and uncoupling 
of oxidative phosphorylation 
Aromatic azos 
 
R = at least one must be NH2, NH 
9 
Inhibition of the electron 
transport chain 
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Anthraquinones 
 
5 
Inhibition of the electron 
transport chain 
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Category 1: 2-nitroaminobenzene and 4-nitroaminobenzene and refined pro-quinone 
structural alerts  
A total of 26 chemicals were identified using the 2-nitroaminobenzene and 4-
nitroaminobenzene structural alerts, with one chemical (HC Yellow No. 10) triggering both 
alerts. The use of these chemicals was split between those chemicals that were used in both 
semi-permanent and permanent hair dye products, as well as those that were solely used in 
semi-permanent hair dye products. The ‘Opinion On’ reports show that these chemicals 
induce a variety of different toxicities within multiple organs, with no one organ 
predominantly exhibiting toxicity (Appendix III). One example is that of HC Orange No. 3 
that has been seen to induce toxicity in the kidney, liver, and spleen, alongside increasing 
enzyme levels (SCCNFP 2003). The nitro group in these chemicals can be readily reduced to 
an amino moiety by nitroreductase via a hydroxylamine intermediate in the gut and the liver 
resulting in the production of 1,2- and/or 1,4-diaminobenzenes (Gorontzy et al. 1993; 
Roldan et al. 2008). These chemicals are then prone to oxidation to the corresponding 1,2- 
and/or 1,4-phenylenediamines (Figure 5.4).  
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Figure 5.4: Reduction of 2-nitroaminobenzene to the corresponding 1,2-diaminobenzene and 
then subsequent oxidation to a 1,2-phenylenediamine 
 
Importantly, the conversion of 1,2-diaminobenzenes into 1,2-phenylenediamines is 
reversible implying that these chemicals are capable of cycling electrons. This also holds 
true for the corresponding 1,4-diaminobenzenes. It is known that this electron cycling 
mechanism allows these types of chemicals to interfere with the electron transport chain 
within the mitochondria (Chapter 1) (Wallace and Starkov 2000). The mechanism leading to 
disruption could therefore involve the 1,2-diaminobenzene moiety within a chemical 
accepting an electron from respiratory Complex I. This could reduce the 1,2-
diaminobenzene moiety to a 1,2-phenylenediamine which thereafter could transport the 
electron several steps down the respiratory chain directly into Complex VI. The release of 
the electron would then oxidise 1,2-phenylenediamine back to a 1,2-diaminobenzene 
allowing the process to be repeated in a cyclic fashion (Figure 5.5). This disruption 
ultimately could lead to a reduction in mitochondrial membrane potential and a subsequent 
reduction in ATP production (Bironaite et al. 1991; Chan et al. 2005; Munday 1992; 
Wallace and Starkov 2000). 
hydroxylamine 1,2-diaminobenzene
1,2-phenylenediamine
1 electron
1 electron
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Figure 5.5: Electron cycling process leading to disruption of the respiratory chain in the 
mitochondria due to the presence of an alternate electron acceptor  
 
The aromatic amine moiety of the reduction products is also known to induce uncoupling of 
oxidative phosphorylation via a protonophoric mechanism (Chapter 1) (Terada 1990a) 
(Figure 5.6). The deprotonated form of these compounds scavenges a free proton from the 
Intermembrane Space (IMS). Upon protonation the compound is able to migrate across the 
Inner Mitochondrial Membrane (IMM) into the Mitochondrial Matrix (MM). Due to the 
increased alkaline environment within the matrix the proton dissociates and the deprotonated 
compound returns to the intermembrane space enabling the cycle to continue. The 
continuation of this cycle increases oxygen consumption and heat production, alongside a 
reduction in the electrochemical gradient and ATP production (Chan et al. 2005; Pessayre et 
al. 2012; Terada 1990a; Wallace and Starkov 2000). Therefore, it is suggested that both 
mechanisms might contribute to the observed mitochondrial dysfunction. 
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Figure 5.6: Cycling of the compound within the inner mitochondrial membrane (IMM), 
scavenging hydrogen ions from within the intermembrane space (IMS) and transporting 
them to the mitochondrial matrix (MM).  
Based upon the mechanistic chemistry identified for the initial 2-nitroaminobenzene and 4-
nitroaminobenzene structural alerts, discussed above, the alert was refined to cover pro-
quinone chemicals substituted with one, or more, hydroxyl, nitro, or primary/secondary 
amine groups (or a combination thereof) (Table 5.2). This refinement could be made due to 
the extensive additional mechanistic chemistry knowledge in the wider literature relating to 
the types of chemicals that are readily converted to the corresponding quinones (Enoch et al 
2011b, Kalgutkar et al. 2005). The refinement of this alert, to cover a wider spectrum of pro-
quinones, significantly extended the number of chemicals assigned to the category: 
identifying twelve additional chemicals. As with the initial chemicals that comprised this 
category the additional chemicals are mainly used within both semi-permanent and 
permanent hair dye products. Again these chemicals have been seen to induce adverse 
effects within a variety of organs; however, the majority of these additional chemicals have 
an effect within the kidney. 
 
Category 2: Anthraquinone and refined quinone structural alerts 
The structural alert based on the anthraquinone moiety identified a total of five chemicals in 
the dataset. These chemicals are all used within semi-permanent hair dye products, with one 
chemical (acid blue 62) also being used in temporary hair dyes products. As with the 
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previous category a range of toxicities was observed, including increase in kidney weight, 
decreased body weight, increased alanine aminotransferase, increased cholesterol and 
decrease in motor activity (Appendix III). The majority of these toxicities were observed in 
the chemical acid blue 62 (SCCP 2005). These chemicals have also been shown to be 
capable of disrupting the electron transport chain in mitochondria by transporting electrons 
from respiratory Complex I directly to Complex IV (Henry and Wallace 1995; Kitani et al. 
1981). This process is similar to that outlined for 1,2- and 1,4-diaminobenzenes in that the 
anthraquinone moiety accepts an electron from Complex I to become a semi-quinone radical. 
This radical species could transport an electron directly to Complex IV, being oxidised back 
to the anthraquinone in the process (Figure 5.7). Again, this reaction is reversible allowing 
the anthraquinone moiety to cycle electrons repeatedly from respiratory Complex I to 
Complex IV. In addition to acting as direct electron transport agents, the production of the 
semi-quinone radical has also been suggested to cause indirect mitochondrial toxicity due to 
their ability to react with molecular oxygen to produce reactive oxygen species. The 
chemical species include hydroxyl and superoxide radicals that are capable of evoking 
widespread damage to mitochondrial DNA, proteins and lipids (Kappus 1986; Ohkuma et al. 
2001).  
2O22O2-.
1e-
 
Figure 5.7: Activation of the anthraquinone moiety into a semi-quinone radical 
 
Chapter 5 
125 
 
The information pertaining to the mechanistic chemistry of the anthraquinone structural alert 
enabled the alert to be refined in order to cover chemicals containing a quinone moiety, 
without the necessity to be bound to two benzene rings (Table 5.2). This refinement was 
based on the related chemistry quinones exhibit and the proven ability of these chemicals to 
disrupt the respiratory chain in mitochondria via the same mechanism as described for the 
anthraquinones (Henry and Wallace 1995; Kitani et al 1981; Scatena et al. 2007). The 
refinement of this alert identified two further chemicals within the data set with the potential 
to induce toxicity towards mitochondria: lawsone and HC Green No. 1. As with the 
chemicals containing the anthraquinone moiety both lawsone and HC Green No. 1 are used 
within semi-permanent hair dye products. In addition, these two chemicals were seen to 
induce multiple adverse effects, such as decreased erythrocyte count, increased hypokalemia 
and increase triglycerides (Appendix III). 
 
Category 3: Aromatic azo structural alert 
The final structural alert identified from the similarity analysis related to chemicals 
containing an aromatic azo moiety and identified six chemicals from the dataset. Four of 
these six chemicals are used solely within semi-permanent hair dye products, a further one 
chemical (Disperse Red 17) is used in both semi-permanent and permanent hair dye products, 
whilst the sixth (Basic Brown 16) is solely used in permanent hair dye products. In 
comparison to the previous two categories, the number of adverse effects is reduced. In 
addition, the adverse effects exhibited by these chemicals are primarily observed in the 
circulatory system, with effects including, but not limited to decreased haemoglobin, 
increased blood phosphorus and decreased haematocrit (Appendix III). Chemicals 
containing an aromatic azo linkage are readily reduced to the free amine by the enzyme 
azoreductase (Nam and Renganathan 2000). The presence of an additional nitro, amine or 
hydroxyl group in the 2- or 4-position on at least one of the aromatic rings could result in the 
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possibility of the production of a 1,2- or 1,4-diaminobenzene moiety (Figure 5.8). This 
moiety might then act as an electron cycling agent resulting in the disruption of the 
respiratory chain in the mitochondria, as outlined previously for the 2-nitroaminobenzene 
and 4-nitroaminobenzene clusters.    
 
Figure 5.8: Reduction of aromatic azo compounds producing a 1,4-diaminobenzene and then 
subsequent oxidation to 1,4-phenylenediamine capable of cycling electrons (using the hair 
dye HC Yellow No. 7 as an example) 
 
5.3.2 Additional chemicals capable of electron cycling 
Category 4: Meta-substituted benzene alert 
The mechanistic chemistry outlined for the four structural alerts identified from the 
similarity analysis suggests that the ability to cycle electrons might represent a key MIE for 
mitochondrial toxicity for aromatic chemicals of this type. The mechanistic analysis further 
suggests that chemicals capable of forming free radicals could trigger this type of MIE 
resulting in toxicity. Therefore, it was possible to develop an additional structural alert based 
2 electrons 2 electrons 2 electrons
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around this mechanistic chemistry to increase the applicable chemical space relating to the 
MIE with respect to electron cycling. The additional alert in question relates to the meta-
substituted benzene alert present in Table 5.2. This alert identified four chemicals as being 
contained in this category (Appendix III). Each of these four chemicals are used in both 
semi-permanent and permanent hair dye products. As with the previous categories the 
chemicals in the meta-substituted benzene category have been seen to induce a variety of 
adverse effects, such as an increase in centrilobular hepatotrophy, increase in kidney and 
liver necrosis, increase in bilirubin, and an increase in kidney and liver degeneration 
(Appendix III). Due to the 1,3-alignment of the substituents these meta-substituted 
chemicals are not able to form a quinone-type species. Therefore, the mechanistic chemistry 
is somewhat different to the structural alerts discussed above. However, it has been reported 
that these chemicals are capable of causing toxicity via a free radical mechanism (Aptula et 
al. 2009) (Figure 5.9). Thus, the inclusion of this additional alert can be justified based on 
the hypothetical mechanistic rationale that a key MIE for mitochondrial toxicity could be 
electron cycling due to free radical formation.  
 
Figure 5.9: Proposed oxidation of 1,3-diaminobenzene resulting in the production of free 
radical species capable of inducing mitochondrial dysfunction (an analogous mechanism is 
possible for the 1,3-dihydroxybenzene and 3-hydroxyaminobenzene containing chemicals)  
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Table 5.2: Refined set of structural alerts capable of free radical cycling chemistry (NOAEL values relate to 90-day oral rat studies)  
Name Key structural features 
Number of 
chemicals 
oral NOAEL ranges 
(mg/kg/day) 
oral LOAEL ranges 
(mg/kg/day) 
Figure 
Pro-quinones 
(R = OH, NH2, 
NH, NO2) 
 
 
37 1.4 – 250.0 4.2 - 800 5.4 
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Quinones 
(X = NH,O) 
 
 
 
7 2.0 – 200.0 7 - 940 5.7 
Meta-substituted 
benzenes 
(R = NH2, OH) 
 
4 50.0 – 100.0 33 - 316 5.9 
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Aromatic azo 
(R = NH2, NH, 
OH) 
 
8 0.3 – 52.6 12 - 99 5.8 
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5.3.3 Mitochondria and repeat dose toxicity 
The hypothetical mechanistic analysis presented above suggests that chemicals capable of 
free radical chemistry might disrupt the respiratory chain in the mitochondria leading to 
chronic toxicity. This is in keeping with previous research into the cardiotoxicity of 
anthracyclines upon extended low dose exposure (Montaigne et al. 2012). This adverse 
reaction has been shown to be related to mitochondrial dysfunction which results in the 
activation of a number of protein kinases. The MIE for this toxicity has been suggested to 
involve the ability of the quinone moiety within these drugs to form a semi-quinone radical 
and thus cycle electrons (Figure 5.7). In addition, these chemicals have been shown to form 
a variety of reactive oxygen species - such as hydroxyl and superoxide anion radicals - also 
capable of disrupting the normal function of mitochondria. These reactive oxygen species 
can subsequently induce damage to (mitochondrial) DNA, proteins, and lipids and may 
initiate membrane permeability transduction (Kappus 1986, Ohkuma et al 2001, Kim et al 
2003). It has also been suggested that mitochondrial dysfunction is a key driver in chronic 
toxicity (Kovacic 2001a; Kovacic 2001b; Porceddu et al. 2012; Vinken et al. 2013a). A 
recent study also outlined how for the same chemical the mechanism driving toxicity can 
change on-going from acute to chronic exposure (Nikam et al. 2013). The importance of 
mitochondrial dysfunction as a driver of chronic toxicity has recently also led to the 
definition of a number of structural alerts, one of which (2-aminonitrophenol) was included 
in the current chapter (Naven et al. 2013). 
Detailed analysis of the repeat dose data highlights that a variety of adverse effects within 
multiple organs are associated with the LOAEL values for chemicals assigned to each 
category (available in the Appendix III). This variability in the toxicity profile adds weight 
to the hypothesis that the observed toxicity might have been initiated by mitochondrial 
dysfunction. This is due to the fact that mitochondria are present within most organ systems, 
performing a number of roles vital to normal cellular functioning. There is an extensive body 
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of literature outlining a range of chemicals that inhibit the mitochondrial physiology 
resulting in toxicity at the organ level (Dykens 2008b). Typically, the most susceptible 
organs are those containing a higher concentration of mitochondria, those exposed to a 
higher concentration of the compound and/or those with a higher aerobic energy demand, 
such as the liver, kidney and cardiac muscle (Amacher 2005; Dykens 2007a; Dykens 2008b). 
In addition, it has been recognised by the pharmaceutical industry that mitochondrial 
dysfunction may be a cause of numerous toxicities within a variety of organs, and has led to 
the withdrawal of a number of therapeutic drugs (Amacher 2005; Dykens 2007a; Dykens 
2008b; Pessayre et al. 2012).  
 
5.3.4 Adverse Outcome Pathway concept, perspectives and proposed future work 
The analysis presented above outlines how structural alerts related to potential MIEs could 
be derived. The main focus of this type of analysis is the development of the mechanistic 
chemistry relating the structural alerts to a possible MIE. This focus is a process that 
involves an in-depth survey of relevant scientific literature in support of the mechanistic 
hypothesis made, enabling in silico profilers to be developed for a given MIE. The current 
chapter has resulted in the development of a profiler capable of identifying chemicals that 
could cycle electrons and, thus, potentially lead to the disruption of the respiratory chain in 
the mitochondria. An important aspect of the on-going development of in silico profilers is 
the experimental verification of the mechanistic hypothesis, which increases confidence in 
the prediction of an MIE for an untested chemical. Such analysis has been recently 
undertaken for the in silico profilers relating to covalent protein binding in the OECD QSAR 
Toolbox (Enoch et al. 2012a; Enoch et al. 2013a; Nelms et al. 2013; Rodriguez-Sanchez et 
al. 2013). In terms of the current chapter, future work would consist of testing of a 
representative number of hair dyes/chemicals from each of the categories outlined to cause 
mitochondrial toxicity in an in vitro experimental set-up. In the longer term, the applicability 
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domain of the in silico profiler could then be much better defined through the use of directed 
and intelligent testing of compounds using assays appropriately defined by the key events of 
the AOP. Work undertaken in Chapter 6 demonstrates how in vitro and in chemico assay 
results can be utilised to verify, and refine, structural alerts. 
To be able to predict oral repeat dose toxicity reliably, it is necessary, in addition to defining 
the applicability domain of the in silico profiler and by extension the MIE associated with 
the profiler, to generate extensive knowledge of subsequent key events in the AOP leading 
to toxicity. This requirement is highlighted by the broad range of oral NOAEL values for the 
categories derived in the current chapter which vary between one and two orders of 
magnitude (Table 5.2 for the ranges, Appendix III for each chemical within each category). 
Importantly, these values show the limitations of the in silico profilers ability to predict oral 
repeat dose toxicity. Assuming no additional information is available, the most realistic 
prediction for an untested chemical, assigned to one of the categories, would be to state that 
the oral NOAEL value would be likely to fall within the range of the values for the other 
category members, i.e. perform read-across. However, even this type of prediction may not 
be appropriate, in that the new untested chemical could be capable of altering a downstream 
key event in the AOP in a different manner to the remaining category members. It is also 
possible that the chemical may have a different toxicokinetic and/or dynamic profile to the 
other category members. It is therefore essential that the mechanistic information relating to 
the MIE contained within an in silico profiler is complimented with information derived 
from other existing in vivo data, in vitro, in silico or in chemico tests designed to target other 
key events in the AOP (and relating to toxicokinetics and dynamics). Only when a 
significant proportion of this information is available will the estimation of values such as 
NOAELs become possible without using animal models. 
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5.4 Conclusions 
This chapter proposes an in silico profiler for chemicals used as hair dyes capable of causing 
mitochondrial dysfunction. It is based on a retrospective analysis of oral repeat dose toxicity 
data for 94 hair dye chemicals and is intended for use in grouping and category formation. It 
is important to note that the proposed profiler does not predict oral repeat dose toxicity; 
instead it provides arguments for a key molecular initiating event that might be responsible 
for initiating an adverse outcome pathway leading to chronic toxicity. In order to be more 
widely applicable for mitochondrial toxicity the structural alerts developed within this 
chapter will need to be combined with additional alerts; both for electron cycling and for 
other molecular initiating events leading to mitochondrial dysfunction, for example those 
discussed in Chapter 4. However, at present this in silico profiler can still be useful for 
identifying novel chemicals, containing the moieties identified herein, with the ability to 
induce mitochondrial toxicity via inhibition of the electron transport chain due to electron 
cycling (Chapter 1). Thereby, enabling the user to identify chemicals within a data set that 
should be prioritised to undergo testing within in vitro or in chemico assays. This work 
generally shows that detailed mechanistic analysis is required for the development of in 
silico profilers and explains how such analysis can be used to identify potential molecular 
initiating events. Clearly future in vitro and/or in chemico work must be undertaken to 
outline additional key events in the biological pathway before a relevant and complete 
adverse outcome pathway could be established (discussed in Chapter 7). 
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*This chapter is based on an a published article by Nelms et al (2013) 
Chapter 6: Experimental verification, and domain definition, of structural alerts for 
protein binding: epoxides, lactones, nitrosos, nitros, aldehydes, and ketones* 
 
6.1 Introduction 
An in silico profiler consists of a series of chemical fragments, derived from knowledge of 
mechanistic organic chemistry, known as structural alerts. These structural alerts can be used 
to group chemicals into categories based upon the knowledge of a well-defined molecular 
initiating event (Enoch et al 2008b, Enoch et al 2011a). The structural alerts developed in 
the previous chapters (Chapters 3, 4, and 5) focussed on the ability to induce mitochondrial 
toxicity via different molecular initiating events. This mechanistic approach to grouping 
allows for interpretable predictions to be made for novel chemicals for which toxicological 
data are absent. It is therefore important that the structural alerts within profilers are well 
defined in terms of the chemical space in which they can be applied and can make reliable 
predictions (also known as the applicability domain). A key advantage of developing 
structural alerts with a well-defined chemical space is that there is less likelihood that a 
chemical will be incorrectly assigned to a category. That is to say, the profiler will be less 
likely to assign non-toxic chemicals as being toxic or assigning chemicals acting via 
different mechanisms to the same category.  
Previous research has shown that the mechanistic domains pertaining to protein binding 
described below can be encoded computationally into in silico profilers (Enoch 2010, Enoch 
and Cronin 2010, Enoch et al 2011a, Enoch et al 2011b). One such computational program 
is the Organisation for Economic Co-operation and Development (OECD) QSAR Toolbox. 
The OECD QSAR Toolbox contains a number of features including: a metabolic simulator, 
which enables predictions to be made regarding a chemicals potential metabolites in a 
variety of test systems; a database containing a vast quantity of acute and repeat dose 
toxicity data, provided by several commercial and governmental sources such as the 
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European Chemicals Agency, the US Environmental Protection Agency, and Fraunhofer 
Institute. Additionally, the QSAR Toolbox provides a method to group chemicals together, 
into categories, based upon structural and/or mechanistic similarities, and enables structure-
activity relationships, such as read-across, to be used to fill data gaps for chemical hazard 
assessment. Furthermore, the QSAR Toolbox contains a number of in silico profilers 
covering a variety of (eco)toxicological endpoints, such as bioaccumulation, carcinogenicity, 
DNA binding, whilst also including two profilers for protein binding; the Optimised 
Approach based on Structural Indices Set (OASIS) and the OECD profilers.  
Traditionally, a chemical’s toxicological profile has been assessed via in vivo testing. 
 owever, since the introduction of chemical legislation, such as the European Union’s 
REACH (Registration, Authorisation, restriction and Evaluation of Chemicals) (EC 2006a, 
EC 2006b) and the 7th amendment to the Cosmetic Directive (EC 2003), a number of 
alternative techniques have been promoted (Schultz 2010, Adler 2011) (discussed in more 
detail in Chapter 1). It is envisaged that these alternatives will generate information that can 
be compiled, and used as part of a weight of evidence, in order to aid hazard and risk 
assessments to be performed for chemicals lacking in vivo data.  
One of the simplest in silico techniques that can be applied to the toxicological assessment 
of chemicals is the creation of chemical categories (ECHA 2008, OECD 2011). Chemical 
categories can be developed based upon similarity across a group of chemicals for a variety 
of properties, such as structural features, physico-chemical properties or mechanism of 
action. These categories can thus be utilised to make predictions based upon the premise that 
similar chemicals should have similar chemical and biological activities (ECHA 2008, 
ECHA 2012). Thus, data for tested chemicals in a particular category can be used to fill data 
gaps for untested chemicals (as discussed in Chapter 1). One of the better ways to assess 
chemical similarity is to apply the principles of mechanistic chemistry to group substances 
by their ability to undergo a common reaction (Schwöbel et al 2011). Of particular relevance 
to category formation are electrophilic reactions, whereby a covalent bond(s) is formed 
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between an electron-poor non-endogenous chemical (an electrophile) and an electron-rich 
biological target (a nucleophile) (Schwöbel et al 2011). An electrophile is a chemical that, 
during chemical reactions, is attracted to an electron-rich centre, acting as a Lewis acid in so 
much as an electron pair is accepted from a nucleophile in order to form a covalent bond. In 
contrast, a nucleophile is a chemical attracted to an electron-deficient centre that donates an 
electron pair within a covalent bond, i.e. a Lewis base.  
It is well known that there are a range of electrophilic reactions that target a variety of 
biological nucleophiles, such as proteins, lipids or other related electron-rich molecules 
(Schwöbel et al 2011). It is, therefore, important to consider the selectivity of an electrophile 
toward a specific nucleophile. This can be explained by the classification of electrophiles 
and nucleophiles according to their chemical “hardness” and “softness”. Briefly stated, hard 
electrophiles bind preferentially to hard nucleophiles while soft electrophiles bind 
preferentially to soft nucleophiles. This concept of “like-reacts-with-like”, whilst not 
absolute, reflects the fact that dissimilarity in electrophilic hardness/softness results in a 
higher potential energy barrier for the electrophilic reaction and subsequently lower 
chemical reactivity. 
Hard electrophiles are molecules with low polarisability having their electron deficiency 
localised as a positive (or partially positive) electrostatic charge. In contrast, soft 
electrophiles are molecules with high polarisability having their electron deficiency spread 
over a larger area of the molecule (resulting in a negative or partially negative charge). In 
this context polarisability can be defined as the amount by which the electron cloud, of an 
electrophile, can be deformed in the presence of a nucleophilic anion (or lone pair of 
electrons), with the electron cloud of soft electrophiles deforming easier, and to a greater 
extent, than hard electrophiles. Nucleophilic targets in biological molecules typically include 
electron-rich heteroatoms such as sulphur, nitrogen, and oxygen. Sulphur is at the soft end 
and oxygen is at the hard end of the nucleophilic range with nitrogen being intermediate. 
This means that harder electrophiles prefer to react with the in-ring oxygen and nitrogen of 
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nucleic acids, while softer electrophiles prefer to react with sulphur and nitrogen of amino 
acids in proteins (Schultz et al 2006). Thus, nucleophilic sites related to protein and DNA 
binding are, in order of increasing hardness: thiol group of cysteine (and glutathione), 
sulphur atoms of methionine, primary amino groups (e.g. of lysine), secondary amino groups 
of histidine, primary amino groups of purine bases (e.g. adenine), ring N-atoms of purine 
and pyrimidine bases, O-atoms of purine and pyrimidine bases, and O-atoms of phosphate 
(Schwöbel et al 2011). Figure 6.1 shows the biological nucleophiles identified above in 
order of increasing hardness. 
 
Figure 6.1: Nucleophilic sites related to protein and DNA binding (circled in red), in order of 
increasing hardness from left to right and top to bottom. 
 
Earlier investigations into the use of mechanistic chemistry to define the reactions that occur 
when a non-endogenous chemical electrophile covalently binds with a biological 
macromolecule outlined six mechanistic domains (Aptula and Roberts 2006, Enoch et al 
2011b). These mechanistic domains are; Michael addition, aromatic nucleophilic 
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substitution (SNAr), unimolecular aliphatic nucleophilic substitution (SN1), bimolecular 
aliphatic nucleophilic substitution (SN2), Schiff base formation, and acylation.  
Michael addition reactions occur between a biological nucleophile and an alkene or alkyne 
polarised by an electron withdrawing group (,-unsaturated alkenes and alkynes). The 
presence of the electron withdrawing group is key to the reactivity as it draws electron 
density away from the -carbon, therefore, making it more positively charged than it would 
otherwise be within an unpolarised alkene or alkyne (Figure 6.2). In addition, the electron 
withdrawing group also stabilises the negative charge that develops on the α-carbon in the 
intermediate, with more electronegative groups increasing reactivity (Aptula and Roberts 
2006). Finally, substituents surrounding the -carbon reactive centre have been shown to be 
influential on the rate of reactivity, with chemicals highly substituted being less reactive than 
unsubstituted chemicals (Koleva et al 2008, Schwöbel et al 2010a, Schwöbel et al 2010b, 
Enoch and Roberts 2013b).  This can be rationalised in terms of the accessibility of the -
carbon, with more highly substituted carbons being less accessible to attack by the 
nucleophile. 
 
Figure 6.2: Scheme showing the Michael addition reaction (X = polarising group e.g. 
aldehyde, ketone, ester or amide) 
 
Both unimolecular and bimolecular nucleophilic substitution reactions (SN1 and SN2 
respectively) involve an aliphatic carbon, nitrogen, sulphur or halogen atom, with an 
electronegative leaving group attached, being attacked by a biological nucleophile. 
Unimolecular nucleophilic substitution reactions occur in two steps, the first step involves 
the formation of a cationic intermediate. The second step involves the cationic intermediate 
X
protein
+ H+
X X
protein protein
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being attacked by the biological nucleophile (Figure 6.3). In contrast, SN2 reactions occur in 
one step via a transition state (Figure 6.4). Typically, these two mechanisms are in 
competition with one another, with the preferred mechanism for a given chemical being 
based upon two key factors: the steric hindrance at the reactive centre and the amount of 
stabilisation provided to the cationic intermediate by the surrounding substituents. For 
example, tertiary halides react via an SN1 mechanism as the bulky substituents surrounding 
the reactive centre act to prevent any back-side attack by the nucleophile due to their steric 
bulk. In addition, the presence of the alkyl groups helps to stabilise the cationic intermediate 
due to the inductive effect. In contrast, primary and secondary halides react via an SN2 
mechanism, as the reactive centre is less sterically hindered coupled with decreased 
stabilisation of the (potential) cationic intermediate due to the lower inductive effect from 
the substituents.  
 
Figure 6.3: Scheme showing the SN1 reaction (X = leaving group e.g. halogen) 
 
Figure 6.4: Scheme showing the SN2 reaction (X = leaving group e.g. halogen) 
 
Substituted aromatic chemicals can react with biological nucleophiles via nucleophilic 
aromatic substitution (SNAr). As with the previously discussed SN2 mechanism, the SNAr 
reaction involves an initial nucleophilic attack producing a resonance stabilised negatively 
charged transition state. This is followed by the elimination of the leaving group to produce 
- X-
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X
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the substituted adduct (Figure 6.5). In order for an SNAr reaction to be viable, at least two 
electron withdrawing groups are required ortho and para to the leaving group, whether as 
substituents or present within the benzene ring, meta-substituted aryl halides have been 
shown to be non-reactive via SNAr (Aptula and Roberts 2006, Enoch et al 2011b). The rate 
of reaction for the SNAr mechanism is dependent upon the number of electron withdrawing 
groups present, i.e. the more electron withdrawing groups that are substituted on (or within) 
the benzene ring the more reactive the chemical (Figure 6.6), this is due to the added 
stability that is conferred onto the carbanion intermediate by the electron withdrawing 
groups (Enoch et al 2012a). 
 
Figure 6.5: Scheme showing the SNAr reaction, using a nitro group as an electron 
withdrawing group (X = leaving group e.g. halogen, R = suitable electron withdrawing 
group e.g. nitro group) 
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Figure 6.6: The effect multiple electron withdrawing groups can have on protein binding 
affinity. Additional withdrawing groups increase toxicity due to added stability conferred 
onto the carbanion intermediates by electron withdrawing groups (X = leaving group e.g. 
halogen, R = electron withdrawing group e.g. nitro group) 
 
Schiff base formation occurs when a primary amine of a lysine acts as a nucleophile by 
attacking the electrophilic carbon of the carbonyl moiety in an aldehyde or ketone (Figure 
6.7). The first stage of Schiff base formation involves the lone pair of electrons on the amine 
reacting with the carbonyl carbon to form a tetrahedral hemiaminal intermediate. Upon 
protonation of the hydroxyl group, the lone pair of electrons on the amine nitrogen atom 
forms a double bond with the neighbouring carbon, expelling the newly formed water 
molecule. The final stage is the deprotonation of the iminium ion and production of the final 
Schiff base product, or imine. The rate of Schiff base formation is understood to increase as 
the side chain of the aldehyde or ketone becomes more electronegative. In contrast, a 
decrease in Schiff base formation has been seen for aldehydes directly bound to a benzene 
ring. It is thought this is due to the additional activation energy required to overcome the 
resonance stabilisation conferred to the aldehyde moiety by the benzene ring (Patlewicz et al 
2001). Additionally, increasing the steric bulk of substituents surrounding the carbonyl 
moiety decreases reactivity by hindering the ability of the nucleophile to attack the carbonyl 
carbon.  
˃ ˃ 
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As ,-unsaturated aldehydes have the potential to react via both Schiff base formation and 
Michael addition it can be problematic to distinguish which reaction mechanism is more 
likely to occur. However, the likelihood of whether a Schiff base or Michael addition 
reaction occurs is dependent upon: the saturation of the aldehyde, the accessibility of the -
carbon, and the nucleophile present. For example, if the aldehyde is fully saturated, or the -
carbon is sterically hindered by bulky substituents groups, and the nucleophile is an amine a 
Schiff base reaction will be favoured. In contrast, if the aldehyde is unsaturated, with little or 
no steric bulk around the -carbon, and the nucleophile is a sulphur group a Michael 
addition reaction will be favoured. 
 
Figure 6.7: Scheme showing the Schiff base reaction 
 
Acylation reactions are similar to Schiff base formation in that the nucleophile attacks the 
carbonyl carbon moiety. However, in an acylation reaction the carbonyl carbon atom is 
attached to an electronegative group that, during the course of the reaction, acts as a leaving 
group. As can be seen in Figure 6.8 the nucleophile attacks the carbonyl group resulting in 
four coordinate, tetrahedral, transition state bonds. There are three main factors that affect 
the rate of an acylation reaction. The first is the electronegativity of the leaving group, with 
more electronegative groups inducing a quicker reaction. This results in both an increase in 
the partial positive charge present on the carbonyl moiety, as the additional electron 
withdrawing group further polarises the carbon atom, and the increase in electronegativity of 
protein
- H2O+ H
+
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the leaving group allows it to more readily accept the negative charge as it is expelled. The 
second factor is the amount of steric bulk surrounding the carbonyl moiety, an increase in 
the bulk of substituents surrounding the carbonyl moiety decreases the rate of reaction by 
reducing the ability of the nucleophile to attack the carbonyl carbon. Finally, as the 
resonance between the carbonyl group and the electronegative leaving group increases the 
reactivity will decrease, due to the electron density being more greatly dispersed decreasing 
the + charge present on the carbonyl carbon. 
 
Figure 6.8: Scheme showing the acylation reaction (X = leaving group e.g. halogen) 
 
Whilst these principles are important for all structural alerts (i.e. not just the protein binding 
alerts described above), the aim of this chapter was to highlight the importance of using 
experimental data obtained from in chemico and in vitro assays to verify the structural alerts 
within the OASIS and OECD in silico profilers for protein binding in the OECD QSAR 
Toolbox. Additionally, the data obtained from these assays were utilised to identify chemical 
space where new structural alerts were needed, or existing alerts needed to be refined. The 
chemical space of the structural alerts for seven chemical classes (epoxides, lactones, 
nitrosos, nitros, aldehydes, ketones and ring-strained hydrocarbons) was investigated using 
data from an in chemico glutathione (GSH) reactivity assay and an in vitro growth inhibition 
assay. 
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6.2 Method 
6.2.1 Data Set 
Thirty three chemicals containing an aldehyde, epoxide, ketone, lactone, nitroso, nitros or a 
strained hydrocarbon ring moiety were evaluated within two separate assays: an in chemico 
assay used to measure the reactivity of a chemical towards the thiol group present within 
glutathione, and an in vitro assay that measures the concentration of a chemical required to 
inhibit the growth of Tetrahymena pyriformis by 50%. The in vitro assay can be used to 
identify chemicals that react with proteins via each of the six mechanisms described above; 
this is due to the presence of multiple protein types within Tetrahymena pyriformis. In 
contrast, the in chemico assay, as it only contains one (tri)peptide (glutathione), can identify 
chemicals that act via all except the Schiff base reaction mechanism; this is due to the 
absence of a lysine moiety within glutathione that is required for Schiff base formation to 
occur. All tested chemicals were purchased from commercial sources (SigmaAldrich.com or 
Alfa.com) in the highest purity available (95% minimum) and were not further purified prior 
to testing. Both the in chemico and in vitro assays were performed by colleagues from the 
University of Tennessee: the data generated were obtained by following the protocols 
detailed below. 
 
6.2.2 In chemico glutathione reactivity 
Reactivity with the thiol group of glutathione (GSH) was measured in a simple and rapid 
spectrophotometric-based assay with the free thiol quantified by its reaction with 5,5’-dithio-
bis(2-nitrobenzoic acid) (DTNB) with the absorption of the product measured at 412 nm 
(Schultz 2005, Enoch 2012a). Briefly, experiments were performed by a) freshly preparing 
GSH at 1.375 mM by dissolving 0.042 g of reduced GSH into 100 ml of phosphate buffer at 
pH 7.4; b) freshly preparing stock solutions of each tested chemical by dissolving the test 
chemical in dimethyl sulphoxide (DMSO) to which phosphate buffer was subsequently 
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added; and c) combining the correct amounts of GSH solution, stock solution, and buffer to 
bring the final concentration of thiol to 0.1375 mM, in a manner so the concentration of 
DMSO in the final solution was always <10%. 
Following range-finding experiments, subsequent experiments were performed with 
concentrations adjusted to 90, 80, 60, 40, 20 and 10% of the stock solution. Associated with 
each assay was a control containing GSH and a blank without GSH. The RC50 values (the 
concentration giving 50% reaction in a fixed time of 2h) were determined from nominal 
chemical concentrations (dependent variable) and absorbance normalised to the control 
(independent variable) using Probit Analysis of the Statistical Analysis System (SAS) 
software (SAS Institute, Cary, NC).  
Chemicals with a RC50 value of greater than 135 mM were considered non-reactive. 
Additional reactivity testing was performed on selected epoxides that were not reactive in 
the more polar environment, as described above. In these cases, the reactivity assessment 
was performed in a medium of 50% methanol and 50% buffer with all other parameters 
being the same as described above. This modification increased the solubility of test 
substances without altering inherent reactivity. The comparability between reactivity 
measurements made in aqueous solution and methanol has been demonstrated previously 
(Enoch et al 2012a). 
 
6.2.3 Aquatic toxicity data 
The protocol described by Schultz (Schultz 1997) was utilised by colleagues at the 
University of Tennessee to obtain the 50% inhibitory growth concentration (IGC50) of the 
common ciliate Tetrahymena pyriformis for chemicals shown in Table 6.1. This assay was 
conducted over a 40 h period with the population density of Tetrahymena pyriformis cells 
being spectrophotometrically quantified at 540 nm as the test endpoint. Two controls, the 
first control containing no test material and Tetrahymena pyriformis and the second 
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containing neither test material nor Tetrahymena pyriformis, were used in order to indicate 
the suitability of the medium and also to help interpret the results produced under test 
conditions. Each chemical was tested in triplicate; these triplicates consisted of a minimum 
of five different concentrations of the test chemical. Following the 40h incubation and the 
spectrophotometric quantification of the population density of Tetrahymena pyriformis for 
each test condition, the IGC50 value was calculated (in millimolar units) by absorbance 
normalised to controls (independent variable) and the nominal concentration of the toxicant 
(dependent variable) using the Probit Analysis in SAS (Statistical Analysis Software) 
software (SAS Institute, Cary, NC). 
 
6.2.4 In silico predictions 
The chemical structure of each chemical was checked against various identifiers, i.e. 
chemical name, CAS and/or other identifiers, before the chemicals were profiled using the 
OASIS and OECD protein binding profilers individually. The chemicals were profiled using 
the OASIS and OECD protein binding profilers in version 3.0 of the OECD QSAR Toolbox 
(available from www.qsartoolbox.org). If a structural alert was triggered for a chemical in 
one, or both, of the profilers then a chemical was deemed to have the ability to covalently 
bind to proteins. For chemicals where an alert for protein binding was identified, the 
electrophilic mechanism was recorded. As neither of the two assays described above 
consider metabolism only chemicals with the potential to directly act as electrophiles were 
investigated, meaning that structural alerts relating to metabolism were not investigated.  
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6.2.5 Verification of alerts 
The in chemico and in vitro assays were subsequently used to verify the in silico predictions. 
A structural alert in a profiler was deemed to be correct if it was in agreement with one, or 
both, of the assay results, i.e. reactive to GSH and/or demonstrating toxicity to Tetrahymena 
that was significantly different from baseline. Those chemicals that exhibited toxicity 
significantly different from baseline demonstrate that factors other than hydrophobicity are 
driving toxicity, i.e. an electrophilic reaction. The calculated narcosis baseline was 
developed by Ellison et al (2008) from a linear regression analysis of toxicity data, within 
the Tetrahymena pyriformis assay, for 87 saturated alcohols and ketones contained within a 
larger dataset of 517 chemicals covering a variety of chemical classes, including, but not 
limited to, amides, esters, haloalkanes and sulphides. The results of this linear regression 
analysis were used to develop Equation (1). In this chapter a chemical was judged to exhibit 
toxicity significantly different from baseline, within the scatterplot of log 1/IGC50 data 
against log   (Figure 6.9) produced using Minitab 16.2.2, if there was a ≥1 log unit deviation 
from the calculated baseline toxicity model developed by Ellison et al (2008). Within this 
scatterplot log P was calculated using the KOWWIN (v1.68) application available in the 
EPISuite software (freely available at www.epa.gov) 
logIGC50-1 = 0.78 logP – 2.01   (1) 
n = 87, r2 = 0.96, s = 0.20, F = 2131 
Where, n is the number of observations; r 2 is the square of the correlation coefficient 
adjusted for degrees of freedom; s is the SE on the estimate; F is Fishers statistic. 
Additional analysis was undertaken to discern the reasoning behind any discrepancy, i.e. 
comparing the results from the in silico profilers and the in chemico and in vitro assays to 
understand how and why variances occurred.  
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6.3 Results and discussion 
The aim of this chapter was to highlight the importance of using experimental data to verify 
the structural alerts within the OASIS and OECD in silico profilers for protein binding in the 
OECD QSAR Toolbox. In addition, the experimental data were used to define new, or refine 
existing, structural alerts contained within the profilers. Seven classes of chemicals with 
various functional groups were studied: epoxides, lactones, nitrosos, nitros, aldehydes, 
ketones and ring-strained hydrocarbons. Despite the fact that the two profilers were 
developed separately there is still a high degree of overlap between them due to the 
underlying data from which they were developed (Patlewicz et al 2007, Enoch et al 2011b). 
The reactivity information was supplemented with that from the presence or absence of 
excess toxicity (in this instance an indication of cellular protein binding) in the Tetrahymena 
pyriformis growth inhibition assay. The in silico, in chemico and in vitro data are 
summarised in Table 6.1. These data showed, as is consistent with organic reaction 
chemistry, chemicals within the epoxide, nitroso, nitros, lactone and aldehyde and di-ketone 
chemical classes to be capable of a covalent reaction with proteins. No reactivity was 
observed in either in vitro or in chemico assay for the mono-ketone and ring-strained 
hydrocarbon classes; this is in agreement with the absence of a structural alert within both of 
the in silico profilers for these chemical classes. 
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Figure 6.9: Plot of log (1/IGC50) to T. pyriformis against log P for each chemical category. 
The solid line represents baseline toxicity as defined by Ellison et al (2008), whilst the 
dashed line represents baseline toxicity plus one log unit (i.e. excess toxicity if above the 
dashed line) as defined by Nendza et al (2007). 
 
6.3.1 Relationship between toxicity to Tetrahymena pyriformis and hydrophobicity 
The relationship of acute (cyto)toxicity (IGC50) with hydrophobicity (log P) shows that as 
hydrophobicity increases there is an associated increase in (cyto)toxicity (Figure 6.9). The 
plot shows that a significant number of chemicals have excess toxicity. A verdict of excess 
toxicity was assigned if a chemical’s toxicity was at least one log unit above the calculated 
baseline (Nendza et al 2007, Ellison et al 2008). Excess toxicity is an indicator, although not 
absolute proof, of reactivity. This is due to there being multiple mechanisms by which 
excess toxicity could be initiated, these being: weak acid respiratory uncoupling, precursor 
to soft electrophiles, precursor to redox cyclers, and soft electrophiles (Schultz et al 1996). 
Importantly, there are a number of reasons why a chemical may be intrinsically reactive yet 
43210-1-2
3
2
1
0
-1
-2
log P
lo
g
 (
1
/
IG
C
5
0
)
4-Ring Lactone
5/6-Ring Lactone
Aldehyde
Di-ketone
Epoxide
Ketone
Nitroso
Strained ring hydrocarbons
Chemical Class
Chapter 6 
151 
 
not exhibit excess toxicity in the Tetrahymena pyriformis assay. The main reason why an 
intrinsically reactive chemical may not exhibit excess toxicity in the in vitro assay relates to 
a chemical’s hydrophobicity. Firstly, the hydrophobicity of the chemical may be such that 
the chemical is not soluble in the test system, i.e. the chemical is too hydrophobic to be 
soluble in the aquatic environment of the Tetrahymena pyriformis assay. Alternatively, a 
chemical may be reactive in the in vitro assay but still appear on the narcosis baseline due to 
the hydrophobicity of the chemical, i.e. the chemical’s log (1   C50) and lop P values may 
coincidentally intersect on the narcosis baseline. In such a case inspection of a series of 
related chemicals often reveals their toxicity to be dependent on reactivity rather than 
hydrophobicity. Therefore, this information is useful and should be considered to be part of 
a weight of evidence to understand the reactivity of a chemical. 
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Table 6.1: Summary of experimental and in silico data (SN2 = bimolecular nucleophilic substitution, AC = acylation, SB = Schiff base formation, Non = no 
alert, NucA = nucleophilic addition NR = not-reactive, Non-cov = non covalent interaction, NSDB = not significantly different from baseline, XS = excess 
toxicity) 
ID Class Chemical Name LogP 
In silico profiler 
Log 1/RC50 In chemico Log 1/IGC50 
Toxicity to 
T. pyriformis OASIS OECD 
1 
Epoxides 
1,2-Epoxybutane 0.86 SN2 SN2 -1.73 Reactive -1.25 NSDB 
2 1,2-Epoxypentane 1.35 SN2 SN2 -1.68 Reactive -1.05 NSDB 
3 1,3-Butadiene diepoxide -0.60 SN2 SN2 -1.06 Reactive 0.13 XS 
4 Cyclohexene oxide 1.66 SN2 SN2 -1.48 Reactive -0.90 NSDB 
5 Glycidyl isopropyl ether 0.53 SN2 SN2 -1.74 Reactive -0.54 NSDB 
6 Glycidyl n-butyl ether 1.08 SN2 SN2 -1.52 Reactive -0.43 NSDB 
7 Glycidyl phenyl ether 1.61 SN2 SN2 -1.39 Reactive -0.46 NSDB 
8 
Lactones 
β –Propiolactone -0.80 AC AC -0.20 Reactive -0.13 XS 
9 γ-Butyrolactone -0.30 Non AC NR NR -1.72 NSDB 
10 γ-Caprolactone 0.60 Non AC NR NR -1.24 NSDB 
11 γ-Valerolactone 0.11 Non AC NR NR -1.67 NSDB 
12 δ-Valerolactone 0.19 AC AC NR NR NR NSDB 
13 ε-Caprolactone 0.68 AC AC NR NR -1.26 NSDB 
14 
Nitrosos  
1-Nitrosopyrrolidine 0.23 Non Non NR NR -1.28 NSDB 
15 2-Nitrosotoluene 2.41 NucA Non 1.55 Reactive 1.88 XS 
16 2-Nitroso-1-naphthol 2.56 NucA Non 0.77 Reactive 2.62 XS 
17 
N,N-dimethyl-4-
nitrosoaniline 
2.04 NucA Non 1.20 Reactive 2.48 XS 
18 Nitros 4-Nitropyridine N-oxide -0.90 Non Non -0.40 Reactive 1.23 XS 
19 
Aldehydes 
Butyraldehyde 0.82 SB SB Non-cov NR -0.38 XS 
20 Hexylaldehyde 1.80 SB SB Non-cov NR -0.17 XS 
21 Phenyl acetylaldehyde 1.54 SB SB Non-cov NR 1.29 XS 
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22 
Ketones 
1-Phenyl-1,2-propanedione 1.11 SB Non Non-cov NR 0.18 XS 
23 2,3-Butanedione -1.30 SB SB Non-cov NR -0.23 XS 
24 2,3-Pentanedione -0.90 SB SB Non-cov NR -0.16 XS 
25 3,4-Hexanedione -0.40 SB SB Non-cov NR 0.00 XS 
26 2-Butanone 0.26 Non Non NR NR -1.75 NSDB 
27 3-Pentanone 0.75 Non Non NR NR -1.46 NSDB 
28 Acetophenone 1.67 Non Non NR NR -0.46 NSDB 
29 Cyclohexanone 1.13 Non Non NR NR -1.23 NSDB 
30 Cyclopropyl phenyl ketone 2.47 Non Non NR NR 0.11 NSDB 
31 
Strained ring 
hydrocarbons 
Cyclopropane methanol 0.66 Non Non NR NR -1.78 NSDB 
32 Cyclopropyl benzene 3.34 Non Non NR NR 0.29 NSDB 
33 Dicyclopropyl benzene 1.87 Non Non NR NR -1.31 NSDB 
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Epoxides 
The seven epoxide-containing chemicals were profiled by the OECD and OASIS profilers as 
being reactive towards proteins via an SN2 mechanism (chemicals 1-7 in Table 6.1, 
mechanism as shown in Figure 6.10). Inspection of the experimental data for these seven 
chemicals showed them to all be reactive towards GSH, confirming the in silico predictions. 
In contrast, only 1,3-butadiene di-epoxide and glycidyl isopropyl ether showed excess 
toxicity when tested in the Tetrahymena pyriformis assay. The experimental toxicity values 
for the remaining epoxides are not significantly different from those predicted from equation 
(1). Inspection of the glutathione reactivity data for these chemicals indicates that the rate of 
covalent bond formation stays relatively consistent across the group even as log P increases 
(Table 6.1). Thus, when investigated together, the toxicity for this group of chemicals is 
predicted by their ability to covalently protein bind rather than the hydrophobicity of the 
chemical. Although the epoxides fall close to the narcosis baseline toxicity is not driven by 
hydrophobicity but rather by covalent bond formation, which is reasonably consistent 
irrespective of log P. This finding is in keeping with several previous structural alert studies 
that did not consistently identify aliphatic epoxides as causing excess toxicity (von der Ohe 
et al 2005, Blaschke et al 2010). 
 
 
Figure 6.10: Scheme for ring opening SN2 reaction for epoxides (X = NH, O, S) 
 
 
XH
protein
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Lactones 
Lactone ring systems contain an electrophilic carbonyl centre that can undergo an acylation 
ring opening reaction. The level of ring strain governs the reactivity of the lactone ring, with 
more highly strained systems being more reactive. This is due to the release of ring strain 
contributing significantly to the ease of ring opening (Figure 6.11). The OECD profiler 
identified a potential acylation mechanism in all six chemicals, whilst the OASIS profiler 
identified only three chemicals capable of the same mechanism (chemicals 8-13 in Table 
6.1). In contrast, the GSH reactivity data showed only the 4-membered lactone ring to be 
reactive (chemical 8 in Table 6.1). In addition, this chemical is the only one in this class to 
show excess toxicity in the T. pyriformis assay. The results show that under biologically 
relevant conditions 5- and 6-membered lactone rings are not reactive. This is because 5- and 
6-membered lactones do not benefit from the release of ring strain upon ring opening; 
therefore, the activation energy required for acylation is greater than for 4-membered 
lactones (Hemminki 1981). Previous research has also shown that 4-membered ring lactones 
can undergo either acylation or SN2 mechanism depending on whether the nucleophile is 
hard or soft (Figure 6.11) (Uittenbogaard et al 2011). This has clear implications for the 
results of the in silico profiling, suggesting that both mechanisms need to be included for 
this class of chemicals. In addition, the in silico predictions indicating 5- and 6-membered 
lactone ring systems are reactive are incorrect. This additional mechanistic information 
needs including in the in silico profilers.  
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Figure 6.11: Scheme showing the potential ring opening acylation reactions for chemicals 
containing a lactone ring system (β-propiolactone is shown) 
 
Nitrosos / nitros 
Profiling of the nitroso chemicals in this class resulted in the OASIS profiler identifying the 
three of them as being potentially reactive towards proteins via nucleophilic addition (Figure 
6.12). In contrast, the OECD profiler did not identify any of the chemicals as being 
potentially reactive. Inspection of the experimental data showed all of the nitroso chemicals 
to be reactive towards GSH and to show excess toxicity towards Tetrahymena pyriformis, 
except 1-nitrosopyrrolidine (chemicals 14-17 in Table 6.1). This chemical is not reactive due 
to it containing an N-nitroso rather than a C-nitroso moiety. The N-nitroso moiety in this 
chemical cannot undergo the direct nucleophilic addition reaction shown in Figure 6.12. The 
fact that the ring system of this chemical is aliphatic rather than aromatic plays a role in its 
lack of reactivity. An aliphatic ring system cannot stabilise the intermediate resulting in a 
significant increase in the activation energy. These prevent the reaction from occurring in the 
in chemico and in vitro test systems, as well as under biologically relevant conditions. These 
results show that the OASIS profiler correctly profiles chemicals of this type, whilst the 
chemistry within the OECD profiler needs expanding. The final chemical in this class, 4-
niropyridine-N-oxide, contains an aromatic nitro and is profiled as being non-reactive by 
both the OASIS and OECD and profilers (chemical 18 in Table 6.1). In contrast, the 
+ H+
protein
+ H+
protein
protein
protein
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experimental data show this chemical to be reactive and exhibit excess toxicity. There are 
two potential reasons for this observed reactivity: the first is that an adduct may be produced 
between the 4-nitropyridine N-oxide and the sulphide group of GSH. The second potential 
reason is that, as 4-nitropyridine N-oxide is an oxidising agent, GSH depletion may occur 
due to oxidation of the thiol group to form a disulphide bond. In order to elucidate the 
mechanism further experimental work is required with additional chemicals containing a 
pyridine N-oxide moiety. 
 
 
Figure 6.12: Scheme showing the nucleophilic addition reaction (showing key resonance 
forms) for aromatic nitroso chemicals with nucleophilic moiety of glutathione (R = N=O, N, 
O or CH3) 
 
Aldehydes and ketones 
The dataset contained 12 chemicals with either an aldehyde or ketone functional group 
(chemicals 19-30 in Table 6.1). Profiling these chemicals with the OASIS profiler resulted in 
the aldehydes and di-ketones being identified as being potentially capable of forming a 
Schiff base (chemicals 19-25, mechanism shown in Figure 6.13). The OECD profiler 
identified all but one of this sub-set of chemicals as also being Schiff base formers, the 
exception being 1-phenyl-1,2-propanedione (chemical 22). The reactivity data for these 
H+ protein
- OH- + OH-
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chemicals showed none of them were capable of reacting with GSH. In contrast, phenyl 
acetaldehyde and the di- ketones exhibited excess toxicity in the T. pyriformis assay. This 
discrepancy can be understood by the requirement for a free lysine side chain in order for a 
Schiff-base reaction to occur. Given that GSH does not contain a suitable lysine unit 
chemicals acting via Schiff base formation do not show reactivity in the GSH based assay. 
In addition, only the most reactive aldehyde showed excess toxicity, with the toxicity of the 
remaining two aldehydes being not significantly different from baseline. Importantly, the 
Schiff base mechanism of toxicity for simple aldehydes and di-ketones highlights the need 
for the development of in chemico methods capable of assessing nitrogen-based chemical 
reactivity. Such methods would not be limited by the effect of narcosis-driven toxicity for 
chemicals with either low reactivity or a high hydrophobicity (or a combination of the two). 
Additionally, the discrepancy with this class of chemicals highlights the need to use multiple 
experimental assays in order to define the chemical space of in silico profilers.  
 
 
Figure 6.13: Scheme showing reaction between an aldehyde and an amine functional group 
leading to the formation of a Schiff base. An analogous reaction can occur for chemicals 
containing a 1,2-di-ketone moiety (R = alkyl or carbonyl group). 
 
The final set of chemicals in this class were simple mono-ketones, these were profiled as 
being non-reactive by both the OASIS and OECD profilers (chemicals 26-30 in Table 6.1). 
The in silico profiling results are in keeping with the experimental data that showed these 
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chemicals to be non-reactive to GSH and not to exhibit excess toxicity. These results are as 
expected due to the decreased reactivity towards Schiff base formation that mono-ketones 
display compared to aldehydes (Roberts et al 2006). This is understood in terms of the 
relative reactivity of the aldehyde carbonyl group compared to the carbonyl group in a 
ketone. The decreased reactivity observed for the mono-ketones, in comparison to aldehydes, 
can be explained by two factors: firstly, the additional alkyl group present at the carbonyl 
carbon adds steric bulk to the reactive site; secondly, the additional alkyl group also acts to 
donate electrons onto the carbonyl carbon via a plus inductive effect. Both of these factors 
contribute to the decrease in reactivity observed within mono-ketones by making the 
reactive site less accessible and reducing the partial positive charge present on the carbonyl 
carbon respectively. This can be seen clearly for the 1,2-di-ketones each of which show 
significant excess toxicity, which as discussed is an indication of covalent reactivity.    
 
Strained Ring Hydrocarbons 
The final group of chemicals investigated were three hydrocarbon chemicals containing a 
cyclopropyl moiety. The three chemicals were profiled as being non-reactive by both the 
OASIS and OECD profilers as a consequence of not triggering a structural alert. The in 
silico predictions were confirmed by the experimental data that showed no reactivity 
towards GSH and no excess toxicity in the T. pyriformis assay (chemicals 31-33 in Table 
6.1). This can be rationalised in terms of the absence of an electrophilic moiety in each of 
these chemicals. Without an electrophilic moiety these chemicals lack the ability to form a 
covalent bond with the proteins present within the test systems, hence the observed results. 
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6.3.2 Verification of structural alerts  
The experimental data outlined can be used to verify the structural alerts in each of the 
profilers investigated. Additionally, the data can be used to identify new, and refine existing, 
structural alerts present within each of the profilers (Table 6.2). A well-defined chemical 
space is important as it gives the user greater confidence in the predictive capabilities of the 
profiler, so long as the query chemical falls within the chemical space used in the 
development of the profiler. The results show that the chemical space for the structural alerts 
relating to epoxides and aldehydes are well defined in both profilers. In contrast, the alerts 
related to lactones (lactones structural alert in Table 6.2) need refining. This refinement is 
two-fold, firstly the profilers need to identify the 4-membered lactones as having the ability 
to act via either acylation or SN2 depending upon the nucleophile. The second refinement 
relates to the removal of the structural alerts for 5- and 6-membered lactones from both 
profilers. This is to prevent the profilers incorrectly identifying non-reactive 5- and 6-
membered lactones as being reactive. In addition, there is the potential for both profilers to 
add a new structural alert to cover 4-nitropyridine N-oxide as neither identified this chemical 
as being capable of depleting glutathione. However, further experimental work must be 
conducted before a mechanistic rationale can be associated with this alert. Finally in contrast 
to the OASIS profiler, the OECD profiler fails to identify nitroso containing chemicals and 
1-phenyl-1,2-propanedione as being reactive. Thus, the OECD profiler needs additional 
structural alerts, relating to aromatic nitroso containing chemicals, that covers the 
nucleophilic addition reaction chemistry exhibited by these types of chemicals (nitrosos 
structural alert within Table 6.2). The data also show the importance of using multiple 
profilers in category formation as, with the exception of 4-nitropyridine-N-oxide, all of the 
potentially reactive chemicals were identified by at least one of the profilers.  The use of 
multiple profilers, to investigate the same endpoint, offers two key benefits over using a 
single profiler in isolation. The first is a wider coverage of the chemical space, meaning 
there will be a greater likelihood that chemicals, within a given dataset, will fall under the 
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boundary of at least one of the profilers. The second benefit is an increase in the confidence 
of the profiling results when each of the in silico profilers agree. 
 
Table 6.2: Summary of the chemical space for the structural alerts investigated  
Structural alert 
Profiler correct 
Additional alerts required 
OASIS OECD 
Epoxides Yes Yes None required  
Lactones No No 
Yes (refinement): 4-ring lactones only 
 
Nitrosos Yes No 
Yes (OECD profiler only): aromatic nitroso  
 
Nitros No No 
Yes 4-Nitropyridine-N-oxide 
 
Aldehydes Yes Yes None required 
Ketones Yes Yes None required 
 
 
6.4 Conclusions 
The aim of this chapter was to illustrate the importance of using in vitro and in chemico 
assay data to verify structural alerts: in this instance the alerts held within the OASIS and 
OECD protein binding profilers in the OECD QSAR Toolbox. However, it is envisaged that 
a similar process, using relevant in vitro/in chemico assays, could be performed in order to 
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verify structural alerts pertaining to other initiating events, for example the alerts identified 
in Chapters 3, 4, and 5 (discussed in Chapter 7). An additional aim was to utilise the 
experimental data to identify where new alerts were required, or to suggest refinements to 
existing alerts, in order to extend the chemical space of the profilers. The structural alerts 
investigated related to acylation, Schiff base formation and the SN2 mechanisms for covalent 
bond formation. The results showed that the structural alerts for epoxides, 4-membered ring 
lactones, nitroso, aldehydes, and di-ketones were correctly profiled by at least one of the in 
silico profilers. In addition, all of the chemicals that the experimental data showed to be non-
reactive were correctly profiled by both profilers; seen by the absence of an alert for the non-
reactive chemicals. However, the experimental data also highlighted the need for 
modification to existing structural alerts or the addition of new structural alerts to one, or 
both, of the profilers. The results outline the importance of using experimental data to define 
the chemical space of the structural alerts associated with in silico profilers. Furthermore, 
iterative refinement of profilers based upon experimental data as they become available 
leads to an increase in confidence, which is necessary for any regulatory use. Finally, the 
utility of using multiple profilers in category formation has been highlighted, i.e. the 
concomitant use of multiple profilers increases the confidence of profiling results and 
widens the chemical space that is covered.  
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Chapter 7: Discussion 
 
The first section of the final chapter of this thesis will summarise, and discuss, the main 
conclusions of the research presented within Chapters 2 to 6. A full discussion of the results 
can be found within each of the respective chapters. The second section will focus on the 
future work that is required in order for progress to be made with regards to developing 
structural alerts for repeat dose toxicity; more specifically toxicity initiated via 
mitochondrial dysfunction; and how this work could be developed into a practical tool for 
end-users. 
 
7.1 Progress in developing structural alerts for repeat dose toxicity 
7.1.1 Summary of work 
From the outset, the work presented in this thesis has been focussed on the development of 
an in silico profiler that can be utilised to assist in the safety assessment of chemicals upon 
repeated exposure. This need has arisen due to the introduction of EU legislation, such as 
REACH and the 7th amendment to the Cosmetics Directive. As part of this legislation, more 
traditional in vivo toxicity testing cannot be used as part of the safety assessment for 
cosmetic products or their ingredients. Therefore, alternative techniques are required to 
ensure the continued safety of these products for consumers. Therefore, Chapter 1 
introduced the broad area of in silico toxicology, with a focus on Adverse Outcome 
Pathways and category formation, and the impact the EU regulation has had on driving 
research in the area of in silico toxicology since its inception and implementation over the 
past decade. 
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The availability, and accessibility, of relevant toxicological data, including observed adverse 
physiological effects, is a necessity prior to the development of any in silico models or 
profilers. There is a multitude of commercially, and freely, available databases that hold a 
wide variety of toxicological data. However, there is a need for a single, comprehensive, and 
freely available database containing repeat dose toxicity data associated with chemical 
structures. Chapter 2 described how novel repeat dose toxicity data were extracted from EU 
regulatory (SCC(NF)P/SCCS) reports and, subsequently, input into the ToxRefDB data 
entry tool in order to be uploaded (by other partners in COSMOS) into the COSMOS 
database. These data were harvested following a standard operating procedure, developed by 
colleagues on the COSMOS project. This SOP provided a consistent method by which each 
of the data harvesters were to extract, and input, the data. Information extracted from the 
reports included the NOAEL and/or LOAEL values and the histopathological findings 
observed whilst undertaking the experiment. The investigation performed at the end of 
Chapter 2 examined whether the results from 28 day repeat dose toxicity studies are 
protective of results from 90 day repeat dose studies held in the COSMOS database. The 
outcome of this investigation identified that for six of the nine chemicals (66%) the 28 day 
study was protective of the 90 study, i.e. if the toxicity value for the 28 day study was over 
1000 mg/kg bw/day the toxicity value for the 90 day study was also over 1000 mg/kg 
bw/day. The percentage of those chemicals that were protective within this investigation was 
marginally under those found previously by the HSE and Taylor et al (2014). This may, 
however, be explainable by the variances in the total number of chemicals in the final 
datasets between the investigation performed in Chapter 2 and those carried out by the HSE 
and Taylor et al (2014). Therefore, the results from the analysis performed in this chapter 
support the findings by the HSE and Taylor et al (2014). This investigation, in conjunction 
with the previous work set out by the HSE and Taylor et al (2014), could have a major 
impact both financially, and in terms of animal usage, with regards to those chemicals 
manufactured (or imported) above 100 tonnes per year under REACH. In addition, this 
investigation demonstrated that having toxicological values, and histopathological findings, 
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compiled within the same database enabled this type of analysis to be performed more easily 
than if multiple databases were used. 
In Chapter 3 a chemoinformatics analysis was performed on a set of chemicals, from the 
scientific literature, with associated qualitative data pertaining to mitochondrial toxicity. 
This analysis was undertaken using the freely available data mining software, ChemoTyper, 
which contains the ToxPrint library of predefined structural fragments. The analysis 
performed in this chapter found two types of structural alerts could be identified utilising 
this software; 1) well-defined alerts that could be associated with a mechanistic hypothesis, 
2) more diverse alerts for which it was not possible to hypothesise a mechanism for the 
entire category. Overall, a total of twenty alerts were developed. Of these alerts, it was 
possible to hypothesise a mechanism encompassing all chemicals identified by the 
ChemoTyper for two alerts. For the remaining alerts it was not possible to hypothesise a 
mechanism that encompassed all the chemicals identified as ‘toxic to mitochondria’ within 
the group. In addition, this chapter also outlined the use of these different types of structural 
alerts; with mechanism-based structural alerts being intended for category formation and 
read-across, whilst chemistry-based alerts could be used for the purposes of screening and 
prioritisation of an inventory. The inherent differences in the two types of alert make them 
suitable for different purposes. Mechanistic information associated with the mechanism-
based alerts provides additional support to both the development of chemical categories and 
subsequent read-across predictions for toxicity. In comparison, chemistry-based alerts, 
whilst lacking mechanistic information, are associated with toxicity, therefore, they can be 
used to identify chemicals, within an inventory, for which further in vitro/in chemico testing 
may be appropriate. 
The work in Chapter 4 focussed on utilising structural similarity and category formation to 
re-analyse the data set from Chapter 3. Overall, 35 chemicals in the data set were identified 
as belonging to categories containing mitochondrial toxicants: local anaesthetics, anti-
anginal, and anti-arrhythmic (6 chemicals); anti-diabetic drugs (3 chemicals); non-steroidal 
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anti-inflammatory drugs (3 chemicals); anthracycline antibiotics (4 chemicals); 
hypolipodemic drugs (3 chemicals); bile acids (6 chemicals); anti-histaminic, anti-psychotic 
and anti-emetic drugs (7 chemicals); and β-blockers (3 chemicals). A total of eight 
mechanism-based alerts were developed covering five initiating events; inhibition of the 
electron transport chain, alternative electron acceptance, initiation of the death receptor 
pathway, uncoupling of oxidative phosphorylation and induction of the membrane 
permeability transition. Additionally, the work carried out in Chapters 3 and 4 demonstrated 
that no one approach can be utilised to identify all possible structural alerts. Therefore, it is 
envisaged that these techniques will be used in combination to cover as large a chemical 
space as possible. 
The toxicological information provided by the regulatory dossiers for 94 hair dye chemicals, 
published by the SCC(NF)P/SCCS, was utilised in Chapter 5 to develop mechanism-based 
structural alerts. These dossiers are a valuable, yet currently under-used, source of 
toxicological data. The analysis performed in Chapter 5 expanded on the work undertaken in 
Chapter 4 by identifying additional mechanism-based alerts associated with mitochondrial 
dysfunction. A total of four mechanism-based alerts were identified covering pro-quinones 
(37 chemicals), quinones (7 chemicals), meta-substituted benzenes (4 chemicals), and 
aromatic azo compounds (8 chemicals). Each of these alerts is associated with inducing 
mitochondrial toxicity via a single Molecular Initiating Event (MIE): inhibition of the 
electron transport chain. The alerts identified in Chapter 5 broadened the chemical space 
regarding those chemicals that have the potential to induce mitochondrial toxicity via 
inhibition of the electron transport chain. These alerts can be utilised to either screen an 
inventory for prioritisation or to develop chemical categories, from which read-across 
predictions could be made regarding to a chemical’s ability to initiate mitochondrial toxicity. 
In order to expand the use of this profiler for mitochondrial toxicity additional alerts are 
required for (alternative) MIEs to account for the toxic potential of the remaining chemicals. 
The work undertaken in Chapters 4 and 5 demonstrate the vital importance of the available 
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literature in providing the mechanistic information necessary for developing mechanism-
based structural alerts. Chapter 5 reiterates the use of mechanistic structural alerts for the 
purposes of grouping and profiling. Furthermore, the work carried out within this chapter 
highlights the usability and usefulness of the information contained within regulatory reports, 
such as those published by the SCC(NF)P/SCCS. 
Upon development of structural alerts it is necessary to substantiate that each of the alerts 
correctly identifies chemicals with the potential to instigate an MIE. Other alternative 
techniques, such as in vitro and/or in chemico assays, can be used to verify the alerts 
developed are correct. However, it should be noted that whilst these alerts may be correct 
other factors, such as the internal concentration or metabolism, may mean the MIE is not 
induced in vivo. Finally, Chapter 6 illustrates the importance of using data generated by in 
vitro and in chemico assays to verify, and refine, structural alerts. These alternative 
techniques are important as they provide experimentally derived mechanistic information. In 
turn, this information can be utilised to verify the correct mechanism is associated with an 
alert, whilst also providing support for possible refinements. In Chapter 6 the structural 
alerts investigated relate to the protein binding alerts in the OECD QSAR Toolbox. However, 
a similar process could be undertaken to verify other structural alerts, such as those 
pertaining to mitochondrial toxicity identified in Chapters 3, 4, and 5.  
 
7.1.2 Conclusions  
Mitochondrial toxicity has been implicated as one of the key drivers of various organ-level 
toxicities (Dykens and Will 2008). The work presented within this thesis has identified a 
variety of structural alerts that have the ability to induce mitochondrial toxicity. This was 
achieved by utilising various in silico approaches in order to analyse two data sets; the first 
containing qualitative mitochondrial data, and the second containing quantitative toxicity 
data from regulatory submissions. Overall, a total of 31 structural alerts were developed. Of 
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these 31 alerts, twelve were mechanism-based alerts, whilst the remaining 19 were 
chemistry-based alerts.  
Since the implementation of both REACH and the 7th amendment to the Cosmetics Directive 
there has been an increased interest in the use of alternative techniques to provide 
information for safety assessments. Whilst numerous alternative techniques are available no 
one method can replace animal testing outright. Therefore, the AOP paradigm has been 
suggested as a framework by which data from in vitro, in chemico, and in silico methods can 
be integrated in order to better organise the toxicological information provided by these 
techniques. An AOP is a scheme that links an MIE, via testable events at different levels of 
biological organisation, to an adverse effect relevant for risk assessment. The MIE provides 
mechanistic information regarding the initial interaction between the chemical and the 
biological system. In silico methods contribute to the AOP paradigm by identifying the 
chemical structures that are associated with inducing an MIE. As discussed in previous 
chapters (Chapters 1, 3, 4 and 5) the twelve mechanism-based alerts are structural fragments 
that have information, from experimental studies, pertaining to the mechanism by which 
toxicity is initiated associated with them. When developing mechanism-based alerts it is 
essential that an in-depth analysis of the relevant scientific literature, and/or information 
generated from in vitro and/or in chemico assays are utilised. This is due to the fact that 
these experimental data provide critical evidence demonstrating how the structural alert(s) 
induce the observed toxicity via the MIE. These mechanism-based alerts can, subsequently, 
be aggregated together to construct a mechanism-based in silico profiler. The main use of a 
mechanism-based profiler should be to develop chemical categories centred on the ability to 
induce the same MIE. Thus, these chemical categories can be used for read-across purposes 
in order to fill data gaps for a novel chemical utilising the toxicological data present for the 
analogous chemicals within the category. The use of the mechanistic information associated 
with the MIE enables any read-across prediction made to be more mechanistically 
interpretable and, therefore, more robust. 
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In comparison, the 19 chemistry-based alerts have been identified as being associated with 
inducing mitochondrial toxicity. However, no accompanying mechanistic information is 
(currently) available that relates the alert with how mitochondrial toxicity is initiated. Given 
the lack of mechanistic information, chemistry-based alerts should not be used in the 
development of chemical categories or subsequent read-across analysis, with respect to 
hypothesising the molecular initiating event of (mitochondrial) toxicity. This is due to the 
fact that whilst the chemistry-based alerts have been associated with toxicity, it may not be 
possible to identify a (single) mechanism by which all chemicals containing the alert initiate 
toxicity, as discussed in Chapter 3. However, chemistry-based alerts can be useful for 
screening, and prioritising, chemicals held in an inventory that should undergo further 
testing within in vitro/in chemico assays. This additional testing could, potentially, enable 
both the mechanistic information relating to a structural alert to be elucidated; thereby, 
converting it into a mechanism-based alert; and/or enable the alert to be refined. 
Additionally, it should be noted that mechanism-based alerts can also be used in order to 
screen an inventory. The results of this screening would have the added benefit of informing 
a user as to the type of in vitro/in chemico tests that should be performed first. 
 
7.1.3 Proposal of a tiered testing strategy for profiling of chemical inventories 
It is envisaged that the mechanism-based alerts (developed in Chapters 4 and 5) will be used 
in conjunction with the chemistry-based alerts (developed in Chapter 3) as part of a two 
tiered testing strategy for profiling chemical inventories. The first tier would comprise 
profiling the chemicals against the mechanism-based alerts. Whilst these alerts are likely to 
trigger only a small proportion of the chemicals in a data set they provide a high level of 
confidence as to the potential of these chemicals to be mitochondrial toxicants. This 
confidence is derived from the mechanistic information, which is associated with the 
chemical structure, being available in the literature and being used in the development of the 
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mechanism-based structural alert. Thus, this information can be used to support the 
identification of potential mitochondrial toxicants. Additionally, if a chemical triggered a 
mechanism-based alert the chemical would be of a high priority to test, with the mechanistic 
information directing the in vitro/in chemico assay(s) that should be undertaken The second 
tier of this profiling strategy would be the use of the chemistry-based structural alerts. In 
comparison to the mechanism-based alerts above, the chemistry-based alerts are likely to 
trigger a significantly larger proportion of the chemicals in the inventory, thereby, increasing 
the chemical space covered; this is due to the more generic nature of the chemistry-based 
alerts. Whilst a larger number of chemicals are identified there is less confidence 
surrounding the identification of potential mitochondrial toxicants. This is due to the fact 
that these chemistry-based alerts do not have any mechanistic information associated with 
their ability to induce toxicity. If a chemical triggered a chemistry-based alert the chemical 
would be of concern. However, due to the absence of inherent mechanistic information and 
the lower confidence in the assignment of a ‘toxic’ prediction a larger quantity of in vitro/in 
chemico testing, and/or supporting information from the available literature, would be 
needed to ascertain the toxic potential of the chemical.  
 
7.2 Prospects for future work 
The work carried out in this thesis has enabled the development of a number of mechanism- 
and chemistry-based structural alerts relating to mitochondrial toxicity. However, further 
work that is needed centres on the verification, and refinement, of the alerts presented in the 
previous chapters, alongside developing additional alerts using other data sets, such as 
ToxCast. This further work is described in detail below. 
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7.2.1 Verification of the developed mechanism-based structural alerts  
Data present in the available scientific literature has enabled twelve mechanism-based 
structural alerts to be developed within this thesis (Chapters 4 and 5). The work outlined in 
Chapter 6 demonstrated the importance of utilising data generated from in vitro/in chemico 
assay in order to verify structural alerts, in this instance for protein binding. Therefore, it is 
envisaged that future work could involve the use of in vitro and/or in chemico assays 
relevant for mitochondrial toxicity to verify the mechanism-based alerts developed in 
previous chapters. This would involve taking a representative sample of chemicals, 
containing one of the alerts developed, and utilising the hypothesised mechanism for each 
alert to guide the mitochondrial assay(s) that the chemicals should be tested in. For example, 
the representative chemical(s) for the local anaesthetics category should be tested within 
assays that identify uncouplers of oxidative phosphorylation, such as the use of oxygen-
sensitive fluorescent probes (Hynes et al 2008). Briefly stated, the level of fluorescence 
emitted by the oxygen-sensitive dye changes with the presence or absence of, either 
intracellular or extracellular, molecular oxygen, i.e. a decreased presence of molecular 
oxygen (due to an increase in electron transport chain activity) increases the level of 
fluorescence, thereby, identifying the mechanism as uncoupling of oxidative 
phosphorylation (Hynes et al 2008). In comparison, the representative chemical(s) for the 
anti-diabetic drugs (thiazolidinedione) category should be tested within assays that identify 
inhibitors of the electron, such immunocapture-based assays (Nadanaciva 2008). These 
immunocapture-based assays use 96-well plates coated with monoclonal antibodies against 
Complexes I, II, IV and V to measure the activity of each of these complexes after exposure 
to the test chemical to help identify which complex is inhibited (Nadanaciva 2008). 
Subsequently, the results from these assays would be used in order to verify whether the 
hypothesised mechanism associated with the structural alert is correct. Additionally, this 
information could be utilised to further refine the developed structural alert. 
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7.2.2 Use of in vitro/in chemico data to discern mechanistic information for chemistry-based 
alerts 
The work performed in Chapter 3 has enabled the development of 19 chemistry-based alerts 
that do not have a mechanistic hypothesis associated with them. This is due to the chemistry-
based alerts being, relatively, more broad, thereby, identifying more diverse chemicals. Thus, 
this diversity increases the likelihood that a variety of mechanisms will initiate the observed 
toxicity. In addition to verifying mechanism-based alerts, the data generated by in vitro 
and/or in chemico assays could be utilised to discern mechanistic information associated 
with a chemical structure. This could, in turn, permit the chemistry-based structural alerts to 
be refined to mechanism-based alerts. Thus, enabling chemicals that contain the same 
chemistry-based alert but that initiate different MIEs to be discerned. The use of such assays 
would allow the refinement of the chemistry-based alert into a mechanism-based alert by 
associating a mechanistic hypothesis with the alert.  
 
7.2.3 Development of additional alerts 
Whilst the work carried out in this thesis developed a number of mechanism- and chemistry-
based structural alerts it is acknowledged that the chemical space covered by these alerts is 
relatively small. Therefore, future work could entail the use of other data sets containing 
mitochondrial toxicity data, for example ToxCast, in order to develop additional mechanism- 
and chemistry-based alerts. It is envisaged that processes similar to those described in 
Chapter 3, 4, and 5 could be used in order to develop these alerts. Subsequently, any alerts 
that are identified using these data sets should undergo the verification, and refinement, 
testing within the in vitro and/or in chemico assays described above. Thus, it is expected that 
these additional alerts would expand the chemical domain of the in silico profiler developed 
within this thesis.  
Chapter 7 
173 
 
It is envisaged that the alerts developed in this thesis (together with any alerts derived in the 
future) will be incorporated into predictive tools or software; such as workflows in KNIME 
or as mechanistic alerts within the OECD QSAR Toolbox. These tools could, subsequently, 
be utilised to screen chemical inventories in order to help identify chemicals with the 
potential to induce mitochondrial toxicity. Furthermore, the use of these alerts, in 
conjunction with other alternative techniques and information available in the literature, 
could be utilised in the development, and verification, of Adverse Outcome Pathways that 
extend up to physiological effects at the organism level. 
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Appendix I. List of the 54 chemicals in the COSMOS DB with short-term and sub-chronic toxicity values (Chapter 2). (Abbreviations: HNEL – 
Highest No Effect Level, LEL – Lowest Effect Level.) 
Chemical name COSMOS ID Short-term toxicity 
study value (mg/kg 
bw/day) 
Length of short-term 
toxicity study (days) 
Sub-chronic toxicity 
study value (mg/kg 
bw/day) 
Length of sub-chronic 
toxicity study (days) 
FD&C Yellow No. 5 CMS-1476 LEL 15 30 HNEL 2500 
LEL 5000 
91 
91 
Vitamin A Acetate CMS-1255 HNEL 34 
HNEL 40 
LEL 51 
LEL 80 
LEL 20 
LEL 250 
HNEL 16 
28 
28 
28 
28 
30 
30 
35 
HNEL 44 
LEL 88 
90 
90 
Ethylene Glycol Monobutyl 
Ether 
CMS-3639 HNEL 500  
LEL 1000 
35 (MOUSE) 
35 (MOUSE) 
LEL 225 
LOAEL 615 
HNEL 553 
LEL 676 
90 (MOUSE) 
90 (MOUSE) 
91 (MOUSE) 
91 (MOUSE) 
DL-Phenylalanine CMS-3235 HNEL 8000 
LEL 5000 
28 
28 
LEL 5000 84 
Hydroxypropyl 
Methylcellulose 
CMS-7567 LEL 3846  
HNEL 10,000 
LEL 25,000 
30 (DOG) 
30 
30 
HNEL 1250  
HNEL 2004  
HNEL 2257 
LEL 8364 
HNEL 2339 
HNEL 5000 
HNEL 6500 
HNEL 7700 
LEL 8209 
HNEL 505 
LEL 1020 
90 (DOG) 
90 (DOG) 
84 
84 
90 
90 
90 
90 
90 
91 
91 
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Glycyrrhizin, ammoniated CMS-8524 HNEL 1000 
HNEL 1000 
LEL 2000 
30 
35 
35 
HNEL 500 90 
Resorcinol CMS-1253 HNEL 260.7 28 LOAEL (♂) 32 
LOAEL (♀) 65 
HNEL 260 
LEL 520 
90 
90 
91 
91 
o-Cresol CMS-1797 HNEL 280 
LEL 763 
HNEL 266 
LEL 861 
28 (MOUSE) 
28 (MOUSE) 
28 
28 
HNEL 794 (MOUSE) 
LEL 1500 (MOUSE) 
HNEL 247 
LEL 510 
90 
90 
90 
90 
Benzoic acid CMS-147 LEL 1100 
LEL 3000 
35 
35 
HNEL 4000 90 
Monosodium glutamate CMS-927 LEL 16700 35 LEL 6000 90 
Allyl isothiocyanate CMS-49 HNEL 25 
LEL 25 
LEL 75 
HNEL 300 
HNEL 0.5 
28 
28 
28 
30 
30 
HNEL 25 91 
Xylitol CMS-9788 LEL 12100 28 LEL 5000 91 
Ethylene oxide/propylene 
oxide copolymer 
CMS-13925 HNEL 300 
LEL 0.5 
LEL 480 
30 
30 
30 
HNEL 40 
HNEL 500 
HNEL 1000 
HNEL 1000 
HNEL 1000 
LEL 200 
LEL 5000 
90 
90 
90 
90 
90 
90 
90 
Ferrous lactate CMS-13965 LEL 625 
LEL 5000 
28 
28 
LEL 313 90 
L-Phenylalanine CMS-8300 HNEL 5000 
LEL 7000 
28 
28 
LEL 5000 84 
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Furfural CMS-663 HNEL 96 
LEL 120 
HNEL 2.5 
LEL 25 
28 
28 
35 
35 
LOAEL (♂) 11 
HNEL 90 
LEL 180 
90 
91 
91 
Butylated hydroxyanisole CMS-223 HNEL 50 
LEL 150 
LEL 2000 
LEL 2000 
LEL 2000 
LEL 1000 
LEL 1000 
28 
28 
28 
28 
28 
32 
35 
HNEL 125 
HNEL 2000 
LEL 125 
LEL 1000 
LEL 2000 
LEL 2000 
HNEL 500 
LEL 2000 
90 
90 
90 
90 
90 
90 
91 
91 
L-Aspartic acid CMS-2493 HNEL 50 
HNEL 1000 
HNEL 1000 
28 
28 
28 
HNEL 715 
LEL 1417 
90 
90 
Polymaleic acid CMS-14369 HNEL 100 28 HNEL 400 90 
Annatto extract (Bixa 
Orellana) 
CMS-3887 LEL 2000 28 HNEL 1000 
HNEL 69 
LEL 204 
90 
91 
91 
Sucrose acetate isobutyrate CMS-5115 HNEL 2226 
HNEL 2592 
28 
28 
HNEL 5300 91 
Propylene glycol CMS-1220 LEL 1600 
LEL 1600 
LEL 1600 
35 (CAT) 
35 (CAT) 
35 (CAT) 
LEL 2750 91 (CAT) 
Choline chloride CMS-329 LEL 1000 25 HNEL 500 
LEL 1350 
90 
90 
Maltodextrin CMS-5576 HNEL 10,000 30 HNEL 3882 90 
p-Cresol CMS-1848 LEL 2000 28 HNEL 50 
LEL 175 
LOAEL 175 
91 
91 
91 
Butyl acetate CMS-1941 HNEL 2000 28 HNEL 600 90 
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LEL 800 30 LEL 2000 90 
Sucralose CMS-7967 LEL 4000 
HNEL 1000 
HNEL 2000 
LEL 2500 
LEL 5000 
26 
28 
28 
28 
28 
LEL 2000 89 
Hydroxypropyl cellulose CMS-10327 HNEL 6000 30 HNEL 5000 90 
Agar (Gelidium spp.) CMS-13069 LEL 25,000 28 HNEL 2500 90 
Vitamin A CMS-3312 LEL 30 28 HNEL 0.24 
LEL 0.48 
90 
90 
Vitamin A Palmitate CMS-1256 LEL 60 26 LEL 33 91 
Potassium bicarbonate CMS-1189 HNEL 2132 
HNEL 4000 
LEL 4385 
28 
28 
28 
HNEL 1482 
HNEL 2000 
LEL 2500 
LEL 3133 
LEL 4300 
91 
91 
91 
91 
91 
Canthaxanthin CMS-2585 HNEL 313 30 HNEL 50 90 
Niacin CMS-952 LEL 1000 30 HNEL 19 
LEL 49 
90 
90 
Cellulose, methyl CMS-7542 HNEL 50 
HNEL 5000 
28 
30 
HNEL 5000 
LEL 25,000 
LEL 5000 
90 
90 
95 
Polyethylene, oxidised CMS-34680 HNEL 4650 32 HNEL 5000 
HNEL 5000 
90 
90 
Tributyl acetylcitrate CMS-4878 LEL 1780 28 HNEL 100 90 
Ascorbic acid CMS-108 HNEL 625 
HNEL 10,000 
LEL 27300 
28 (MOUSE) 
28 
28 
HNEL 3750 
LEL 7500 
HNEL 2500 
LEL 2500 
LEL 5000 
91 (MOUSE) 
91 (MOUSE) 
90 
90 
90 
Allyl Heptanoate CMS-10786 LOAEL 100 28 LOAEL 49.6 90 
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4-pyrimidinol, 2,5,6-
triamino-, monosulfate 
CMS-46638 LOAEL 1000 28 LOAEL 1000 90 
Formaldehyde CMS-653 HNEL 25 
LEL 20 
LEL 125 
28 
28 
28 
HNEL 50 
HNEL 100 
LEL 100 
LEL 150 
90 
90 
90 
90 
β-Carotene CMS-261 
 
 
LEL 1000 
HNEL 5 
HNEL 5 
HNEL 80 
28 
30 
30 
35 
HNEL 3127 
LEL 1000 
90 
91 
Adipic acid CMS-1627 HNEL 440 
HNEL 2400 
HNEL 3400 
28 
28 
28 
HNEL 1700 
LEL 8000 
90 
90 
3-ethyl-2-hydorxy-2-
cyclopenten-1-one 
CMS-10298 HNEL 800 30 LEL 100 90 
Quinine hydrochloride CMS-10282 HNEL 250 
LEL 25 
28 
28 
HNEL 10 
HNEL 40 
HNEL 60 
LEL 40 
LEL 85 
LEL 85 
LEL 100 
90 
90 
90 
90 
90 
90 
90 
Ethylenediamine CMS-1857 HNEL 250 28 HNEL 250 
LEL 1000 
HNEL 100 
LEL 200 
90 
90 
91 
91 
D-Limonene CMS-797 LEL 75 
HNEL 100 
LEL 25 
LEL 200 
LEL 400 
LEL 277 
27 
28 
28 
28 
28 
30 
LEL 150 
LOAEL (♂) 30 
LOAEL (♂) 150 
LOAEL (♀) 2400 
HNEL 30 
LEL 75 
89 
90 
90 
90 
91 
91 
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LEL 150 91 
Phenol CMS-1136 LEL 1.8 
HNEL 86.2 
28 (MOUSE) 
28 
HNEL 750 
LEL 2500 
HNEL 300 
LEL 1000 
91 (MOUSE) 
91 (MOUSE) 
91 
91 
Caffeine CMS-240 LEL 40 
HNEL 100 
LEL 50 
LEL 500 
28 (MOUSE) 
28 
28 
28 
HNEL 80 
LEL 122 
LOAEL 87 
HNEL 163 
LEL 279 
LOAEL 280 
90 (MOUSE) 
90 (MOUSE) 
90 (MOUSE) 
90 
90 
90 
p-Ethylphenol CMS-1937 HNEL 100 
LEL 300 
28 
28 
HNEL 342 90 
Ethylene Glycol Monoethyl 
Ether 
CMS-3637 LEL 150 28 HNEL 740 
LEL 1890 
HNEL 92.9 
LEL 122 
LEL 185.8 
90 
90 
91 
91 
91 
Butylated hydroxytoluene CMS-224 LEL 300 
HNEL 25 
HNEL 250 
HNEL 1000 
LEL 250 
LEL 500 
LEL 700 
LEL 1500 
LE 100 
28 (DOG) 
28 
28 
28 
28 
28 
28 
28 
30 
HNEL 2000 
HNEL 200 
LEL 25 
LEL 200 
LEL 500 
90 (DOG) 
90 
90 
90 
90 
Isoeugenyl Methyl Ether CMS-15322 HNEL 91 
LEL 264 
31 
31 
HNEL 6 91 
Sodium benzoate CMS-144 LEL 2000 28 HNEL 8000 
LOAEL 6290 
LEL 1250 
90 
90 
91 
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Appendix II. Data set extracted from Zhang et al (2009) used to develop the chemical 
categories and subsequent mechanism-based structural alerts (Chapters 3 and 4) 
(+ve - mitochondrial toxicant, -ve - non-mitochondrial toxicant) 
Chemical ID Chemical Name Toxicity SMILES 
1 Menadione +ve O=C\2c1c(cccc1)C(=O)/C(=C/2)C 
2 Pentamidine +ve [H]/N=C(\N)/c1ccc(cc1)OCCCCCOc2cc
c(cc2)/C(=N/[H])/N 
3 Nalidixic acid +ve CCn1cc(c(=O)c2c1nc(cc2)C)C(=O)O 
4 Diazepam +ve CN1c2ccc(cc2C(=NCC1=O)c3ccccc3)Cl 
5 Clofibric acid +ve Clc1ccc(OC(C(=O)O)(C)C)cc1 
6 Niclofolan +ve Clc2cc(c(O)c(c1c(O)c([N+]([O-
])=O)cc(Cl)c1)c2)[N+]([O-])=O 
7 Lonidamine +ve Clc1ccc(c(Cl)c1)Cn3nc(c2ccccc23)C(=O
)O 
8 Sulofenur +ve Clc1ccc(cc1)NC(=O)NS(=O)(=O)c2ccc3
c(c2)CCC3 
9 Ciprofloxacin +ve c1c2c(cc(c1F)N3CCNCC3)n(cc(c2=O)C(
=O)O)C4CC4 
10 Tolcapone +ve [O-
][N+](=O)c2cc(C(=O)c1ccc(cc1)C)cc(O)
c2O 
11 Hexachlorophene +ve Clc1c(c(O)c(Cl)cc1Cl)Cc2c(O)c(Cl)cc(C
l)c2Cl 
12 Buquinolate +ve CCOC(=O)c1cnc2cc(c(cc2c1O)OCC(C)
C)OCC(C)C 
13 Menoctone +ve O=C1c3ccccc3C(\O)=C(/C1=O)CCCCC
CCCC2CCCCC2 
14 Amquinate +ve O=C\2c1c(cc(c(c1)CCC)N(CC)CC)N/C=
C/2C(=O)OC 
15 Decoquinate +ve O=C\2c1c(cc(OCC)c(OCCCCCCCCCC)
c1)N/C=C/2C(=O)OCC 
16 Tioxaprofen +ve Clc3ccc(c2oc(SC(C(=O)O)C)nc2c1ccc(C
l)cc1)cc3 
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17 Cyhalothrin +ve CC1([C@@H]([C@H]1C(=O)OC(C#N)
c2cccc(c2)Oc3ccccc3)/C=C(\C(F)(F)F)/C
l)C 
18 Myxothiazol +ve O=C(N)\C=C(\OC)[C@H](C)[C@@H](
OC)/C=C/c1nc(sc1)c2nc(sc2)[C@H](\C=
C\C=C\C(C)C)C 
19 Haloperidol +ve c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3cc
c(cc3)Cl)O)F 
20 Indomethacin +ve Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)O
C)CC(=O)O 
21 Phenytoin +ve c1ccc(cc1)C2(C(=O)NC(=O)N2)c3ccccc
3 
22 Lindane +ve Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@
@H](Cl)[C@H](Cl)[C@H]1Cl 
23 Procaine +ve O=C(OCCN(CC)CC)c1ccc(N)cc1 
24 Methionine +ve CSCCC(C(=O)O)N 
25 Fluphenazine +ve c1ccc2c(c1)N(c3cc(ccc3S2)C(F)(F)F)CC
CN4CCN(CC4)CCO 
26 Salicylic acid +ve c1ccc(c(c1)C(=O)O)O 
27 Valproic acid +ve O=C(O)C(CCC)CCC 
28 Phenformin +ve N(=C(/N=C(\N)N)N)\CCc1ccccc1 
29 Lidocaine +ve CCN(CC)CC(=O)Nc1c(cccc1C)C 
30 Butacaine +ve O=C(OCCCN(CCCC)CCCC)c1ccc(N)cc
1 
31 Metformin +ve [H]/N=C(/N=C(N)N)\N(C)C 
32 Buformin +ve N(=C(/N)N)\C(=N\CCCC)N 
33 Porfiromycin +ve O=C\1C/2=C(\C(=O)/C(N)=C/1C)[C@H
]([C@]3(OC)N\2C[C@@H]4N([C@H]3
4)C)COC(=O)N 
34 Anthralin +ve O=C2c1c(O)cccc1Cc3c2c(O)ccc3 
35 Propofol +ve Oc1c(cccc1C(C)C)C(C)C 
36 Flutamide +ve O=C(Nc1cc(c(cc1)[N+]([O-
])=O)C(F)(F)F)C(C)C 
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37 Ibuprofen +ve CC(C)Cc1ccc(cc1)C(C)C(=O)O 
38 Zidovudine +ve Cc1cn(c(=O)[nH]c1=O)[C@H]2C[C@@
H]([C@H](O2)CO)N=[N+]=[N-] 
39 Ropivacaine +ve O=C(Nc1c(cccc1C)C)[C@H]2N(CCC)C
CCC2 
40 Etidocaine +ve O=C(Nc1c(cccc1C)C)C(N(CC)CCC)CC 
41 Nabumetone +ve O=C(C)CCc1ccc2c(c1)ccc(OC)c2 
42 Nimesulide +ve [O-
][N+](=O)c2cc(Oc1ccccc1)c(cc2)NS(=O
)(=O)C 
43 Ciprofibrate +ve CC(C)(C(=O)O)Oc1ccc(cc1)C2CC2(Cl)
Cl 
44 Fluoxetine +ve CNCCC(c1ccccc1)Oc2ccc(cc2)C(F)(F)F 
45 Idarubicin +ve O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23
)C[C@@](O)(C(=O)C)C[C@@H]5O[C
@@H]4O[C@H]([C@@H](O)[C@@H]
(N)C4)C 
46 Nicorandil +ve c1cc(cnc1)C(=O)NCCO[N+](=O)[O-] 
47 Carvedilol +ve COc1ccccc1OCCNCC(COc2cccc3c2c4c
cccc4[nH]3)O 
48 Nefazodone +ve Clc4cccc(N3CCN(CCCN1/N=C(\N(C1=
O)CCOc2ccccc2)CC)CC3)c4 
49 Didanosine +ve c1nc2c(c(n1)O)ncn2[C@H]3CC[C@H](
O3)CO 
50 Stavudine +ve O=C1/C(=C\N(C(=O)N1)[C@@H]/2O[
C@@H](\C=C\2)CO)C 
51 Nevirapine +ve Cc1ccnc2c1NC(=O)c3cccnc3N2C4CC4 
52 Entacapone +ve [O-
][N+](=O)c1cc(\C=C(/C#N)C(=O)N(CC)
CC)cc(O)c1O 
53 Lamivudine +ve c1cn(c(=O)nc1N)[C@@H]2CS[C@@H]
(O2)CO 
54 Diclofenac +ve c1ccc(c(c1)CC(=O)O)Nc2c(cccc2Cl)Cl 
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55 Chloramphenicol +ve c1cc(ccc1[C@H]([C@@H](CO)NC(=O)
C(Cl)Cl)O)[N+](=O)[O-] 
56 Minocycline +ve CN(C)c1ccc(c2c1C[C@H]3C[C@H]4[C
@@H](C(=C(C(=O)[C@]4(C(=C3C2=O
)O)O)C(=O)N)O)N(C)C)O 
57 Naproxen +ve C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)
O 
58 Butylated Hydroxy +ve  
59 Linezolid +ve O=C1O[C@@H](CNC(=O)C)CN1c3cc(
F)c(N2CCOCC2)cc3 
60 Celecoxib +ve O=S(=O)(c3ccc(n1nc(cc1c2ccc(cc2)C)C(
F)(F)F)cc3)N 
61 Efavirenz +ve FC(F)(F)[C@@]3(C#CC1CC1)OC(=O)
Nc2ccc(Cl)cc23 
62 Rosiglitazone +ve O=C1NC(=O)SC1Cc3ccc(OCCN(c2nccc
c2)C)cc3 
63 Chlorpromazine +ve CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)Cl 
64 Mefenamic acid +ve O=C(O)c2c(Nc1cccc(c1C)C)cccc2 
65 Flufenamic acid +ve FC(F)(F)c1cc(ccc1)Nc2ccccc2C(=O)O 
66 Tolfenamic acid +ve Clc2cccc(Nc1ccccc1C(=O)O)c2C 
67 Fenofibrate +ve O=C(c1ccc(Cl)cc1)c2ccc(OC(C(=O)OC(
C)C)(C)C)cc2 
68 Atovaquone +ve c1cc2c(cc1)C(=O)C(=C(C2=O)[C@H]3
CC[C@@H](CC3)c4ccc(cc4)Cl)O 
69 Troglitazone +ve O=C1NC(=O)SC1Cc4ccc(OCC3(Oc2c(c
(c(O)c(c2CC3)C)C)C)C)cc4 
70 Tamoxifen +ve O(c1ccc(cc1)/C(c2ccccc2)=C(\c3ccccc3)
CC)CCN(C)C 
71 Tetracycline +ve C[C@]1(c2cccc(c2C(=O)C3=C([C@]4([
C@@H](C[C@@H]31)[C@@H](C(=C(
C4=O)C(=O)N)O)N(C)C)O)O)O)O 
72 Dieldrin +ve ClC5(Cl)[C@]3(Cl)C(\Cl)=C(\Cl)[C@@
]5(Cl)[C@H]4[C@H]1C[C@H]([C@@
H]2O[C@H]12)[C@@H]34 
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73 Sulindac +ve O=S(c1ccc(cc1)\C=C3/c2ccc(F)cc2\C(=
C3C)CC(=O)O)C 
74 Amiodarone +ve Ic1cc(cc(I)c1OCCN(CC)CC)C(=O)c2c3c
cccc3oc2CCCC 
75 Saquinavir +ve O=C(N)C[C@H](NC(=O)c1nc2c(cc1)cc
cc2)C(=O)N[C@@H](Cc3ccccc3)[C@H
](O)CN5[C@H](C(=O)NC(C)(C)C)C[C
@@H]4CCCC[C@@H]4C5 
76 Daunorubicin +ve C[C@H]1[C@H]([C@H](C[C@@H](O
1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)
C(=O)c5cccc(c5C4=O)OC)O)(C(=O)C)
O)N)O 
77 Nelfinavir +ve O=C(c1cccc(O)c1C)N[C@@H](CSc2ccc
cc2)[C@H](O)CN4[C@H](C(=O)NC(C)
(C)C)C[C@@H]3CCCC[C@@H]3C4 
78 Doxorubicin +ve C[C@H]1[C@H]([C@H](C[C@@H](O
1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)
C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO
)O)N)O 
79 Epirubicin +ve O=C2c1c(O)c5c(c(O)c1C(=O)c3cccc(OC
)c23)C[C@@](O)(C(=O)CO)C[C@@H]
5O[C@@H]4O[C@H]([C@H](O)[C@
@H](N)C4)C 
80 Ritonavir +ve CC(C)c1nc(cs1)CN(C)C(=O)N[C@@H]
(C(C)C)C(=O)N[C@@H](Cc2ccccc2)C[
C@@H]([C@H](Cc3ccccc3)NC(=O)OC
c4cncs4)O 
81 2,4-
Dichlorophenoxylace
tic acid 
+ve Clc1cc(Cl)ccc1OCC(=O)O 
82 2-Methylhamine +ve O(C=2/C=C\C1=C3/C=C\N(\C(=C3\N=
C1C=2)C)C)C 
83 Aldicarb +ve O=C(O\N=C\C(SC)(C)C)NC 
84 Betulinic acid +ve O=C(O)[C@@]54[C@@H]([C@@H]3[
C@@]([C@]1([C@@H]([C@]2(C)[C@
@H](CC1)C(C)(C)[C@@H](O)CC2)CC
3)C)(C)CC4)[C@H](C(=C)\C)CC5 
85 CCCP +ve Clc1cc(N\N=C(/C#N)C#N)ccc1 
 Appendix II 
210 
 
86 DAPI +ve [H]/N=C(/c1ccc(cc1)c2cc3ccc(cc3[nH]2)
/C(=N/[H])/N)\N 
87 DASPEI +ve c2(\C=C\c1[n](cccc1)CC)ccc(N(C)C)cc2 
88 DDD +ve Oc4ccc3cc(SSc2ccc1c(ccc(O)c1)c2)ccc3
c4 
89 DDT +ve Clc1ccc(cc1)C(c2ccc(Cl)cc2)C(Cl)(Cl)Cl 
90 Dequalinium +ve c12ccccc1c(cc([n+]2CCCCCCCCCC[n+]
4c3ccccc3c(N)cc4C)C)N 
91 Diethylstilbestrol +ve CC/C(=C(/CC)\c1ccc(cc1)O)/c2ccc(cc2)
O 
92 Ellipticine +ve Cc1c2ccncc2c(c3c1[nH]c4c3cccc4)C 
93 Ethidium bromide +ve CC[n]1c2cc(ccc2c3ccc(cc3c1c4ccccc4)N
)N 
94 FCCP +ve FC(F)(F)Oc1ccc(cc1)N/N=C(\C#N)C#N 
95 JC 1 +ve Clc1cc2N(/C(N(c2cc1Cl)CC)=C\C=C\c4
[n](c3cc(Cl)c(Cl)cc3n4CC)CC)CC 
96 Methyltriphenyl-
phosphonium 
+ve c1(ccccc1)[P+](c2ccccc2)(c3ccccc3)C 
97 MPCU +ve Clc2ccc(NC(=O)NS(=O)(=O)c1ccc(cc1)
C)cc2 
98 Nitroxynil +ve Ic1cc(C#N)cc([N+]([O-])=O)c1O 
99 Nonylacridine 
Orange 
+ve c3(ccc2cc1ccc(N(C)C)cc1[n+](c2c3)CC
CCCCCCC)N(C)C 
100 o-Phenanthroline +ve c1cc2ccc3cccnc3c2nc1 
101 Perfluorodecanoic 
acid 
+ve FC(F)(C(F)(F)C(=O)O)C(F)(F)C(F)(F)C(
F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F 
102 Perfluorooctane-
sulfonamide 
+ve FC(F)(C(F)(F)S(=O)(=O)N)C(F)(F)C(F)(
F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F 
103 Perfluorooctanoic 
acid 
+ve FC(F)(C(F)(F)C(=O)O)C(F)(F)C(F)(F)C(
F)(F)C(F)(F)C(F)(F)F 
104 PK 11195 +ve Clc3ccccc3c2nc(cc1ccccc12)C(=O)N(C(
C)CC)C 
105 Rhein +ve O=C2c1cccc(O)c1C(=O)c3c2cc(cc3O)C(
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=O)O 
106 Rhodamine 6G +ve CCOC(=O)c4ccccc4C=1c3cc(C)c(cc3O/
C/2=C/C(=N/CC)C(/C)=C\C=1\2)NCC 
107 Rhodamine 123 +ve O=C(OC)c4ccccc4C=1c3c(OC=2C=1\C
=C/C(=[NH2])/C=2)cc(cc3)N 
108 Rhodamine B +ve CCN(CC)c1ccc2c(c1)oc-
3cc(=[N](CC)CC)ccc3c2c4ccccc4C(=O)
O 
109 TBTP +ve O=P(SCCCC)(SCCCC)SCCCC 
110 Tebufenpyrad +ve Clc2c(nn(c2C(=O)NCc1ccc(cc1)C(C)(C)
C)C)CC 
111 Trichlorophen-
Oxyacetic acid 
+ve Clc1cc(OCC(=O)O)c(Cl)cc1Cl 
112 TTFB +ve FC(F)(F)c2nc1c(Cl)c(Cl)c(Cl)c(Cl)c1n2 
113 Victoria blue B +ve C/[N](C)=C1\C=C/C(C=C1)=C(\c4ccc(N
c2ccccc2)c3ccccc34)c5ccc(cc5)N(C)C 
114 Zalcitabine +ve O=C1/N=C(/N)\C=C/N1[C@@H]2O[C
@@H](CC2)CO 
115 2,4-Dinitrophenol +ve c1cc(c(cc1[N+](=O)[O-])[N+](=O)[O-
])O 
116 Amytal +ve O=C1NC(=O)NC(=O)C1(CCC(C)C)CC 
117 Antimycin A +ve O=CNc1cccc(c1O)C(=O)N[C@@H]2C(
=O)O[C@H]([C@H](OC(=O)CC(C)C)[
C@H](C(=O)O[C@@H]2C)CCCCCC)C 
118 Azidothymidine +ve Cc1cn(c(=O)[nH]c1=O)[C@H]2C[C@@
H]([C@H](O2)CO)N=[N+]=[N-] 
119 Carbaryl +ve O=C(Oc2cccc1ccccc12)NC 
120 Chenodeoxycholic 
acid 
+ve C[C@H](CCC(=O)O)[C@H]1CC[C@@
H]2[C@@]1(CC[C@H]3[C@H]2[C@@
H](C[C@H]4[C@@]3(CC[C@H](C4)O)
C)O)C 
121 Cholic acid +ve C[C@H](CCC(=O)O)[C@H]1CC[C@@
H]2[C@@]1([C@H](C[C@H]3[C@H]2
[C@@H](C[C@H]4[C@@]3(CC[C@H]
(C4)O)C)O)O)C 
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122 Deguelin +ve O=C2c5c(O[C@@H]3COc1cc(OC)c(OC
)cc1[C@H]23)c4\C=C/C(Oc4cc5)(C)C 
123 Deoxycholic acid +ve C[C@H](CCC(=O)O)[C@H]1CC[C@@
H]2[C@@]1([C@H](C[C@H]3[C@H]2
CC[C@H]4[C@@]3(CC[C@H](C4)O)C
)O)C 
124 Diazinon +ve S=P(OCC)(OCC)Oc1nc(nc(c1)C)C(C)C 
125 Diphenylamine +ve c1ccc(cc1)Nc2ccccc2 
126 Glycocholic +ve C[C@H](CCC(=O)NCC(=O)O)[C@H]1
CC[C@@H]2[C@@]1([C@H](C[C@H]
3[C@H]2[C@@H](C[C@H]4[C@@]3(
CC[C@H](C4)O)C)O)O)C 
127 Lithocholic +ve O=C(O)CC[C@H]([C@H]1CC[C@@H]
2[C@]1(C)CC[C@H]4[C@H]2CC[C@
@H]3C[C@H](O)CC[C@@]34C)C 
128 Mitomycin C +ve CC1=C(C(=O)C2=C(C1=O)N3C[C@H]
4[C@@H]([C@@]3([C@@H]2COC(=
O)N)OC)N4)N 
129 MPTP +ve c2c(/C1=C/CN(C)CC1)cccc2 
130 Naproxen +ve C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)
O 
131 Paraquat +ve C[n+]1ccc(cc1)c2cc[n+](cc2)C 
132 Pentachlorophenol +ve Clc1c(O)c(Cl)c(Cl)c(Cl)c1Cl 
133 Perhexiline +ve N3C(CC(C1CCCCC1)C2CCCCC2)CCC
C3 
134 Rotenone +ve CC(=C)[C@H]1Cc2c(ccc3c2O[C@@H]
4COc5cc(c(cc5[C@@H]4C3=O)OC)OC
)O1 
135 Ranolazine +ve O=C(Nc1c(cccc1C)C)CN3CCN(CC(O)C
Oc2ccccc2OC)CC3 
136 Chloroquine +ve Clc1cc2nccc(c2cc1)NC(C)CCCN(CC)C
C 
137 Atenolol +ve CC(C)NCC(COc1ccc(cc1)CC(=O)N)O 
138 Amineptine +ve O=C(O)CCCCCCNC3c1ccccc1CCc2c3c
ccc2 
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139 Tianeptine +ve Clc1cc2c(cc1)C(c3c(N(C)S2(=O)=O)ccc
c3)NCCCCCCC(=O)O 
140 Quinidine +ve O(c4cc1c(nccc1[C@H](O)[C@@H]2N3
CC[C@@H](C2)[C@@H](/C=C)C3)cc4
)C 
141 Abacavir +ve n3c1c(ncn1[C@H]2/C=C\[C@@H](CO)
C2)c(nc3N)NC4CC4 
142 Cerivastatin +ve O=C(O)C[C@H](O)C[C@H](O)/C=C/c
1c(nc(c(c1c2ccc(F)cc2)COC)C(C)C)C(C
)C 
143 Cinnarizine +ve c1c(cccc1)C(c2ccccc2)N3CCN(CC3)C/C
=C\c4ccccc4 
144 Flunarizine +ve c1ccc(cc1)/C=C/CN2CCN(CC2)C(c3ccc
(cc3)F)c4ccc(cc4)F 
145 Ketoconazole +ve O=C(N5CCN(c4ccc(OC[C@@H]1O[C
@](OC1)(c2ccc(Cl)cc2Cl)Cn3ccnc3)cc4)
CC5)C 
146 Bupivacaine +ve CCCCN1CCCCC1C(=O)Nc2c(cccc2C)C 
147 Clofibrate +ve Clc1ccc(OC(C(=O)OCC)(C)C)cc1 
148 Prilocaine +ve O=C(Nc1ccccc1C)C(NCCC)C 
149 Gemfibrozil +ve Cc1ccc(c(c1)OCCCC(C)(C)C(=O)O)C 
150 Fenoprofen +ve O=C(O)C(c2cc(Oc1ccccc1)ccc2)C 
151 Risperidone +ve Cc1c(c(=O)n2c(n1)CCCC2)CCN3CCC(
CC3)c4c5ccc(cc5on4)F 
152 Amphetamine +ve CC(Cc1ccccc1)N 
153 Deoxycholic acid +ve C[C@H](CCC(=O)O)[C@H]1CC[C@@
H]2[C@@]1([C@H](C[C@H]3[C@H]2
CC[C@H]4[C@@]3(CC[C@H](C4)O)C
)O)C 
154 Taurocholic +ve C[C@H](CCC(=O)NCCS(=O)(=O)O)[C
@H]1CC[C@@H]2[C@@]1([C@H](C[
C@H]3[C@H]2[C@@H](C[C@H]4[C
@@]3(CC[C@H](C4)O)C)O)O)C 
155 Phentolamine -ve Oc3cc(N(c1ccc(cc1)C)CC/2=N/CCN\2)c
cc3 
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156 Dopamine -ve c1cc(c(cc1CCN)O)O 
157 Guanethidine -ve N(=C(\N)N)\CCN1CCCCCCC1 
158 Diphenhydramine -ve O(CCN(C)C)C(c1ccccc1)c2ccccc2 
159 Promethazine -ve S2c1ccccc1N(c3c2cccc3)CC(N(C)C)C 
160 Oxymetazoline -ve Oc1c(c(c(cc1C(C)(C)C)C)CC/2=N/CCN\
2)C 
161 Tropicamide -ve CCN(Cc1ccncc1)C(=O)C(CO)c2ccccc2 
162 Warfarin -ve CC(=O)CC(c1ccccc1)c2c(c3ccccc3oc2=
O)O 
163 Phenindione -ve O=C2c1ccccc1C(=O)C2c3ccccc3 
164 Trimeprazine -ve S2c1ccccc1N(c3c2cccc3)CC(C)CN(C)C 
165 Tripelennamine -ve n1ccccc1N(CCN(C)C)Cc2ccccc2 
166 Bromodiphen-
Hydramine 
-ve Brc1ccc(cc1)C(OCCN(C)C)c2ccccc2 
167 Trimethobenzamide -ve O=C(c1cc(OC)c(OC)c(OC)c1)NCc2ccc(
OCCN(C)C)cc2 
168 Diphenylpyraline -ve O(C(c1ccccc1)c2ccccc2)C3CCN(C)CC3 
169 Benzphetamine -ve N(C)(Cc1ccccc1)[C@@H](C)Cc2ccccc2 
170 Metoclopramide -ve Clc1cc(c(OC)cc1N)C(=O)NCCN(CC)CC 
171 Methoxamine -ve O(c1ccc(OC)cc1C(O)C(N)C)C 
172 Phenprocoumon -ve OC=1c3ccccc3OC(=O)C=1C(CC)c2cccc
c2 
173 Crotamiton -ve O=C(N(c1ccccc1C)CC)/C=C/C 
174 Alprostadil -ve O=C1C[C@@H](O)[C@H](/C=C/[C@
@H](O)CCCCC)[C@H]1CCCCCCC(=
O)O 
175 Diphenidol -ve OC(c1ccccc1)(c2ccccc2)CCCN3CCCCC
3 
176 Methdilazine -ve S2c1ccccc1N(c3c2cccc3)CC4CCN(C)C4 
177 Disopyramide -ve O=C(N)C(c1ncccc1)(c2ccccc2)CCN(C(C
)C)C(C)C 
 Appendix II 
215 
 
178 Azatadine -ve n4c3\C(=C1/CCN(C)CC1)c2ccccc2CCc3
ccc4 
179 Pentoxifylline -ve CC(=O)CCCCn1c(=O)c2c(ncn2C)n(c1=
O)C 
180 Dobutamine -ve Oc1ccc(cc1O)CCNC(C)CCc2ccc(O)cc2 
181 Alprenolol -ve O(c1ccccc1C\C=C)CC(O)CNC(C)C 
182 Naltrexone -ve O=C4[C@@H]5Oc1c2c(ccc1O)C[C@H]
3N(CC[C@]25[C@@]3(O)CC4)CC6CC
6 
183 Prazosin -ve O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n
2)N)CC3)c4occc4 
184 Minaprine -ve n2nc(NCCN1CCOCC1)c(cc2c3ccccc3)C 
185 Guanfacine -ve Clc1cccc(Cl)c1CC(=O)\N=C(/N)N 
186 Tocainide -ve O=C(Nc1c(cccc1C)C)C(N)C 
187 Nadolol -ve OC(CNC(C)(C)C)COc1cccc2c1C[C@H]
(O)[C@H](O)C2 
188 Midodrine -ve O=C(NCC(O)c1cc(OC)ccc1OC)CN 
189 Flecainide -ve FC(F)(F)COc2cc(C(=O)NCC1NCCCC1)
c(OCC(F)(F)F)cc2 
190 Fenoldopam -ve Clc1c3c(cc(O)c1O)C(c2ccc(O)cc2)CNC
C3 
191 Dapiprazole -ve n1nc(n2c1CCCC2)CCN4CCN(c3ccccc3
C)CC4 
192 Enalapril -ve O=C(O)[C@H]2N(C(=O)[C@@H](N[C
@H](C(=O)OCC)CCc1ccccc1)C)CCC2 
193 Lisinopril -ve c1ccc(cc1)CC[C@@H](C(=O)O)N[C@
@H](CCCCN)C(=O)N2CCC[C@H]2C(
=O)O 
194 Quinapril -ve O=C(OCC)[C@@H](N[C@H](C(=O)N2
[C@H](C(=O)O)Cc1c(cccc1)C2)C)CCc3
ccccc3 
195 Ondansetron -ve O=C3c2c1ccccc1n(c2CCC3Cn4ccnc4C)
C 
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196 Ridogrel -ve FC(F)(F)c2cccc(C(=N\OCCCCC(=O)O)/
c1cccnc1)c2 
197 Benazepril -ve O=C(OCC)[C@@H](N[C@@H]2C(=O)
N(c1ccccc1CC2)CC(=O)O)CCc3ccccc3 
198 Ramipril -ve CCOC(=O)[C@H](CCc1ccccc1)N[C@
@H](C)C(=O)N2[C@H]3CCC[C@H]3C
[C@H]2C(=O)O 
199 Trandolapril -ve O=C(OCC)[C@@H](N[C@H](C(=O)N1
[C@H](C(=O)O)C[C@H]2CCCC[C@H]
12)C)CCc3ccccc3 
200 Granisetron -ve CN4[C@@H]1CCC[C@H]4C[C@H](C
1)NC(=O)c3nn(C)c2ccccc23 
201 Acamprosate -ve O=S(=O)(O)CCCNC(=O)C 
202 Moexipril -ve O=C(OCC)[C@@H](N[C@H](C(=O)N2
[C@H](C(=O)O)Cc1c(cc(OC)c(OC)c1)C
2)C)CCc3ccccc3 
203 Dofetilide -ve O=S(=O)(Nc1ccc(cc1)CCN(CCOc2ccc(c
c2)NS(=O)(=O)C)C)C 
204 Brimonidine -ve Brc2c1nccnc1ccc2N/C3=N/CCN3 
205 Losartan -ve Clc1nc(n(c1CO)Cc4ccc(c2ccccc2c3nnnn
3)cc4)CCCC 
206 Arbutamine -ve Oc1ccc(cc1O)[C@@H](O)CNCCCCc2c
cc(O)cc2 
207 Valsartan -ve CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3[n
H]nnn3)[C@@H](C(C)C)C(=O)O 
208 Atropine -ve CN3[C@H]1CC[C@@H]3C[C@@H](C
1)OC(=O)C(CO)c2ccccc2 
209 Levorphanol -ve Oc3ccc4C[C@H]1N(C)CC[C@@]2(CC
CC[C@@H]12)c4c3 
210 Pilocarpine -ve O=C2OC[C@H](Cc1n(cnc1)C)[C@@H]
2CC 
211 Triamcinolone -ve C[C@]12C[C@@H]([C@]3([C@H]([C
@@H]1C[C@H]([C@@]2(C(=O)CO)O)
O)CCC4=CC(=O)C=C[C@@]43C)F)O 
212 Spironolactone -ve O=C5O[C@@]4([C@@]3([C@H]([C@
@H]2[C@H](SC(=O)C)C/C1=C/C(=O)
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CC[C@]1(C)[C@H]2CC3)CC4)C)CC5 
213 Fluocinonide -ve O=C(OCC(=O)[C@]45OC(O[C@@H]5
C[C@@H]2[C@@]4(C[C@H](O)[C@]
3(F)[C@]/1(/C=C\C(=O)\C=C\1[C@@H
](F)C[C@@H]23)C)C)(C)C)C 
214 Betamethasone -ve O=C(CO)[C@]3(O)[C@]2(C[C@H](O)[
C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)
CC[C@H]4[C@@H]2C[C@@H]3C)C)
C 
215 Fluorometholone -ve O=C(C)[C@]3(O)[C@]2(C[C@H](O)[C
@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[
C@@H](C)C[C@H]4[C@@H]2CC3)C)
C 
216 Methyldopa -ve O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C 
217 Nicergoline -ve Cn1cc2c3c1cccc3[C@]4(C[C@H](CN([
C@@H]4C2)C)COC(=O)c5cc(cnc5)Br)
OC 
218 Captopril -ve C[C@H](CS)C(=O)N1CCC[C@H]1C(=
O)O 
219 Olopatadine -ve O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CC
N(C)C)cccc3 
220 Tirofiban -ve O=S(=O)(N[C@H](C(=O)O)Cc2ccc(OC
CCCC1CCNCC1)cc2)CCCC 
221 Palonosetron -ve O=C5N([C@H]2C1CCN(CC1)C2)C[C@
@H]4c3c5cccc3CCC4 
222 Scopolamine -ve OC[C@H](c1ccccc1)C(=O)O[C@@H]2
C[C@H]3N(C)[C@@H](C2)[C@@H]4
O[C@H]34 
223 Desloratadine -ve c1cc2c(nc1)C(=C3CCNCC3)c4ccc(cc4C
C2)Cl 
224 Betanidine -ve N(=C(/NCc1ccccc1)NC)\C 
225 Sibutramine -ve Clc1ccc(cc1)C2(C(N(C)C)CC(C)C)CCC
2 
226 Thiethylperazine -ve S(c2cc1N(c3c(Sc1cc2)cccc3)CCCN4CC
N(C)CC4)CC 
227 Mequitazine -ve c1ccc2c(c1)N(c3ccccc3S2)CC4CN5CCC
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4CC5 
228 Terfenadine -ve OC(c1ccccc1)(c2ccccc2)C4CCN(CCCC(
O)c3ccc(cc3)C(C)(C)C)CC4 
229 Nabilone -ve O=C3CC[C@@H]1[C@H](c2c(OC1(C)
C)cc(cc2O)C(C)(C)CCCCCC)C3 
230 Acitretin -ve Cc1cc(c(c(c1/C=C/C(=C/C=C/C(=C/C(=
O)O)/C)/C)C)C)OC 
231 Azelastine -ve Clc1ccc(cc1)CC\3=N\N(C(=O)c2ccccc2/
3)C4CCCN(C)CC4 
232 Famotidine -ve c1c(nc(s1)N=C(N)N)CSCC/C(=N/S(=O)
(=O)N)/N 
233 Loratadine -ve CCOC(=O)N1CCC(=C2c3ccc(cc3CCc4c
2nccc4)Cl)CC1 
234 Sibutramine -ve Clc1ccc(cc1)C2(C(N(C)C)CC(C)C)CCC
2 
235 Remikiren -ve O=S(=O)(C(C)(C)C)C[C@H](C(=O)N[C
@H](C(=O)N[C@@H](CC1CCCCC1)[
C@@H](O)[C@@H](O)C2CC2)Cc3cnc
n3)Cc4ccccc4 
236 Deserpidine -ve O=C(OC)[C@H]6[C@H]4C[C@@H]3c
2nc1ccccc1c2CCN3C[C@H]4C[C@@H
](OC(=O)c5cc(OC)c(OC)c(OC)c5)[C@
@H]6OC 
237 Irbesartan -ve CCCCC1=NC2(CCCC2)C(=O)N1Cc3cc
c(cc3)c4ccccc4c5[nH]nnn5 
238 Fexofenadine -ve O=C(O)C(c1ccc(cc1)C(O)CCCN2CCC(
CC2)C(O)(c3ccccc3)c4ccccc4)(C)C 
239 Eprosartan -ve CCCCc1ncc(n1Cc2ccc(cc2)C(=O)O)/C=
C(\Cc3cccs3)/C(=O)O 
240 Dipyridamole -ve C1CCN(CC1)c2c3c(c(nc(n3)N(CCO)CC
O)N4CCCCC4)nc(n2)N(CCO)CCO 
241 Fosinopril -ve O=C(CP(=O)(CCCCc1ccccc1)OC(OC(=
O)CC)C(C)C)N2C[C@@H](C[C@H]2C
(O)=O)C3CCCCC3 
242 Candoxatril -ve O=C(N[C@H]1CC[C@H](CC1)C(O)=O
)C4(C[C@@H](COCCOC)C(=O)Oc2cc
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3CCCc3cc2)CCCC4 
243 Lactulose -ve O[C@H]2[C@H](O[C@@H]1O[C@H](
CO)[C@H](O)[C@H](O)[C@H]1O)[C
@H](O[C@]2(O)CO)CO 
244 Rescinnamine -ve O=C(OC)[C@H]6[C@H]4C[C@@H]3c
2nc1cc(OC)ccc1c2CCN3C[C@H]4C[C
@@H](OC(=O)\C=C\c5cc(OC)c(OC)c(
OC)c5)[C@@H]6OC 
245 Tobramycin -ve C1[C@@H]([C@H]([C@@H]([C@H]([
C@@H]1N)O[C@@H]2[C@@H]([C@
H]([C@@H]([C@H](O2)CO)O)N)O)O)
O[C@@H]3[C@@H](C[C@@H]([C@
H](O3)CN)O)N)N 
246 Argatroban -ve O=C(O)[C@@H]3N(C(=O)[C@@H](N
S(=O)(=O)c1cccc2c1NCC(C2)C)CCC/N
=C(\N)N)CC[C@@H](C)C3 
247 Trimethaphan -ve O=C2N(C4C[S+]1CCCC1C4N2Cc3cccc
c3)Cc5ccccc5 
248 Bretylium -ve Brc1ccccc1C[N+](CC)(C)C 
249 Clidinium -ve O=C(OC2C1CC[N+](CC1)(C)C2)C(O)(c
3ccccc3)c4ccccc4 
250 Marinol -ve CCCCCc1cc(c2c(c1)OC([C@H]3[C@H]
2C=C(CC3)C)(C)C)O 
251 Methantheline -ve O=C(OCC[N+](CC)(CC)C)C2c3c(Oc1c2
cccc1)cccc3 
252 Oxyphenonium -ve O=C(OCC[N+](CC)(CC)C)C(O)(c1cccc
c1)C2CCCCC2 
253 Propantheline -ve O=C(OCC[N+](C(C)C)(C(C)C)C)C2c3c
(Oc1c2cccc1)cccc3 
254 Meperidine +ve O=C(OCC)C2(c1ccccc1)CCN(C)CC2 
255 Isoniazid +ve O=C(NN)c1ccncc1 
256 Acetaminophen +ve CC(=O)Nc1ccc(cc1)O 
257 Propranolol +ve CC(C)NCC(COc1cccc2c1cccc2)O 
258 Clozapine +ve CN1CCN(CC1)C2=Nc3cc(ccc3Nc4c2cc
cc4)Cl 
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259 Piroxicam +ve CN1C(=C(c2ccccc2S1(=O)=O)O)C(=O)
Nc3ccccn3 
260 Ribavirin +ve c1nc(nn1[C@H]2[C@@H]([C@@H]([C
@H](O2)CO)O)O)C(=O)N 
261 Pioglitazone +ve O=C1NC(=O)SC1Cc3ccc(OCCc2ncc(cc
2)CC)cc3 
262 Xanthomegnin +ve COC=2C(=O)c1c6C(=O)OC(C)Cc6cc(O
)c1C(=O)C=2\C5=C(/OC)C(=O)c4c(c(O
)cc3CC(C)OC(=O)c34)C5=O 
263 Malachite green +ve OC(c1ccc(N(C)C)cc1)(c2ccccc2)c3ccc(N
(C)C)cc3 
264 Methyl benzoquate +ve O=C\3c2c(cc(OCc1ccccc1)c(c2)CCCC)
N/C=C/3C(=O)OC 
265 MKT-077 +ve O=C2C(\S/C(=C\c1cccc[n+]1CC)N2CC)
=C3/Sc4ccccc4N3C 
266 MTT +ve Cc1c(sc(n1)[n+]2nc(nn2c3ccccc3)c4cccc
c4)C 
267 Safranine O +ve n1c4c([n+](c2c1cc(c(N)c2)C)c3ccccc3)c
c(c(c4)C)N 
268 Vacor +ve [O-
][N+](=O)c1ccc(cc1)NC(=O)NCc2cccnc
2 
269 Aspirin +ve CC(=O)Oc1ccccc1C(=O)O 
270 Meloxicam +ve Cc1cnc(s1)NC(=O)C2=C(c3ccccc3S(=O
)(=O)N2C)O 
271 Cysteamine -ve SCCN 
272 Phentermine -ve NC(Cc1ccccc1)(C)C 
273 Triprolidine -ve n3c(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc
c3 
274 Flucytosine -ve FC=1\C=N/C(=O)NC=1N 
275 Tolmetin -ve O=C(c1ccc(n1C)CC(=O)O)c2ccc(cc2)C 
276 Timolol -ve O[C@H](COc1nsnc1N2CCOCC2)CNC(
C)(C)C 
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277 Cisapride -ve Clc1cc(c(OC)cc1N)C(=O)NC3CCN(CC
COc2ccc(F)cc2)CC3OC 
278 Dexmedetomidine -ve n1cc(nc1)C(c2c(c(ccc2)C)C)C 
279 Mannitol -ve C([C@H]([C@H]([C@@H]([C@@H](C
O)O)O)O)O)O 
280 Clotrimazole -ve c1ccc(cc1)C(c2ccccc2)(c3ccccc3Cl)n4cc
nc4 
281 Levothyroxine -ve c1c(cc(c(c1I)Oc2cc(c(c(c2)I)O)I)I)C[C@
@H](C(=O)O)N 
282 Telmisartan -ve CCCc1nc2c(cc(cc2n1Cc3ccc(cc3)c4cccc
c4C(=O)O)c5nc6ccccc6n5C)C 
283 Natamycin -ve OC(=O)[C@@H]3[C@@H](O)C[C@@
]2(O)C[C@@H](O)C[C@H]4O[C@@H
]4/C=C/C(=O)O[C@H](C)C\C=C\C=C\
C=C\C=C\[C@H](OC1O[C@H](C)[C@
@H](O)[C@H](N)[C@@H]1O)C[C@@
H]3O2 
284 Dolasetron -ve O=C5CN4[C@@H]1C[C@H]5C[C@H]
4C[C@H](C1)OC(=O)c3cnc2ccccc23 
285 Ramelteon -ve O=C(NCC[C@H]3c2c(ccc1OCCc12)CC
3)CC 
286 Tolazoline -ve N\1=C(\NCC/1)Cc2ccccc2 
287 Levocarnitine -ve [O-]C(=O)C[C@@H](O)C[N+](C)(C)C 
288 Apraclonidine -ve Clc1c(c(Cl)cc(N)c1)N/C2=N/CCN2 
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Appendix III. 90-day repeat dose toxicity data associated to each compound within the categories developed (Chapter 5). (Abbreviations: AAT – 
Alanine aminotransferase, APTT – Activated Partial Thromboplastin Time, AST – Aspartate aminotransferase, BWG – Body Weight Gain, GI – 
GastroIntestinal, MCH – Mean Corpuscular/cell Haemoglobin, MCV – Mean Corpuscular/cell Volume, PT – Prothrombin Time, RBC – Red Blood Cell.) 
Compound 
Number 
Category 
Name 
Structure Compound 
Name 
NO(A)EL 
(mg/kg 
bw/day) 
LO(A)EL 
(mg/kg 
bw/day) 
Adverse effects used to derive LO(A)EL 
within SCC(NF)P and SCCS opinions 
1 Quinone 
 
Disperse Violet 1 2 20 ↑ Centrilobular/Midzonal hepatocyte 
hypertrophy 
↑ Triglycerides (♀) 
↑ Cholesterol 
↓ Motor activity 
2 Quinone 
 
Lawsone 2 7 ↓ Erythrocyte count (♀) 
↓ Blood urea (♀) 
↓ Albumin:Globulin ratio (♀) 
↑ Bilirubin (♀) 
↑ Kidney weight (♀) 
↓ Blood glucose (♂) 
↑ Triglycerides (♂) 
↑ Haematopoiesis, spleen (♂) 
↑ (Multi)focal ulceration of mucosa, 
forestomach 
↑ Interstitial oedema, forestomach 
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3 Quinone 
 
Acid Green 25 100 
(95 due to 
active 
ingredient) 
300 
(285 due to 
active 
ingredient) 
↑ Kidney weight 
4 Quinone 
 
HC Green No. 1 100 300 ↓ Food consumption (♀) 
↓ Body weight (♀) 
↑ Hypokalemia 
↑ Oliguria (♂) 
5 Quinone 
 
Acid Blue 62 300 
(160 due to 
active 
ingredient) 
1000  
(534 due to 
active 
ingredient) 
↑ Kidney weight 
↑ Liver weight 
↑ Ptyalism 
↑ Tubular nephrosis 
↑ Centrilobular hepatocyte hypertrophy 
↑ Blood Urea 
↑ Albumin 
↑ Cholesterol 
↑ AAT 
↓ Body weight 
↓ Glucose 
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6 Quinone 
 
Hydroxyanthraquinone 
Aminopropyl Methyl 
Morpholinium 
Methosulfate 
200 800 ↓ Absolute thymus weight (♀) 
↓ Body weight (♂) 
↓ Relative thymus weight 
7 Quinone 
 
Acid Violet 43 300 
(282 due to 
active 
ingredient) 
1000 
(940 due to 
active 
ingredient) 
↑ PT 
↑ APTT 
8 Pro-quinone 
 
Toluene-2,5-diamine 10 20 ↑ AST 
↑ Mononuclear cell infiltrates, 
diaphragm 
↑ Mononuclear cell infiltrates, eye 
↑ Mononuclear cell infiltrates, thigh 
↑ Mononuclear cell infiltrates, tongue 
↑ Muscular degeneration, diaphragm 
↑ Muscular degeneration, thigh 
↑ Muscular degeneration, tongue 
↑ Muscular regeneration, diaphragm 
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9 Pro-quinone 
 
Picramic Acid 5 (3.2 due 
to active 
ingredient) 
15 (9.4 due 
to active 
ingredient) 
↑ Ulceration of GI tract 
↑ Inflammation of GI tract 
↑ Fibrosis of GI tract 
↑ Tubular cell swelling 
↑ MCV 
↑ MCH 
↑ Reticulocyte count 
10 Pro-quinone 
 
HC Red No. 13 No NO(A)EL 5  
(4.2 due to 
active 
ingredient) 
↑ Creatinine (♀) 
↑ Kidney weight 
↑ PT (♂) 
↓ Albumin:Globulin ratio (♀) 
↓ Glucose (♀) 
↓ MCH (♂) 
↓ MCV 
11 Pro-quinone 
 
2,2'-Methylenebis-4-
aminophenol 
5 15 ↑ Cast formation, kidney 
↑ Thickened basement membrane, 
kidney 
↑ Tubular basophilia, kidney 
↑ Tubular degeneration, kidney 
12 Pro-quinone 
 
4-Nitrophenyl 
aminoethylurea 
5 25 ↓ RBC count 
↓ Haemoglobin concentration 
↑ MCV 
↑ Reticulocyte count 
↑ Extramedullary haematopoiesis, 
spleen 
↑ Haemosiderosis (♀) 
↓ Packed cell volume (♂) 
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13 Pro-quinone 
 
HC Red No. 1 5 20 ↓ Erythrocytes (♀) 
↑ Leukocytes (♀) 
↑ Lymphocytes (♀) 
↓ Thymus weight (♂) 
↑ MCH (♂) 
14 Pro-quinone 
 
Tetrahydro-6-
nitroquinoxaline 
5 25 ↑ Ptyalism 
↑ Liver weight 
↑ Spleen weight 
15 Pro-quinone 
 
p-Phenylenediamine 8 16 ↑ Myodegeneration, skeletal muscle 
16 Pro-quinone 
 
2-Chloro-6-ethylamino-4-
nitrophenol 
10 30 ↑ Liver weight 
17 Pro-quinone 
 
Dihydroxyindoline 10 20 ↑ Pigmentation, kidney 
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18 Pro-quinone 
 
PEG-3-2',2'-di-p-
phenylenediamine 
10 25 ↑ Intracellular pigmentation, kidney 
tubules 
↑ Pigmentation, thyroid epithelium 
↑ Pigmentation, duodenum 
19 Pro-quinone 
 
p-Methylaminophenol 
sulphate 
10 30 ↑ Tubular epithelial degeneration, 
kidney 
↑ Single cell necrosis, kidney 
↓ Specific gravity (♂) 
↑ Urinary volume (♂) 
20 Pro-quinone 
 
2-Hydroxyethyl picramic 
Acid 
15 60 ↑ Protein cylinders, kidneys 
↑ Activation of thyroid epithelial cells 
21 Pro-quinone 
 
HC Yellow No. 13 21 90 ↑ Degeneration, Islet cells 
↑ Inflammation, endocrine pancreas 
↑ Fibrosis, endocrine pancreas 
↑ Serum cholesterol (♂) 
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22 Pro-quinone 
 
3-Methylamino-4-
nitrophenoxyethanol 
25 100 ↑ Ptyalism 
↓ Lymphoid in thymus 
23 Pro-quinone 
 
HC Orange No.1 25 No LO(A)EL  
24 Pro-quinone 
 
2-Amino-6-chloro-4-
nitrophenol 
30 90 ↓ Body weight 
↑ Kidney weight 
25 Pro-quinone 
 
4-Hydroxypropylamino-3-
nitrophenol 
30 90 ↑ Thyroid weight 
↓ AST 
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26 Pro-quinone 
 
Acid Yellow 1 30 100 ↑ Mean absolute reticulocyte 
↑ Haematopoiesis 
↑ Lesions, caecum 
↑ Lesions, intestine 
↑ Lesions, liver 
↑ Lesions, spleen 
↑ Haemosiderosis (♀) 
↑ MCV (♀) 
↑ Spleen weight (♂) 
27 Pro-quinone 
 
1,2,4-Trihydroxybenzene 50 100 ↑ Piloerection 
↑ Ptyalism 
↑ Mean RBC volume 
↑ MCH 
↑ Platelets 
↓ Haematocrit 
↓ RBC count 
↓ Haemoglobin 
↑ Kidney weight 
↑ Liver weight 
↑ Spleen weight 
↓ Body weight (♂) 
28 Pro-quinone 
 
4-Amino-3-nitrophenol 50 250 ↑ Liver weight (♂) 
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29 Pro-quinone 
 
HC Violet No. 2 50 200 ↑ Liver weight 
↓ RBC 
↓ PT 
30 Pro-quinone 
 
HC Yellow No. 11 50 200 ↑ Acidophilic globules in cortical tubular 
epithelium 
↑ Liver weight (♀) 
↑ Kidney weight 
↓ Thymus weight 
↓ Creatinine 
31 Pro-quinone 
 
HC Yellow No. 2 50 No LO(A)EL  
32 Pro-quinone 
 
2-Nitro-4-amino-
diphenylamine-2’-
carboxylic acid 
60 180 ↑ Thrombocytes 
↑ Water consumption (♀) 
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33 Pro-quinone 
 
4-Amino-m-cresol 60 120 ↑ Spleen weight 
34 Pro-quinone 
 
HC Blue No. 12 60 No LO(A)EL  
35 Pro-quinone 
 
HC Blue No. 11 80 160 ↑ Kidney weight 
↑ Vacuolated tubular cell 
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36 Pro-quinone 
 
HC Red No. 3 90 250 ↓ Body weight 
37 Pro-quinone 
 
2-Hydroxyethylamino-5-
nitroanisole 
100 500 ↑ Liver weight 
↑ Spleen weight 
↑ PT 
↑ Fibrinogen level 
↑ Blood urea nitrogen 
↑ AAT (♂) 
↑ Urinary volume 
38 Pro-quinone 
 
HC Orange No. 3 100 300 ↑ Kidney weight 
↑ Liver weight 
↑ Spleen weight 
↑ AAT 
↑ AST 
39 Pro-quinone 
 
HC Yellow No. 10 100 500 ↑ Staining, body 
↑ Staining, fur 
↑ Body weight 
↑ Ptyalism 
↑ Food consumption 
↑ Liver weight 
↑ Spleen weight (♂) 
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40 Pro-quinone 
 
HC Orange No.  2 150 500 ↑ Ptyalism 
↓ BWG 
↓ Food consumption 
↓ Blood glucose 
41 Pro-quinone 
 
Acid Blue 62 300 
(160 due to 
active 
ingredient) 
1000  
(534 due to 
active 
ingredient) 
↑ Kidney weight 
↑ Liver weight 
↑ Ptyalism 
↑ Tubular nephrosis 
↑ Centrilobular hepatocyte hypertrophy 
↑ Blood urea 
↑ Albumin 
↑ Cholesterol 
↑ AAT 
↓ BWG 
↓ Glucose 
42 Pro-quinone 
 
2-Nitro-5-glyceryl 
methylaniline 
200 800 ↑ Ptyalism 
↑ Vacuolated pancreatic cells 
↑ Vacuolated renal tubular cells 
↑ Tubular nephrosis 
↑ Piloerection 
↑ Hunched back 
↑ Hypokinesia 
↑ Bilateral opacity 
↑ Adrenal weight 
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↑ Kidney weight 
↑ Liver weight 
↓ BWG 
43 Pro-quinone 
 
3-Nitro-p-
hydroxyethylaminopheno
l 
200 No LO(A)EL  
44 Pro-quinone 
 
N,N'-bis(hydroxyethyl)-2-
nitro-p-
phenylenediamine 
240 720 ↑ Kidney weight 
↑ Liver weight 
↓ Activity (♀) 
↓ Ataxia (♀) 
↑ Ptyalism (♀) 
↑ Ocular discharge (♀) 
↑ Lethargy (♀) 
↑ Hunched posture (♀) 
↑ Triglycerides (♂) 
↑ Urea (♂) 
↑ Urinary specific gravity 
45 Pro-quinone 
 
HC Yellow No. 4 250 500 ↓ Body weight 
↑ Thyroid lesions 
↑ Uterine lesions (♀) 
↑ Kidney lesions (♂) 
1 Mortality 
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46 Pro-quinone 
 
HC Yellow No. 9 250 No LO(A)EL  
47 Meta-
hydroquinone 
 
5-amino-6-chloro-o-
cresol 
No NO(A)EL 100 
(33 after 
adjustment 
factor of 3) 
↑ Centrilobular hepatotrophy, liver 
↑ MCV 
↑ Mean corpuscular Hb (♀) 
↑ MCH concentration (♀) 
48 Meta-
hydroquinone 
 
3-Amino-2,4-
dichlorophenol 
80 160 ↑ Liver degeneration 
↑ Liver necrosis 
↑ Foci mononuclear cell infiltration 
↑ Kidney degeneration 
↑ Kidney necrosis 
↑ Tubular epithelial cell hypertrophy 
↑ Phosphorus (♂) 
↑ Sodium (♂) 
↑ Chloride (♂) 
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49 Meta-
hydroquinone 
 
2,6-
Dihydroxyethylaminotolu
ene 
100 316 ↑ Bilirubin 
↑ Urobilinogen 
↓ Serum creatinine (♀) 
50 Meta-
hydroquinone 
 
2-Methylresorcinol 100 200 ↑ Clonic spasms 
↑ Ptyalism 
↑ Scratching movements 
↑ Body weight (♂) 
↑ Liver weight (♂) 
↑ AST (♂) 
↑ AAT (♂) 
51 Aromatic azo 
 
Basic Brown 16 50 
(32 due to 
dye 
content) 
150 
(99 due to 
dye 
content) 
↓ BWG (♂) 
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52 Aromatic azo 
 
Basic Brown 17 60  
(46 due to 
dye 
content) 
120  
(93 due to 
dye 
content) 
↑ Extramedullary haemopoiesis 
53 Aromatic azo 
 
Basic Red 76 20 60 ↓ RBC (♂) 
↓ Haemoglobin 
↓ Haematocrit (♂) 
↓ MCH concentration (♀) 
54 Aromatic azo 
 
Disperse Black 9 100 
(52.6 due 
to dye 
content) 
No LO(A)EL  
55 Aromatic azo 
 
Disperse Red 17 10 
(4 due to 
dye 
content) 
30 
(12 due to 
dye 
content) 
↑ Spleen weight 
56 Aromatic azo 
 
HC Yellow No. 7 10 40 ↑ Kidney weight 
↑ Bilateral discolouration of fundus 
↑ Pytalism 
↑ Tubular basophilia 
↑ Blood phosphorous (♀) 
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↓ Blood glucose (♀) 
↑ Blood sodium (♂) 
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